Research

Pea, A., He, X., Upstill-Goddard, R., Luchini, C., Schubert Santana, L. P., Dreyer, S., Duthie, F., Jamieson, N. B., McKay, C. J., Dickson, E. J., Pulvirenti, A., Rebus, S., Genomics Innovation Alliance, ., Scottish Genome Partnership, ., Piccoli, P., Sperandio, N., Lawlor, R. T., Milella, M., Froeling, F. E.M., Salvia, R., Scarpa, A., Bainkin, A. V., Wedge, D. C., Chang, D. K. (2026) Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Nature Communications, (doi: 10.1038/s41467-026-69762-w)

Williams, H. L., Poulain, N., Powley, I., Martinelli, S., Bielik, R., Leslie, H., Nixon, C., Wilson, C. R., Sereno, M., He, Z., Offier-Jones, L., Ballantyne, F., Pennie, R., Wood, C. S., Lewis, D. Y., Jamieson, N. B., Le Quesne, J. (2026) Spatial molecular plasticity underpins lethal morphologies in lung adenocarcinoma. Modern Pathology, 39, (doi: 10.1016/j.modpat.2026.100960)

Himonas, E., de Beauchamp, L., Zerbst, D., Desmares-Romain, E., Sarnello, D., Kalkman, E., Rattigan, K., James, D., Shokry, E., Copland, M., Griessinger, E., Récher, C., de Mas, V., Vergez, F., Sumpton, D., Schimmer, A., Minden, M., Gottlieb, E., Shanks, E., Sarry, J.-E., Helgason, V. (2026) A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia. Blood, (doi: 10.1182/blood.2024027853)

White, M. et al. (2026) MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. Nature, 650, pp. 748-758. (doi: 10.1038/s41586-025-09916-w)

Bryce, A. S., Martinelli, S., Schubert Santana, L., Officer-Jones, L., Baird, R. L., Ballantyne, F., Rakovic, K., Powley, I. R., Tataran, D., Meltzer, D. J., Walsh, C., Duthie, F., Farndale, L., Claudio Quiros, A., Yuan, K., Le Quesne, J., Froeling, F. E.M., Dreyer, S. B., Chang, D. K. (2026) Morphospatial profiling of cancer-associated fibroblasts reveals architectural subtypes of pancreatic ductal adenocarcinoma. bioRxiv, (doi: 10.64898/2026.02.06.704414)

Centeno, P. P., Chester, C., Kanellos, G., Ford, C. A., Cammarezi, P., Inman, G. J., Jamieson, T., Ridgeway, R. A., Marais, R., Campbell, A. D., Sansom, O. J. (2026) SOX2 confers tumour permissiveness in a specific skin progenitor population. Nature Communications, 17, (doi: 10.1038/s41467-025-66251-4)

Tham, A., McMillan, D. C., Talwar, D., McSorley, S. T. (2026) Adjusting iron markers for inflammation reduces misclassification of iron deficiency after total hip arthroplasty. Journal of Clinical Medicine, 15, (doi: 10.3390/jcm15010259)

Xiao, J., Wetherall, K., Cleare, S., Ernst, M., Robb, K. A., O'Connor, R. C. (2026) Longitudinal temporal mediation within the motivational phase of the Integrated Motivational-Volitional (IMV) Model of suicidal behaviour with moderation of loneliness and resilience. Suicide and Life-Threatening Behavior, 56, (doi: 10.1111/sltb.70081)

Smith, C. D.L., McMahon, A. D., Inman, G. J., Conway, D. I., Douglas, C. M., Paterson, C. (2026) The COVID-19 pandemic has not influenced survival outcomes of head and neck cancer squamous cell carcinomas in the West of Scotland: a retrospective cohort study. BJC Reports, 4, (doi: 10.1038/s44276-026-00203-3)

Kanellos, G. et al. (2025) Nucleophosmin supports WNT-driven hyperproliferation and tumour initiation. Nature Genetics, (doi: 10.1038/s41588-025-02408-7)

Gajic, N., Christie, R., Lam, S., Ackermann, T., Himonas, E., Josephs-Spaulding, J., Manoharan, A., Assmann, V., Martin, J., Collings, A., Dunn, K., Shokry, E., Huerta Uribe, A., Burns, S., O'Connor, D., Mansour, M., Sumpton, D., Helgason, G. V., Vande Voorde, J., Tardito, S., Tait, S., Halsey, C. (2025) Selenocysteine Dependency Renders Central Nervous System Leukaemia Therapeutically Sensitive to Ferroptosi. (doi: 10.1182/blood-2025-1526)

Lourenço, F. C., Sadien, I. D., Wong, K., Adler, S., Sawle, A., Schubert Santana, L., Hazelwood, L., Giavara, G., Nicholson, A. M., Eldridge, M. D., Maka, N., Lynch, G., McSorley, S. T., Edwards, J., Kemp, R., Adams, D. J., Winton, D. J. (2025) Decay of driver mutations shapes the landscape of intestinal transformation. Nature, (doi: 10.1038/s41586-025-09762-w)

Baird, R. L., Mason, D., Rakovic, K., Ballantyne, F., Powley, I. R., Georgakopoulou, A., Hillary, L., Bird, T. G., Officer-Jones, L., Le Quesne, J. (2025) PixlMap: a generalisable pixel classifier for cellular phenotyping in multiplex immunofluorescence images. PLoS ONE, 20, (doi: 10.1371/journal.pone.0317865)

Glen, C., Dobbin, S. J.H., Mangion, K., Henderson, A., Brooksbank, K., Coats, C. J., Epstein, F. H., Kellman, P., Butler, E., Evans, T. R. J., Jones, R., McClure, J., Roditi, G., Yi Tan, Y., Waterston, A., Welsh, P., Petrie, M. C., Lang, N. N. (2025) Prospective evaluation of the cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma. JACC: CardioOncology, 7, pp. 852-866. (doi: 10.1016/j.jaccao.2025.08.006)

Randhawa, M., Buchanan, G., Stratton, I.M., Race, G., Challapalli, A., Bottomley, D., Logue, J., Sundar, S., Robinson, A., Mclaren, D.B., Stevenson, R., O'Sullivan, J.M., Sweeney, L., McGrane, J., Xue, J., Mazhar, D., Khoo, V., McPhail, N., Jones, R. J. (2025) UK real world data of Radium-223-dichloride in metastatic prostate cancer. Nuclear Medicine Communications, 46, pp. 1155-1162. (doi: 10.1097/MNM.0000000000002050)

Raven, A. et al. (2025) Hepatic zonation determines tumorigenic potential of mutant β-catenin. Nature, (doi: 10.1038/s41586-025-09733-1)

Malik, A. K., Geh, D., Evans, T. R. J., Chow, P. K.H., Mann, D. A., White, S. A. (2025) Improving surgical treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, (doi: 10.1038/s41575-025-01143-y)

Bilsland, A. E., Degerman, S., Landfors, M., Wadsley, J., Wall, L., Thompson, C., Damyanova, I., Samuel, L., Petty, R., Jain, A., Lewsley, L.-A., MacMillan, A., MacLeod, M., Walker, J., McCormick, C., McCartney, E., Roxburgh, P., Stobo, J., Thomson, F., Evans, T.R. J., Keith, W. N. (2025) Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma. British Journal of Cancer, (doi: 10.1038/s41416-025-03221-z)

Roche, J. J., Seyedshahi, F., Rakovic, K., Thu, A. W., Le Quesne, J., Blyth, K. G. (2025) Current and future applications of artificial intelligence in lung cancer and mesothelioma. Thorax, 80, pp. 957-965. (doi: 10.1136/thorax-2024-222054)

Christie-de Jong, F., Eberhardt, J., Oyeniyi, O. S., Ratcliffe, E., Kabuye, J., Kalemba, M., Nnyanzi, L. A., Murphy, M. K., Robb, K. A. (2025) A mixed-methods evaluation of a peer-led, co-produced, asset-based intervention for early diagnosis of prostate cancer for Black men: the PROCAN-B study. BMJ Open, 15, (doi: 10.1136/bmjopen-2025-105803)

Knox, J. J. et al. (2025) PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 43, pp. 3355-3368. (doi: 10.1200/JCO-25-00436)

Browne, I. M., Pascual, J., Cutts, R. J., Kingston, B., Hrebien, S., Kilburn, L. S., Pearson, A., Moretti, L., Wardley, A. M., MacPherson, I. R., Baird, R. D., Roylance, R., Gil-Gil, M. J., Guerrero-Zotano, A. L., Garcia-Murillas, I., Bliss, J. M., Ring, A., Martín, M., Turner, N. C. (2025) The prognostic and predictive impact of circulating tumour DNA levels in patients with advanced breast cancer enrolled on the plasmaMATCH trial. Clinical Cancer Research, (doi: 10.1158/1078-0432.CCR-24-0651)

Wyllie, J. M., Robb, K. A., O'Connor, R. C. (2025) Understanding the relationship between suicide-related stigma and suicidal thoughts through the lens of the Integrated Motivational-Volitional (IMV) model of suicide. BMC Psychiatry, 25, (doi: 10.1186/s12888-025-07449-0)

Bone, M., Inman, G. J. (2025) Alternative transcription increases isoform complexity in Long Non-Coding RNAs and alters their functions in cancer. Non-coding RNA Research, 14, pp. 38-50. (doi: 10.1016/j.ncrna.2025.04.008)

Bennett, S., Robb, K. A., Adán, R., Zortea, T., O'Connor, R. C. (2025) Exploring childhood challenges and male suicide risk: findings from a global survey. Journal of Men's Studies, 33, pp. 549-574. (doi: 10.1177/10608265251329358)

Hussain, S., Carr, A., Crabb, S. J., Dodhia, V., Fearfield, L., Malik, J. M., Lapuente, M., Lau, D., Petruskin, H., Sarwar, N., Smith, N. J., Stevenson, R., Jones, R. (2025) UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma. Oncologist, 30, (doi: 10.1093/oncolo/oyaf220)

Dobbin, S. J. H., Mangion, K., Berry, C., Roditi, G., Basak, S., McClure, J. D., Brooksbank, K., Sonecki, P., Sourbron, S., Evans, J., White, J., Welsh, P., Butler, E., Venugopal, B., Touyz, R. M., Jones, R. J., Petrie, M. C., Lang, N. N. (2025) Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. Heart, 111, pp. 925-932. (doi: 10.1136/heartjnl-2024-325535)

Keith, N., Smykowski, A., Welisch, G., Mannarprayil, N., Emadi, A., De Smet, I., Chipole, B.’e., Yousafzai, Y., Thorne, J., van Teijlingen Bakker, N. (2025) Career Moments: Stories that Shape our Journeys. (doi: 10.17605/OSF.IO/VQNS2)

Wyllie, J.M., Robb, K.A., Belkadi, N., O'Connor, R.C. (2025) “I still think there’s like a huge stigma”: understanding suicide-related stigma among those with lived experiences. Death Studies, (doi: 10.1080/07481187.2025.2556106)

Bone, M., Schreyer, D., Treanor-Taylor, M., Proby, C., Harwood, C., Leigh, I. M., Bailey, P., Inman, G. (2025) The landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression. British Journal of Dermatology, 193, pp. 490-501. (doi: 10.1093/bjd/ljaf108)

Whyte, D. et al. (2025) Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes. EMBO Reports, 26, pp. 4248-4282. (doi: 10.1038/s44319-025-00520-7)

Parker, C. T.A. et al. (2025) External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol. Lancet Digital Health, 7, (doi: 10.1016/j.landig.2025.100885)

Gounis, M., Campos, A. V., Shokry, E., Mitchell, L., Deshmukh, R., Dornier, E., Rooney, N., Dhayade, S., Pardo, L., Moore, M., Novo, D., Mowat, J., Jamieson, C., Kay, E., Zanivan, S., Paul, N. R., Mitchell, C., Nixon, C., MacPherson, I., Tardito, S., Sumpton, D., Blyth, K., Norman, J. C., Clarke, C. (2025) Metabolic adaptations of micrometastases alter EV production to generate invasive microenvironments. Journal of Cell Biology, 224, (doi: 10.1083/jcb.202405061)

Tate, M. et al. (2025) Clinical effectiveness, safety and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomised, phase III trial. Antimicrobial Agents and Chemotherapy, 69, (doi: 10.1128/aac.00054-25)

Herbert, K. J., Upstill-Goddard, R., Dreyer, S. B., Rebus, S., Pilarsky, C., Debabrata, M., Lord, C. J., Biankin, A. V., Froeling, F. E.M., Chang, D. K. (2025) Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. British Journal of Cancer, 133, pp. 381-393. (doi: 10.1038/s41416-025-03051-z)

Keith, N. et al. (2025) Reciprocal Systems of Health in the Climate Era: Personal, Public & Planetary Health. (doi: 10.17605/OSF.IO/UHR94)

Jones, R., Wu, O., Love, S., Chakera, A., Dragojlovic-Oliveira, S., Goulao, B., Boinard, E., Taggart, D., Lowe, D., Mcmeekin, N., MacLeod, L., Laurie, E., Swensson, A., Keith, N. (2025) Driving the Carbon Economy through Healthcare. (doi: 10.17605/OSF.IO/DHACN)

Christie-de Jong, F., Oyeniyi, O. S., Nnyanzi, L. A., Ling, J., Murphy, M. K., Eberhardt, J., Jarrar, R., Kabuye, J., Kalemba, M., Robb, K. A. (2025) Barriers and facilitators to accessing healthcare for early diagnosis of prostate cancer for black men—a qualitative exploration in North-East England and Scotland. BMC Public Health, 25, (doi: 10.1186/s12889-025-23650-y)

Pea, A. et al. (2025) Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization. Journal of Pathology, 266, pp. 421-434. (doi: 10.1002/path.6437)

Inanc, B., Fang, Q., Roos, W. P., Andrews, J. F., Zeng, X., Clark, J., Li, J., Dey, N. B., Ibrahim, M., Sykora, P., Yu, Z., Pearson, C. R., Braganza, A., Verheij, M., Jonkers, J., Yates, N. A., Vens, C., Sobol, R. W. (2025) TRIP12's role in the governance of DNA polymerase β involvement in DNA damage response and repair. Nucleic Acids Research, 53, (doi: 10.1093/nar/gkaf574)

Saeed, R., McSorley, S., Cascales, A., McMillan, D. (2025) The prognostic/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer, 25, (doi: 10.1186/s12885-025-13822-9)

Dreyer, S. B., Beer, P., Hingorani, S. R., Biankin, A. (2025) Improving outcomes of patients with pancreatic cancer. Nature Reviews Clinical Oncology, 22, pp. 439-456. (doi: 10.1038/s41571-025-01019-9)

Hurley, R., Paterson, C., Conway, D. I., Inman, G. J., Douglas, C. M. (2025) Laryngeal cancer in the West of Scotland 2014–2020: trends and survival in a cohort of 867 patients. Laryngoscope, 135, pp. 2051-2061. (doi: 10.1002/lary.31992)

Rovers, S., Farahmand, P., Liu, D., Brants, L., Hermans, C., Peeters, D., McKinven, D., Doig, J., Lardon, F., van Meerbeeck, J., Marcq, E., Murphy, D. J., Smits, E. (2025) A minimally invasive transthoracic injection technique for reproducible intrapleural delivery in mice. Methods and Protocols, 8, (doi: 10.3390/mps8030055)

Pusztai, L., Sondak, V. K., Aguiar-Ibáñez, R., Cappuzzo, F., Chouaid, C., Elder, C., Hirasawa, Y., Ishida, M., Jones, R., Lee, S. H., Mizuno, R., Nagata, M., Okonji, D., Parente, P., Shah, B., Sun, A., Ferreira, D., Spiteri, C., Lauer, A., Kaliasethi, A., Kao, C., Kothari, S., McKendrick, J. (2025) Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study. Journal for ImmunoTherapy of Cancer, 13, (doi: 10.1136/jitc-2024-011184)

Elyan, B. M.P., Tan, B., Lambourg, E., McAllister, D. A., Jones, R. J., Lang, N. N., Mark, P. B., Lees, J. S., Bell, S. (2025) Incidence of cancer in people with CKD not requiring kidney replacement therapy: a systematic review and meta-analysis. Clinical Kidney Journal, 18, (doi: 10.1093/ckj/sfaf084)

Dehghani, P., Salehirozveh, M., Tajabadi, A., Yeung, C. C., Lam, M., Leung, H. Y., Roy, V. A.L. (2025) Next-gen point-of-care tool for ultra-sensitive detection of urinary spermine for prostate cancer diagnosis. ACS Sensors, 10, pp. 2640-2651. (doi: 10.1021/acssensors.4c03250)

Hartley, A., Galbraith, L. C.A., Shaw, R., Tibbo, A., Veeratterapillay, R., Wilson, L., Heer, R., Blyth, K., Leung, H., Ahmad, I. (2025) Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos. British Journal of Cancer, 132, pp. 502-512. (doi: 10.1038/s41416-025-02944-3)

Hurley, R., Osbourne, J., Inman, G. J., Conway, D. I., Paterson, C., Douglas, C. (2025) Pre-treatment serum prognostic scores and survival in curatively treated laryngeal cancer. Laryngoscope Investigative Otolaryngology, 10, (doi: 10.1002/lio2.70124)

Mathews, C., Nauman, A., Johnstone, M., Stoops, R., Tham, A., Parsons, E. C., Robb, K. A., Sloan, W., Lynch, G., Edwards, J., McSorley, S. T. (2025) Retrospective cohort study: scope for improvement - barriers to post-polypectomy surveillance in the integrated technologies for improved polyp surveillance cohort. Alimentary Pharmacology and Therapeutics, 61, pp. 1381-1386. (doi: 10.1111/apt.18514)

Omar, R., Lee, M. A.W., Gonzalez-Trueba, L., Thomson, C. R., Hansen, U., Lianos, S., Hazarika, S., El Abdallah, O., Ammar, M. A., Cassels, J., Michie, A. M., Bulleid, N. J., Malfait, F., Van Agtmael, T. (2025) The chemical chaperone 4-phenylbutyric acid rescues molecular cell defects of COL3A1 mutations that cause vascular Ehlers Danlos Syndrome. Cell Death Discovery, 11, (doi: 10.1038/s41420-025-02476-y)

Robb, K. A., Young, B., Murphy, M. K., Duklas, P., McConnachie, A., Hollands, G. J., Mccowan, C., Macdonald, S., O'Carroll, R. E., O'Connor, R. C., Steele, R. J. C. (2025) Behavioural interventions to increase uptake of FIT colorectal screening in Scotland (TEMPO): a nationwide, eight-arm, factorial, randomised controlled trial. Lancet, 405, pp. 1081-1092. (doi: 10.1016/S0140-6736(24)02813-7)

Floor, C.-d. J., Jarrar, R., Padela, A., Sadiq, C., Haider, F., Kotzur, M., McConnachie, A., Pepler, T., Amiri, R., Robb, K. A. (2025) Improving Muslim Women's Uptake of Breast, Colorectal and Cervical Cancer Screening: Insights from a non-randomised study of a peer-led, faith-based intervention in North East England and Scotland.

Müller, M. et al. (2025) Human-correlated genetic models identify precision therapy for liver cancer. Nature, 639, pp. 754-764. (doi: 10.1038/s41586-025-08585-z)

Biesma, N.C., Graus, M.U.J.E., Cirkel, G.A., Besselink, M.G., de Groot, J.W.B., Groot Koerkamp, B., Herbschleb, K.H., Los, M., Verdonk, R.C., Wilmink, J.W., Cervantes, A., Valle, J.W., Valkenburg-van Iersel, L.B.J., Froeling, F.E.M., Molenaar, I.Q., Daamen, L.A., de Vos-Geelen, J., van Santvoort, H.C., Dutch Pancreatic Cancer Group, (2025) Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. European Journal of Surgical Oncology, 51, (doi: 10.1016/j.ejso.2024.109544)

Wyllie, J. M., Robb, K. A., Sandford, D., Etherson, M. E., Belkadi, N., O'Connor, R. C. (2025) Suicide-related stigma and its relationship with help-seeking, mental health, suicidality and grief: a scoping review. BJPsych Open, 11, (doi: 10.1192/bjo.2024.857)

White, S. E., Schwartze, T. A., Mukundan, A., Schoenherr, C., Singh, S. P., van Dinther, M., Cunningham, K. T., White, M. P. J., Campion, T., Pritchard, J., Hinck, C. S., ten Dijke, P., Inman, G. J., Maizels, R. M., Hinck, A. P. (2025) TGM6 is a helminth secretory product that mimics TGF-β binding to TGFBR2 to antagonize signaling in fibroblasts. Nature Communications, 16, (doi: 10.1038/s41467-025-56954-z)

van Duuren, P., Wieringa, T. H., Duiverman, M., Witjes, M., Snijder, A., Welisch, G., Smykowski, A., Keith, N. (2025) Reimagining Patient Involvement in Research. (doi: 10.17605/OSF.IO/5H9DY)

Dolan, R. D., Pennel, K., Thompson, J., McKenzie, M., Alexander, P., Richards, C., Black, D., Abbass, T., Maka, N., McGovern, J., Roseweir, A., McSorley, S. T., Horgan, P. G., Roxburgh, C., McMillan, D. C., Edwards, J. (2025) The relationship between tumour necrosis, systemic inflammation, body composition and survival in patients with colon cancer. BJC Reports, 3, (doi: 10.1038/s44276-024-00119-w)

Iwata, T., Ammar, A., Maka, N., Jawny, J., Hay, J., Martinelli, S., Officer-Jones, L., Le Quesne, J., Lynch, G., McSorley, S., Edwards, J. (2025) Does Immune Suppression in the Pre-malignant Microenvironment of Colorectal Neoplastic Lesions Associate with Development of Metachronous Polyp and Cancer Risk?

Kocher, H. M., Ackermann, C., Priyadarshini, G., Lawrence, C., Kotriwala, N., Georgescu, R., Roberts, R., Hughes, C., Imrali, A., Chelala, C., Dixon-Hughes, J., Chang, D. K., Sasieni, P., Corrie, P., McNamara, M. G., Sarker, D., Froeling, F. E.M., Christie, A., Gillmore, R., Khan, K., Propper, D. (2025) Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. BMC Cancer, 25, (doi: 10.1186/s12885-024-13333-z)

Singh, S. P., Smyth, D. J., Cunningham, K. T., Mukundan, A., Byeon, C.-H., Hinck, C. S., White, M. P.J., Ciancia, C., Wąsowska, N., Sanders, A., Jin, R., White, R. F., Lilla, S., Zanivan, S., Schoenherr, C., Inman, G., van Dinther, M., ten Dijke, P., Hinck, A. P., Maizels, R. M. (2025) The TGF-β mimic TGM4 achieves cell specificity through combinatorial surface co-receptor binding. EMBO Reports, 26, pp. 218-244. (doi: 10.1038/s44319-024-00323-2)

Ibrahim, I., Kouli, O., Ilangovan, S., Sneddon, M., Nalagatla, S., Marshall, C., Dutto, L., Leung, H. Y., Ahmad, I. (2025) Impact of centralisation of radical prostatectomy driven by the introduction of robotic systems on positive surgical margin and biochemical recurrence in pT2 prostate cancer. Cancer Medicine, 14, (doi: 10.1002/cam4.70514)

Estcourt, L. J. et al. (2025) Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. Lancet Haematology, 12, pp. e14-e22. (doi: 10.1016/S2352-3026(24)00317-X)

Seyedshahi, F., Rakovic, K., Poulain, N., Claudio Quiros, A., Powley, I. R., Richards, C., Uraiby, H., Klebe, S., Moore, D. A., Nakas, A., Wilson, C. R., Sereno, M., Officer-Jones, L., Ficken, C., Teodosio, A., Ballantyne, F., Murphy, D., Yuan, K., Le Quesne, J. (2025) A histomorphological atlas of resected mesothelioma discovered by self-supervised learning from 3446 whole-slide images. Nature Communications, 16, (doi: 10.1038/s41467-025-63846-9)

Omar, R., Lee, M. A.W., Gonzalez-Trueba, L., Thomson, C. R., Hansen, U., Lianos, S., Hazarika, S., El Abdallah, O. H., Ammar, M. A., Cassels, J., Michie, A. M., Bulleid, N. J., Malfait, F., Van Agtmael, T. (2025) Correction: The chemical chaperone 4-phenylbutyric acid rescues molecular cell defects of COL3A1 mutations that cause vascular Ehlers Danlos Syndrome. Cell Death Discovery, 11, (doi: 10.1038/s41420-025-02529-2)

Ingham, A. R., McSorley, S. T., McMillan, D. C., Chong, D., Mackay, G. J., Wrobel, A., Kong, C. Y., Alani, A., Nicholson, G., Roxburgh, C. S.D. (2025) Does robotic assisted surgery mitigate obesity related systemic inflammatory response and clinical outcomes in left sided colorectal cancer resections? Journal of Robotic Surgery, 19, (doi: 10.1007/s11701-025-02261-0)

Liu, D., Young, F., Lamb, K., Claudio Quiros, A., Pancheva, A., Miller, C., Macdonald, C., Robertson, D. L., Yuan, K. (2025) PLM-interact: extending protein language models to predict protein-protein interactions. Nature Communications, 16, (doi: 10.1038/s41467-025-64512-w)

Christie-de Jong, F., Eberhardt, J., Ling, J., Kotzur, M., Oyeniyi, O. S., Nnyanzi, L., Kabuye, J., Kalemba, M., Robb, K. A. (2024) The PROCAN-B Study Protocol: Early diagnosis of PROstate CANcer for Black men - a community-centred participatory approach in Scotland and the North-East of England. PLoS ONE, 19, (doi: 10.1371/journal.pone.0315288)

Allan, S., Sinclair, F., Correia, M., FRAGKANDREA-NIXON, I., Phiri, A., Jones, G., Thomson, D., Yanga, F., Brown, G., McCann, M., Simpson, S., Evans, J., Robb, K., Gumley, A. (2024) Co-designing a low-intensity psychological therapy for fear of recurrence in psychosis using translational learning from fear of recurrence in oncology: protocol for intervention development for future testing in a feasibility study. BMJ Open, 14, (doi: 10.1136/bmjopen-2024-090566)

Seyedshahi, F., Rakovic, K., Poulain, N., Claudio Quiros, A., Powley, I. R., Richards, C., Uraiby, H., Klebe, S., Nakas, A., Wilson, C., Sereno, M., Officer-Jones, L., Ficken, C., Teodosio, A., Ballantyne, F., Murphy, D., Yuan, K., Le Quesne, J. (2024) A histomorphological atlas of resected mesothelioma discovered by self-supervised learning from 3446 whole-slide images. bioRxiv, (doi: 10.1101/2024.11.18.624103)

Maldonado, H., Dreger, M., Bedgood, L. D., Kyriakou, T., Wolanska, K. I., Rigby, M. E., Marotta, V. E., Webster, J. M., Wang, J., Rusilowicz-Jones, E. V., Marshall, J. F., Coulson, J. M., MacPherson, I. R., Hurlstone, A., Morgan, M. R. (2024) A trafficking regulatory subnetwork governs α V β 6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance. Science Advances, 10, (doi: 10.1126/sciadv.adk9944)

Aldadi, A. H. M., Robb, K. A., Williamson, A. (2024) Factors influencing multiple non-utilized healthcare appointments from patients’ and healthcare providers’ perspectives: a qualitative systematic review of the global literature. BMJ Open, 8, (doi: 10.3399/BJGPO.2024.0075)

Kiourtis, C. et al. (2024) Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ. Nature Cell Biology, 26, pp. 2075-2083. (doi: 10.1038/s41556-024-01543-3)

Liu, D., Young, F., Lamb, K. D., Claudio Quiros, A., Pancheva, A., Miller, C., Macdonald, C., Robertson, D. L., Yuan, K. (2024) PLM-interact: extending protein language models to predict protein-protein interactions. bioRxiv, (doi: 10.1101/2024.11.05.622169)

Xavier, V., Martinelli, S., Corbyn, R., Pennie, R., Rakovic, K., Powley, I. R., Officer-Jones, L., Ruscica, V., Galloway, A., Carlin, L. M., Cowling, V. H., Le Quesne, J., Martinou, J.-C., MacVicar, T. (2024) Mitochondrial double-stranded RNA homeostasis depends on cell-cycle progression. Life Science Alliance, 7, (doi: 10.26508/lsa.202402764)

Skalka, G. L., Whyte, D., Lubawska, D., Murphy, D. J. (2024) NUAK: never underestimate a kinase. Essays In Biochemistry, 68, pp. 295-307. (doi: 10.1042/EBC20240005)

McGuigan, M.-C., Hadjicosti, R., Cameron, A. J., Coats, M., Chang, D., Dickson, E. J., Holroyd, D., McKay, C. J., Jamieson, N. B. (2024) The surveillance strategy for Intraductal Pancreatic Mucinous Neoplasms: Criteria for discontinuation. Annals of Surgery, (doi: 10.1097/SLA.0000000000006580)

Sahni, D. S., Morrison, J., Leung, H. Y. (2024) Grid-based cognitive diagnostic prostatic biopsies without transrectal ultrasound imaging. BJU International, 134, pp. 659-663. (doi: 10.1111/bju.16396)

Smith, C. D.L., McMahon, A. D., Purkayastha, M., Creaney, G., Clements, K., Inman, G. J., Bhatti, L. A., Douglas, C. M., Paterson, C., Conway, D. I. (2024) Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: a population epidemiological study (2001-2020) BJC Reports, 2, (doi: 10.1038/s44276-024-00089-z)

Innes, A. I. et al. (2024) Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leukemia, 38, pp. 2443-2455. (doi: 10.1038/s41375-024-02411-7)

Strathearn, L. S., Spender, L. C., Schoenherr, C., Mason, S., Edwards, R., Blyth, K., Inman, G. (2024) C1orf106 (INAVA) is a SMAD3-dependent TGF-β target gene that promotes clonogenicity and correlates with poor prognosis in breast cancer. Cells, 13, (doi: 10.3390/cells13181530)

Smith, C. D.L., McMahon, A. D., Lyall, D. M., Goulart, M., Inman, G., Ross, A., Gormley, M., Dudding, T., Macfarlane, G. J., Robinson, M., Richiardi, L., Serraino, D., Polesel, J., Canova, C., Ahrens, W., Healy, C. M., Lagiou, P., Holcatova, I., Alemany, L., Znoar, A., Waterboer, T., Brennan, P., Virani, S., Conway, D. I. (2024) Development and external validation of a head and neck cancer risk prediction model. Head and Neck, 46, pp. 2261-2273. (doi: 10.1002/hed.27834)

Patterson, S. D., Massett, M. E., Huang, X., Jørgensen, H. G., Michie, A. M. (2024) The MYC–NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells. Molecular Oncology, 18, pp. 2234-2254. (doi: 10.1002/1878-0261.13630)

Ward, L. M., Cooper, S.-A., Sosenko, F., Morrison, D., Fleming, M., McCowan, C., Robb, K., Hanna, C. R., Hughes-McCormack, L., Dunn, K., Conway, D., Henderson, A., Smith, G., Truesdale, M., Cairns, D. (2024) Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland: a retrospective cohort study with record linkage. BMJ Open, 14, (doi: 10.1136/bmjopen-2024-084421)

Elyan, B. M.P., Sullivan, M. K., Hedley, J., De La Mata, N., Webster, A. C., Venugopal, B., Jones, R. J., Lang, N. N., Mark, P. B., Lees, J. S. (2024) The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis. BJC Reports, 2, (doi: 10.1038/s44276-024-00081-7)

Mon, H. M., Robb, K. A., Demou, E. (2024) Effectiveness of workplace cancer screening interventions: a systematic review. BMC Cancer, 24, (doi: 10.1186/s12885-024-12649-0)

Pea, A., He, X., Upstill-Goddard, R., Luchini, C., Schubert Santana, L. P., Dreyer, S., Duthie, F., Jamieson, N. B., McKay, C. J., Dickson, E. J., Pulvirenti, A., Rebus, S., Innovation Alliance, G., Genome Partnership, S., Piccoli, P., Sperandio, N., Lawlor, R. T., Milella, M., Froeling, F. E.M., Salvia, R., Scarpa, A., Bainkin, A. V., Wedge, D. C., Chang, D. K. (2024) Clonal evolutionary analysis reveals patterns of malignant transformation in pancreatic cancer from Intraductal Papillary Mucinous IPMN Neoplasms (IPMN) bioRxiv, (doi: 10.1101/2024.08.02.606217)

Wiesheu, R. et al. (2024) IL-27 maintains cytotoxic Ly6C+ T cells that arise from immature precursors. EMBO Journal, 43, pp. 2878-2907. (doi: 10.1038/s44318-024-00133-1)

Donnelly, H., Ross, E., Xiao, Y., Hermantara, R., Taqi, A., Doherty-Boyd, W. S., Cassels, J., Tsimbouri, P. M., Dunne, K. M., Hay, J., Cheng, A., Meek, R.M. D., Jain, N., West, C., Wheadon, H., Michie, A. M., Peault, B., West, A. G., Salmeron-Sanchez, M., Dalby, M. J. (2024) Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells. Nature Communications, 15, (doi: 10.1038/s41467-024-50054-0)

Keith, N. et al. (2024) Emerging Ecologies of Health, Heritage, and Habitat: Looking into Living and Working in 2033. (doi: 10.17605/OSF.IO/BTNZ9)

Frankell, A. M. et al. (2024) Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 631, (doi: 10.1038/s41586-024-07738-w)

Pereira, B. A. et al. (2024) Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Science Advances, 10, (doi: 10.1126/sciadv.adl1197)

Vincelette, N. D. et al. (2024) Trisomy 8 defines a distinct subtype of myeloproliferative neoplasms driven by the MYC-alarmin axis. Blood Cancer Discovery, 5, pp. 276-297. (doi: 10.1158/2643-3230.BCD-23-0210)

Hanna, D. et al. (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130, pp. 1916-1920. (doi: 10.1038/s41416-024-02685-9)

Khalaf, A., de Beauchamp, L., Kalkman, E., Rattigan, K., Himonas, E., Jones, J., James, D., Shokry, E. S. A., Scott, M. T., Dunn, K., Tardito, S., Copland, M., Sumpton, D., Shanks, E., Helgason, V. (2024) Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia. Science Translational Medicine, 16, (doi: 10.1126/scitranslmed.adi5336)

Quiros, A. C., Coudray, N., Yeaton, A., Yang, X., Liu, B., Le, H., Chiriboga, L., Karimkhan, A., Narula, N., Moore, D. A., Park, C. Y., Pass, H., Moreira, A. L., Le Quesne, J., Tsirigos, A., Yuan, K. (2024) Mapping the landscape of histomorphological cancer phenotypes using self-supervised learning on unannotated pathology slides. Nature Communications, 15, (doi: 10.1038/s41467-024-48666-7)

Shiu, K.-K., Jiang, Y., Saunders, M., Seligmann, J. F., Iveson, T., Wilson, R. H., Graham, J. S., Khan, K. H., Militello, A.-M., Irvine, S., Adedoyin, T., Begum, R., Bhat, R., Wilson, W., Plumb, A., Obichere, A., Rodriguez-Justo, M., Jansen, M. (2024) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. (doi: 10.1200/jco.2024.42.17_suppl.lba3504)

Malla, S. B. et al. (2024) Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer. Nature Genetics, 56, (doi: 10.1038/s41588-024-01809-4)

Agnew, S., Crawford, M., MacPherson, I., Shiramizu, V., Fleming, L. (2024) The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer. Breast, 75, (doi: 10.1016/j.breast.2024.103731)

Boey, A., Bryce, A., Dickson, E., Coats, M., McKay, C., Jamieson, N., Chang, D., Holroyd, D., Dreyer, S. (2024) The Impact of Pre-operative Indeterminate Lung Nodules in the Surgical Management of Pancreatic Ductal Adenocarcinoma. (doi: 10.1016/j.hpb.2024.03.269)

Rescigno, P. et al. (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205, (doi: 10.1016/j.ejca.2024.114103)

Birtle, A. J., Jones, R., Chester, J., Lewis, R., Biscombe, K., Johnson, M., Blacker, A., Bryan, R., Catto, J. W.F., Choudhury, A., Das, P., Jagdev, S., Powles, T., Wagstaff, J., Cheung, K. C., Cafferty, F., Hall, E. (2024) Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: Final results of the POUT trial. Journal of Clinical Oncology, 42, pp. 466-1471. (doi: 10.1200/jco.23.01659)

Bennett, S., Robb, K. A., O'Connor, R. C. (2024) Male suicide and barriers to accessing professional support: a qualitative thematic analysis. Current Psychology, 43, pp. 15125-15145. (doi: 10.1007/s12144-023-05423-1)

Keith, N., Ross, K., Campbell, H., McCrum, P., Uribe, V., Rowan, F. (2024) Designing Future Experiences: The value of exhibition spaces as creative environments for collaborative, multidisciplinary research, exhibitions, and audiences. (doi: 10.17605/OSF.IO/N7MD9)

Vens, C., van Luijk, P., Vogelius, R.I., El Naqa, I., Humbert-Vidan, L., von Neubeck, C., Gomez-Roman, N., Bahn, E., Brualla, L., Böhlen, T.T., Ecker, S., Koch, R., Handeland, A., Pereira, S., Possenti, L., Rancati, T., Todor, D., Vanderstraeten, B., Van Heerden, M., Ullrich, W., Jackson, M., Alber, M., Marignol, L., ESTRO DREAM team, (2024) A joint physics and radiobiology DREAM team vision - towards better response prediction models to advance radiotherapy. Radiotherapy and Oncology, 196, (doi: 10.1016/j.radonc.2024.110277)

Cooke, S. F., Wright, T. A., Sin, Y. Y., Ling, J., Kyurkchieva, E., Phanthaphol, N., McSkimming, T., Herbert, K., Rebus, S., Biankin, A. V., Chang, D. K., Baillie, G. S., Blair, C. M. (2024) Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC. Scientific Reports, 14, (doi: 10.1038/s41598-024-59451-3)

Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B., Lees, J. S., Petrie, M. C., Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6, pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010)

Glen, C., Morrow, A., Roditi, G., Hopkins, T., Macpherson, I., Stewart, P., Petrie, M. C., Berry, C., Epstein, F., Lang, N. N., Mangion, K. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110, pp. 650-656. (doi: 10.1136/heartjnl-2023-323437)

Murphy, D. J. (2024) Investigating lung cancer using genetically engineered mouse models (GEMMS) Open Access Government, 42, pp. 112-113. (doi: 10.56367/oag-042-11090)

Brown, L. R., Thomson, G. G., Gardner, E., Chien, S., McGovern, J., Dolan, R. D., McSorley, S. T., Forshaw, M. J., McMillan, D. C., Wigmore, S. J., Crumley, A., Skipworth, R. J.E. (2024) Cachexia index for prognostication in surgical patients with locally advanced oesophageal or gastric cancer: multicentre cohort study. British Journal of Surgery, 111, (doi: 10.1093/bjs/znae098)

Ahmadian, M., Bodalal, Z., van der Hulst, H. J., Vens, C., Karssemakers, L. H.E., Bogveradze, N., Castagnoli, F., Landolfi, F., Hong, E. K., Gennaro, N., Pizzi, A. D., Beets-Tan, R. G.H., van den Brekel, M. W.M., Castelijns, J. A. (2024) Overcoming data scarcity in radiomics/radiogenomics using synthetic radiomic features. Computers in Biology and Medicine, 174, (doi: 10.1016/j.compbiomed.2024.108389)

Derby, S. et al. (2024) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis. Neuro-Oncology, 26, pp. 625-639. (doi: 10.1093/neuonc/noad210)

Ernst, M., Schwinn, T., Hirschmiller, J., Cleare, S., Robb, K. A., Brähler, E., Zwerenz, R., Wiltink, J., O'Connor, R. C., Beutel, M. E. (2024) To what extent are psychological variables considered in the study of risk and protective factors for suicidal thoughts and behaviours in individuals with cancer? A systematic review of 70 years of research. Clinical Psychology Review, 109, (doi: 10.1016/j.cpr.2024.102413)

Dehghani, P., Karthikeyan, V., Tajabadi, A., Assi, D. S., Catchpole, A., Wadsworth, J., Leung, H. Y., Roy, V. A.L. (2024) Rapid near-patient impedimetric sensing platform for prostate cancer diagnosis. ACS Omega, 9, pp. 14580-14591. (doi: 10.1021/acsomega.4c00843)

Ingham,, A. R., Kong, C. Y., Wong, T.-N., McSorley, S. T., McMillan, D. C., Nicholson, G. A., Alani, A., Mansouri, D., Chong, D., Mackay, G. J., Roxburgh, C. S.D. (2024) Robotic-assisted surgery for left sided colon and rectal resections is associated with reduction in the postoperative surgical stress response and improved short-term outcomes: a cohort study. Surgical Endoscopy, (doi: 10.1007/s00464-024-10749-3)

Dickson, A. L., Zickuhr, G. M., Um, I. H., Zhang, Y., Plummer, R., Blagden, S. P., Symeonides, S. N., Cook, N., Evans, T.R. J., Elshani, M., Harrison, D. J. (2024) Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy. (doi: 10.1158/1538-7445.am2024-6222)

Sacco, J. J., Jackson, R., Corrie, P., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J., Karydis, I., Steven, N., Lorigan, P., Plummer, R., Patel, P., Psarelli, E., Olsson-Brown, A., Shaw, H., Leyvraz, S., Handley, L., Rawcliffe, C., Nathan, P. (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202, (doi: 10.1016/j.ejca.2024.114009)

Zhang, S. et al. (2024) Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Cell Death Discovery, 10, (doi: 10.1038/s41420-024-01890-y)

Skeldon, K. et al. (2024) HACK the ARC - A Grassroots Improvement Initiative. (doi: 10.17605/OSF.IO/WSTZV)

Zarou, M. M., Rattigan, K. M., Sarnello, D., Shokry, E., Dawson, A., Ianniciello, A., Dunn, K., Copland, M., Sumpton, D., Vazquez, A., Helgason, V. (2024) Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1-mediated purine sensing. Nature Communications, 15, (doi: 10.1038/s41467-024-46114-0)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, (doi: 10.1186/s13046-024-02958-4)

Critchlow, S., Bullement, A., Crabb, S., Jones, R., Christoforou, K., Amin, A., Xiao, Y., Kapetanakis, V., Benedict, Á., Chang, J., Kearney, M., Eccleston, A. (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20, pp. 459-470. (doi: 10.2217/fon-2023-0372)

Scobie, H., Robb, K. A., Macdonald, S., Harrow, S., Sullivan, F. (2024) Optimising recruitment to a lung cancer screening trial: a comparison of general practitioner and community-based recruitment. Journal of Medical Screening, 31, pp. 46-52. (doi: 10.1177/09691413231190785)

Malla, S. B. et al. (2024) Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer. Nature Genetics, 56, pp. 458-472. (doi: 10.1038/s41588-024-01654-5)

Riviere, D., Aarntzen, E., van Geenen, E., Chang, D., de Geus-Oei, L.-F., Brosens, L., van Laarhoven, K., Gotthardt, M., Hermans, J. (2024) Qualitative flow metabolic phenotype of pancreatic cancer: a new prognostic biomarker? HPB, 26, pp. 389-399. (doi: 10.1016/j.hpb.2023.11.010)

Bryce, A., Dreyer, S., Dolan, R., Froeling, F., Chang, D. (2024) Host phenotypic adversity independently predicts progression to resection in neoadjuvantly-treated pancreatic cancer. (doi: 10.1016/j.ejso.2023.107753)

Dreyer, S., Bryce, A., Australian Pancreatic Cancer Genome Initiative, , Biankin, A., Jamieson, N., Chang, D. (2024) The clinical and molecular landscape of early onset pancreatic cancer. (doi: 10.1016/j.ejso.2023.107348)

Coakley, M., Villacampa, G., Sritharan, P., Swift, C., Dunne, K., Kilburn, L., Goddard, K., Pipinikas, C., Rojas, P., Emmett, W., Hall, P., Harper-Wynne, C., Hickish, T., MacPherson, I., Okines, A., Wardley, A., Wheatley, D., Waters, S., Palmieri, C., Winter, M., Cutts, R. J., Garcia-Murillas, I., Bliss, J., Turner, N. C. (2024) Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer. Clinical Cancer Research, 30, pp. 895-903. (doi: 10.1158/1078-0432.CCR-23-2326)

Cuypers, M., Cairns, D., Robb, K. (2024) Identifying the deficits in cancer care for people with intellectual disabilities. BMJ Oncology, 3, (doi: 10.1136/bmjonc-2023-000171)

Vringer, E., Heilig, R., Riley, J. S., Black, A., Cloix, C., Skalka, G., Montes-Gómez, A. E., Aguado, A., Lilla, S., Walczak, H., Gyrd-Hansen, M., Murphy, D. J., Huang, D. T., Zanivan, S., Tait, S. W.G. (2024) Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-κB-mediated inflammatory response. EMBO Journal, 43, pp. 904-930. (doi: 10.1038/s44318-024-00044-1)

Dawson, A. et al. (2024) Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nature Communications, 15, (doi: 10.1038/s41467-024-45471-0)

Kingston, B., Pearson, A., Herrera-Abreu, M. T., Sim, L.-X., Cutts, R. J., Shah, H., Moretti, L., Kilburn, L. S., Johnson, H., Macpherson, I. R., Ring, A., Bliss, J. M., Hou, Y., Toy, W., Katzenellenbogen, J. A., Chandarlapaty, S., Turner, N. C. (2024) ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer Discovery, 14, pp. 274-289. (doi: 10.1158/2159-8290.CD-22-1387)

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C.C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Healy, C. G., Di Santo, N., Laird, A. D., Zohren, F., Agarwal, N. (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30, (doi: 10.1038/s41591-024-02835-9)

Skalka, G. L., Tsakovska, M., Murphy, D. (2024) Kinase signaling adaptation supports dysfunctional mitochondria in disease. Frontiers in Molecular Biosciences, 11, (doi: 10.3389/fmolb.2024.1354682)

Scott, M. T., Liu, W., Mitchell, R., Clarke, C. J., Kinstrie, R., Warren, F., Almasoudi, H., Stevens, T., Dunn, K., Pritchard, J., Drotar, M. E., Michie, A. M., Jorgensen, H. G., Higgins, B., Copland, M., Vetrie, D. (2024) Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nature Communications, 15, (doi: 10.1038/s41467-024-44771-9)

Welisch, G., Keith, N., Jones, R., Hanna, C. (2024) Creative approaches to reimagining patient and public involvement (PPI) in cancer research. (doi: 10.17605/OSF.IO/243XN)

Ward, L.A., Cooper, S.-A., Sosenko, F., Morrison, D., Fleming, M., McCowan, C., Robb, K., Hanna, C., Hughes-McCormack, L., Dunn, K., Conway, D., Henderson, A., Smith, G., Truesdale, M., Cairns, D. (2024) Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland. medRxiv, (doi: 10.1101/2024.01.18.23300433)

Johnstone, M. S., McSorley, S. T., McMillan, D. C., Horgan, P. G., Mansouri, D. (2024) The relationship between systemic inflammatory response, screen detection and outcome in colorectal cancer. Colorectal Disease, 26, pp. 81-94. (doi: 10.1111/codi.16824)

Keith, N., Donaldson, M. (2024) Professional and Technical Staff supporting Open Research: Case Study 4. Research-enabling staff and Open Research.

Skeldon, K. et al. (2023) Research Firsts Exhibition. (doi: 10.17605/OSF.IO/ZQC5P)

Wang, J., Harwood, C. A., Bailey, E., Bewicke-Copley, F., Anene, C. A., Thomson, J., Qamar, M. J., Laban, R., Nourse, C., Schoenherr, C., Treanor-Taylor, M., Healy, E., Lai, C., Craig, P., Moyes, C., Rickaby, W., Martin, J., Proby, C., Inman, G. J., Leigh, I. M. (2023) Transcriptomic analysis of cutaneous squamous cell carcinoma reveals a multigene prognostic signature associated with metastasis. Journal of the American Academy of Dermatology, 89, pp. 1159-1166. (doi: 10.1016/j.jaad.2023.08.012)

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Healy, C. G., Di Santo, N., Laird, A. D., Zohren, F., Agarwal, N. (2023) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nature Medicine, 30, pp. 257-264. (doi: 10.1038/s41591-023-02704-x)

Ring, A., Kilburn, L. S., Pearson, A., Moretti, L., Afshari-Mehr, A., Wardley, A. M., Gurel, B., MacPherson, I. R., Riisnaes, R., Baird, R. D., Martin, S., Roylance, R., Johnson, H., Ferreira, A., Winter, M. C., Dunne, K., Copson, E., Hickish, T., Burcombe, R., Randle, K., Serra, V., Llop-Guevara, A., Bliss, J. M., Turner, N. C. (2023) Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010) Clinical Cancer Research, 29, pp. 4751-4759. (doi: 10.1158/1078-0432.CCR-23-1696)

Malik, N., Hay, J., Almuhanna, H. N.B., Dunn, K. M., Lees, J., Cassels, J., Li, J., Nakagawa, R., Sansom, O. J., Michie, A. M. (2023) mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia, 37, pp. 2414-2425. (doi: 10.1038/s41375-023-02043-3)

Henriksen, P. A. et al. (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE trial. Circulation, 148, pp. 1680-1690. (doi: 10.1161/CIRCULATIONAHA.123.064274)

McLaren, A. S., Spoor, J. A., Cartwright, D., Naylor, G., Barclay, S., Priest, M., Puttagunta, S., Armstrong, K., Ballantyne, S., Stanley, A., Evans, T. R. J., West of Scotland HCC MDT, (2023) Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the west of Scotland: a cohort study. BMJ Open Gastroenterology, 10, (doi: 10.1136/bmjgast-2023-001231)

Chrisochoidou, Y., Roy, R., Farahmand, P., Gonzalez, G., Doig, J., Krasny, L., Rimmer, E. F., Willis, A. E., MacFarlane, M., Huang, P. H., Carragher, N. O., Munro, A. F., Murphy, D. J., Veselkov, K., Seckl, M. J., Moffatt, M. F., Cookson, W. O. C., Pardo, O. E. (2023) Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells. Cell Death and Disease, 14, (doi: 10.1038/s41419-023-06240-x)

Zarou, M. M., Dawson, A., Prasad, B., Bittencourt-Silvestre, J., Zerbst, D., Rodriguez Blanco, G., Scott, M., Dunn, K., Krishnan, V., Copland, M., Vetrie, D., Bhatia, R., Coffelt, S., Ong, S. T., Wheadon, H., Zanivan, S., Kirschner, K., Helgason, G. V. (2023) Leukaemia Exposure Alters the Transcriptional Profile and Function of Macrophages in the Bone Marrow Niche. (doi: 10.1182/blood-2023-181630)

Taggart, R., Dutto, L., Leung, H. Y., Salji, M., Ahmad, I. (2023) A contemporary analysis of disease upstaging of Gleason 3+3 prostate cancer patients after Robot-Assisted Laparoscopic Prostatectomy (RALP) Cancer Medicine, 12, pp. 20830-20837. (doi: 10.1002/cam4.6651)

Conroy, S., Catto, J. W.F., Bex, A., Brown, J. E., Cartledge, J., Fielding, A., Jones, R. J., Khoo, V., Nicol, D., Stewart, G. D., Sullivan, M., Tran, M. G.B., Woodward, R., Cumberbatch, M. G. (2023) Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019. BJU International, 132, pp. 541-553. (doi: 10.1111/bju.16128)

Bergamini, A., Ramaswami, R., Froeling, F., Papanastasopoulos, P., Short, D., Aguiar, X., Savage, P. M., Sarwar, N., Kaur, B., Saso, S., Fotopoulou, C., Sharma, A., Rustin, G. J. S., Seckl, M. (2023) Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study. International Journal of Gynecological Cancer, 33, pp. 1750-1756. (doi: 10.1136/ijgc-2023-004699)

Rattigan, K. M., Zarou, M. M., Brabcova, Z., Prasad, B., Zerbst, D., Sarnello, D., Kalkman, E. R., Ianniciello, A., Scott, M. T., Dunn, K., Shokry, E., Sumpton, D., Copland, M., Tardito, S., Vande Voorde, J., Mussai, F., Cheng, P., Helgason, G. V. (2023) Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Reports, 24, (doi: 10.15252/embr.202256279)

Johnstone, M. S., McSorley, S. T., McMahon, A. J. (2023) Management of malignant T1 colorectal cancer polyps: results from a 10-year prospective observational study. Colorectal Disease, 25, pp. 1960-1972. (doi: 10.1111/codi.16716)

Van der Hulst, H. J., Jansen, R. W., Vens, C., Bos, P., Schats, W., De Jong, M. C., Martens, R. M., Bodalal, Z., Beets-Tan, R. G. H., Van den Brekel, M. W. M., De Graaf, P., Castelijns, J. A. (2023) The prediction of biological features using magnetic resonance imaging in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Cancers, 15, (doi: 10.3390/cancers15205077)

Palmieri, C., Musson, A., Harper-Wynne, C., Wheatley, D., Bertelli, G., Macpherson, I. R., Nathan, M., McDowall, E., Bhojwani, A., Verrill, M., Eva, J., Doody, C., Chowdhury, R. (2023) A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. British Journal of Cancer, 129, pp. 852-860. (doi: 10.1038/s41416-023-02352-5)

Bennett, S., Robb, K. A., Andoh-Arthur, J., Chandler, A., Cleary, A., King, K., Oliffe, J., Rice, S., Scourfield, J., Seager, M., Seidler, Z., Zortea, T. C., O'Connor, R. C. (2023) Establishing research priorities for investigating male suicide risk and recovery: a modified Delphi Study with lived experience experts. Psychology of Men and Masculinities, (doi: 10.1037/men0000448)

Nikolatou, K., Sandilands, E., Román-Fernández, A., Cumming, E. M., Freckmann, E., Lilla, S., Buetow, L., McGarry, L., Neilson, M., Shaw, R., Strachan, D., Miller, C., Huang, D. T., Mcneish, I. A., Norman, J. C., Zanivan, S., Bryant, D. M. (2023) PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer. EMBO Journal, 42, (doi: 10.15252/embj.2023113987)

Bailey, P., Ridgway, R. L., Cammareri, P., Treanor-Taylor, M., Bailey, U.-M., Schoenherr, C., Bone, M., Schreyer, D., Purdie, K., Thomson, J., Rickaby, W., Jackstadt, R., Campbell, A. D., Dimonitsas, E., Stratigos, A. J., Arron, S. T., Wang, J., Blyth, K., Proby, C. M., Harwood, C. A., Sansom, O. J., Leigh, I. M., Inman, G. J. (2023) Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression. Nature Communications, 14, (doi: 10.1038/s41467-023-40822-9)

Rattigan, K. M., Brabcova, Z., Sarnello, D., Zarou, M. M., Roy, K., Kwan, R., de Beauchamp, L., Dawson, A., Ianniciello, A., Khalaf, A., Kalkman, E. R., Scott, M. T., Dunn, K., Sumpton, D., Michie, A. M., Copland, M., Tardito, S., Gottlieb, E., Helgason, G. V. (2023) Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells. Nature Communications, 14, (doi: 10.1038/s41467-023-40222-z)

Kristeleit, R., Plummer, R., Jones, R., Carter, L., Blagden, S., Sarker, D., Arkenau, T., Evans, T. R. J., Danson, S., Symeonides, S. N., Veal, G. J., Klencke, B. J., Kowalski, M. M., Banerji, U. (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer, 129, pp. 38-45. (doi: 10.1038/s41416-023-02279-x)

Olajide, N. A., Jani, B. D., Niedzwiedz, C. L., Johnman, C., Robb, K. A. (2023) Awareness of cervical cancer and screening in Benin and Cameroon: analysis of the Demographic and Health Survey, 2017-2018. Journal of Global Health Reports, 7, (doi: 10.29392/001c.82158)

Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Espinasse, A., Ursino, M., Patel, D., Kightley, A., Hughes, S., Jaki, T., Mander, A., Evans, T. R. J., Lee, S., Hopewell, S., Rantell, K. R., Chan, A.-W., Bedding, A., Stephens, R., Richards, D., Roberts, L., Kirkpatrick, J., de Bono, J., Yap, C. (2023) Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study. BMC Medicine, 21, (doi: 10.1186/s12916-023-02937-0)

Murphy, M., McCaughan, E., Thompson, G., Carson, M. A., Hanna, J. R., Donovan, M., Wilson, R. H., Fitzsimons, D. (2023) Trusting relationships between patients with non-curative cancer and healthcare professionals create ethical obstacles for informed consent in clinical trials: a grounded theory study. BMC Palliative Care, 22, (doi: 10.1186/s12904-023-01204-6)

Elyan, B. M.P., Rankin, S., Jones, R., Lang, N. N., Mark, P. B., Lees, J. S. (2023) Kidney disease patient representation in trials of combination therapy with VEGF-signaling pathway inhibitors and immune checkpoint inhibitors: a systematic review. Kidney Medicine, 5, (doi: 10.1016/j.xkme.2023.100672)

Bennett, S., Robb, K. A., Zortea, T. C., Dickson, A., Richardson, C., O'Connor, R. C. (2023) Male suicide risk and recovery factors: a systematic review and qualitative meta-synthesis of two decades of research. Psychological Bulletin, 149, pp. 371-417. (doi: 10.1037/bul0000397)

Whyte, D., Skalka, G., Walsh, P., Wilczynska, A., Paul, N. R., Mitchel, C., Nixon, C., Clarke, W., Bushell, M., Morton, J. P., Murphy, D. J., Muthalagu, N. (2023) NUAK1 governs centrosome replication in pancreatic cancer via MYPT1/PP1β and GSK3β-dependent regulation of PLK4. Molecular Oncology, 17, pp. 1212-1227. (doi: 10.1002/1878-0261.13425)

Khattak, H. M., Woof, V. G., French, D. P., Donnelly, L. S., Ruane, H., Ulph, F., Qureshi, N., Khan, N., Evans, D. G., Robb, K. A. (2023) The role of knowledge, primary care and community engagement to improve breast-screening access for Pakistani women in the United Kingdom: a secondary analysis of a qualitative study. Journal of Health Services Research and Policy, 28, pp. 149-156. (doi: 10.1177/13558196231155824)

Farahmand, P., Gyuraszova, K., Rooney, C., Raffo-Iraolagoitia, X. L., Jayasekera, G., Hedley, A., Johnson, E., Chernova, T., Malviya, G., Hall, H., Monteverde, T., Blyth, K., Duffin, R., Carlin, L. M., Lewis, D., le Quesne, J., MacFarlane, M., Murphy, D. J. (2023) Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma. Frontiers in Toxicology, 5, (doi: 10.3389/ftox.2023.1200650)

Hatthakarnkul, P., Ammar, A., Pennel, K. A.F., Officer-Jones, L., Cusumano, S., Quinn, J. A., Matly, A. A. M., Alexander, P. G., Hay, J., Andersen, D., Lynch, G., Van Wyk, H. C., Maka, N., McMillan, D. C., Le Quesne, J., Thuwajit, C., Edwards, J. (2023) Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer. Journal of Cancer, 14, pp. 1837-1847. (doi: 10.7150/jca.83910)

Tibbo, A. J., Hartley, A., Vasan, R., Shaw, R., Galbraith, L., Mui, E., Leung, H. Y., Ahmad, I. (2023) MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer. British Journal of Cancer, 128, pp. 1991-1999. (doi: 10.1038/s41416-023-02237-7)

Catto, J. W.F., Mandrik, O., Quayle, L. A., Hussain, S. A., McGrath, J., Cresswell, J., Birtle, A. J., Jones, R. J., Mariappan, P., Makaroff, L. E., Knight, A., Mostafid, H., Chilcott, J., Sasieni, P., Cumberbatch, M. (2023) Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU International, 131, pp. 734-744. (doi: 10.1111/bju.15970)

Mar, N., Zakharia, Y., Falcon, A., Morales-Barrera, R., Mellado, B., Duran, I., Oh, D.-Y., Williamson, S. K., Gajate, P., Arkenau, H.-T., Jones, R. J., Teo, M. Y., Turan, T., McLaughlin, R. T., Peltier, H. M., Chong, E., Atluri, H., Dean, J. P., Castellano, D. (2023) Results from a phase 1b/2 study of ibrutinib combination therapy in advanced urothelial carcinoma. Cancers, 15, (doi: 10.3390/cancers15112978)

Johnstone, M. S., Stoops, R., Lynch, G., Hay, J., Jawny, J., Sloan, W., Edwards, J., McSorley, S. T. (2023) Risk stratification for the detection of metachronous polyps after bowel screening polypectomy: clinical outcomes from the Integrated Technologies for Improved Polyp Surveillance (INCISE) study cohort. BJS Open, 7, (doi: 10.1093/bjsopen/zrad034)

Hamid, O., Hassel, J. C., Shoushtari, A. N., Meier, F., Bauer, T. M., Salama, A. K.S., Kirkwood, J. M., Ascierto, P. A., Lorigan, P. C., Mauch, C., Orloff, M., Evans, T. R. J., Holland, C., Edukulla, R., Abedin, S. E., Middleton, M. R. (2023) Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Journal for ImmunoTherapy of Cancer, 11, (doi: 10.1136/jitc-2023-006747)

Yang, F., Nourse, C., Helgason, G. V., Kirschner, K. (2023) Unraveling heterogeneity in the aging hematopoietic stem cell compartment: an insight from single-cell approaches. HemaSphere, 7, (doi: 10.1097/hs9.0000000000000895)

Rattigan, K. M., Zarou, M.-M., Helgason, G. V. (2023) Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity. Blood, 141, pp. 2553-2565. (doi: 10.1182/blood.2022018258)

McGovern, J., Leadbitter, S., Miller, G., Hounat, A., Kamande, I., Dolan, R. D., Horgan, P. G., Chang, D. K., Jamieson, N. B., McMillan, D. C. (2023) The relationship between heart rate variability and TNM stage, co-morbidity, systemic inflammation and survival in patients with primary operable colorectal cancer. Scientific Reports, 13, (doi: 10.1038/s41598-023-35396-x)

Lees, J., Hay, J., Moles, M. W., Michie, A. M. (2023) The discrete roles of individual FOXO transcription factor family members in B-cell malignancies. Frontiers in Immunology, 14, (doi: 10.3389/fimmu.2023.1179101)

Zhang, H., AbdulJabbar, K., Moore, D. A., Akarca, A., Enfield, K., Jamal-Hanjani, M., Raza, S. E. A., Veeriah, S., Salgado, R., McGranahan, N., Le Quesne, J., Swanton, C., Marafioti, T., Yuan, Y. (2023) Spatial Positioning of Immune Hotspots Reflects the Interplay between B and T Cells in Lung Squamous Cell Carcinoma. Cancer Research, 83, pp. 1410-1425. (doi: 10.1158/0008-5472.CAN-22-2589)

Attard, G. et al. (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncology, 24, pp. 443-456. (doi: 10.1016/S1470-2045(23)00148-1)

May, S., Muller, M., Livingstone, C. R., Skalka, G. L., Walsh, P. J., Nixon, C., Hedley, A., Shaw, R., Clark, W., Vande Voorde, J., Officer-Jones, L., Ballantyne, F., Powley, I. R., Drake, T. M., Kiourtis, C., Keith, A., Rocha, A. S., Tardito, S., Sumpton, D., Le Quesne, J., Bushell, M., Sansom, O. J., Bird, T. G. (2023) Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. Journal of Hepatology, 78, pp. 1028-1036. (doi: 10.1016/j.jhep.2023.01.009)

Vitale, I. et al. (2023) Apoptotic cell death in disease—current understanding of the NCCD 2023. Cell Death and Differentiation, 30, pp. 1097-1154. (doi: 10.1038/s41418-023-01153-w)

Ashley, L., Robb, K. A., O’Connor, D. B., Platt, R., Price, M., Robinson, O., Travis, E., Lipscombe, L., Ajjan, R., Birch, R. (2023) Increased breast and colorectal cancer risk in type 2 diabetes: awareness among adults with and without diabetes and information provision on diabetes websites. Annals of Behavioral Medicine, 57, pp. 386-398. (doi: 10.1093/abm/kaac068)

Robb, K. A., Kotzur, M., Young, B., McCowan, C., Hollands, G. J., Irvine, A., Macdonald, S., McConnachie, A., O'Carroll, R. E., O'Connor, R. C., Steele, R. J.C. (2023) Increasing uptake of FIT colorectal screening: protocol for the TEMPO randomised controlled trial testing a suggested deadline and a planning tool. BMJ Open, 13, (doi: 10.1136/bmjopen-2022-066136)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer, 185, pp. 178-215. (doi: 10.1016/j.ejca.2023.02.018)

Richardson, C., Robb, K. A., McManus, S., O'Connor, R. C. (2023) Psychosocial factors that distinguish between men and women who have suicidal thoughts and attempt suicide: findings from a national probability sample of adults. Psychological Medicine, 53, pp. 3133-3141. (doi: 10.1017/S0033291721005195)

Lees, J. S., Elyan, B. M.P., Hermann, S. M., Lang, N. N., Jones, R. J., Mark, P. B. (2023) The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrology Dialysis Transplantation, 38, pp. 1071-1079. (doi: 10.1093/ndt/gfac011)

Ng, K. W. et al. (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616, pp. 563-573. (doi: 10.1038/s41586-023-05771-9)

Martínez-Ruiz, C. et al. (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616, pp. 543-552. (doi: 10.1038/s41586-023-05706-4)

Frankell, A. M. et al. (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616, pp. 525-533. (doi: 10.1038/s41586-023-05783-5)

Al Bakir, M. et al. (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616, pp. 534-542. (doi: 10.1038/s41586-023-05729-x)

Abbosh, C. et al. (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616, pp. 553-562. (doi: 10.1038/s41586-023-05776-4)

Woodley, K., Dillingh, L. S., Giotopoulos, G., Madrigal, P., Rattigan, K. M., Philippe, C., Dembitz, V., Magee, A. M. S., Asby, R., van de Lagemaat, L. N., Mapperley, C., James, S. C., Prehn, J. H. M., Tzelepis, K., Rouault-Pierre, K., Vassiliou, G. S., Kranc, K. R., Helgason, G. V., Huntly, B. J. P., Gallipoli, P. (2023) Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Nature Communications, 14, (doi: 10.1038/s41467-023-37652-0)

Hill, W. et al. (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616, pp. 159-167. (doi: 10.1038/s41586-023-05874-3)

Chung, T., Garcia, L., Swamynathan, M. M., Froeling, F. E.M., Trotman, L. C., Tuveson, D. A., Lyons, S. K. (2023) Internally controlled and dynamic optical measures of functional tumor biology. Analytical Chemistry, 95, pp. 5661-5670. (doi: 10.1021/acs.analchem.2c05450)

Sandilands, E., Freckmann, E. C., Cumming, E. M., Román-Fernández, A., McGarry, L., Anand, J., Galbraith, L., Mason, S., Patel, R., Nixon, C., Cartwright, J., Leung, H. Y., Blyth, K., Bryant, D. M. (2023) The small GTPase ARF3 controls invasion modality and metastasis by regulating N-cadherin levels. Journal of Cell Biology, 222, (doi: 10.1083/jcb.202206115)

Al-Sawaf, O. et al. (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29, pp. 846-858. (doi: 10.1038/s41591-023-02232-8)

Karasaki, T. et al. (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29, pp. 833-845. (doi: 10.1038/s41591-023-02230-w)

Bennett, S. S., Leung, H. Y., Ahmad, I. (2023) A cohort analysis of patients receiving neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy during the Covid-19 pandemic. Journal of Clinical Urology, 16, pp. 13-139. (doi: 10.1177/20514158211022216)

AlRasheedi, M., Han, S., Thygesen, H., Neilson, M., Hendry, F., Alkarn, A., Maclay, J. D., Leung, H. Y. (2023) A comparative evaluation of mediastinal nodal SUVmax and derived ratios from 18F-FDG PET/CT imaging to predict nodal metastases in non-small cell lung cancer. Diagnostics, 13, (doi: 10.3390/diagnostics13071209)

Villar, V. H., Allega, M. F., Deshmukh, R., Ackermann, T., Nakasone, M. A., Vande Voorde, J., Drake, T. M., Oetjen, J., Bloom, A., Nixon, C., Müller, M., May, S., Tan, E. H., Vereecke, L., Jans, M., Blancke, G., Murphy, D. J., Huang, D. T., Lewis, D. Y., Bird, T. G., Sansom, O. J., Blyth, K., Sumpton, D., Tardito, S. (2023) Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology, 19, pp. 292-300. (doi: 10.1038/s41589-022-01154-9)

Gillessen, S. et al. (2023) Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. European Urology, 83, pp. 267-293. (doi: 10.1016/j.eururo.2022.11.002)

Espinasse, A., Solovyeva, O., Dimairo, M., Weir, C., Jaki, T., Mander, A., Kightley, A., Evans, J., Lee, S., Bedding, A., Hopewell, S., Rantell, K., Liu, R., Chan, A.-W., De Bono, J., Yap, C. (2023) SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol. BMJ Open, 13, (doi: 10.1136/bmjopen-2022-068173)

Leak, S., Horne, G., Copland, M. (2023) Targeting BCR-ABL1-positive leukaemias, a review article. Cambridge Prisms: Precision Medicine, 1, (doi: 10.1017/pcm.2023.9)

Schmidt, T., Dąbrowska, A., Waldron, J. A., Hodge, K., Koulouras, G., Gabrielsen, M., Munro, J., Tack, D. C., Harris, G., McGhee, E., Scott, D., Carlin, L. M., Huang, D., Le Quesne, J., Zanivan, S., Wilczynska, A., Bushell, M. (2023) eIF4A1-dependent mRNAs employ purine-rich 5’UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation. Nucleic Acids Research, 51, pp. 1859-1879. (doi: 10.1093/nar/gkad030)

Rushworth, L. K., Loveridge, C., Salji, M., MacLeod, M., Mui, E., Sumpton, D., Neilson, M., Hedley, A., Alexander, L., McCartney, E., Patel, R., Wallace, J., Delles, C., Jones, R., Leung, H. Y. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131, pp. 236-243. (doi: 10.1111/bju.15851)

Keith, N. et al. (2023) Regenerative Futures: From Global to Local Development in 2032. (doi: 10.36399/gla.pubs.295862)

Turner, N. C. et al. (2023) Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer. Annals of Oncology, 34, pp. 200-211. (doi: 10.1016/j.annonc.2022.11.005)

Dreyer, S. B., Rae, S., Bisset, K., Upstill-Goddard, R., Gemenetzis, G., Johns, A. L., Australian Pancreatic Cancer Genome Initiative3,, , Glasgow Precision Oncology Laboratory1, , Dickson, E. J., Mittal, A., Gill, A. J., Duthie, F., pea, A., Lawlor, R. T., Scarpa, A., Salvia, R., Pulvirenti, A., Zerbi, A., Marchesi, F., McKay, C. J., Biankin, A. V., Samra, J. S., Chang, D. K., Jamieson, N. B. (2023) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, 277, pp. e396-e405. (doi: 10.1097/SLA.0000000000005050)

Gravestock, P., Clark, E., Morton, M., Sharma, S., Fisher, H., Walker, J., Wood, R., Hancock, H., Waugh, N., Cooper, A., Maier, R., Marshall, J., Chandler, R., Bahl, A., Crabb, S., Jain, S., Pedley, I., Jones, R., Staffurth, J., Heer, R. (2023) Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research, 2, (doi: 10.3310/nihropenres.13284.2)

Crabb, S. J., Hussain, S., Soulis, E., Hinsley, S., Dempsey, L., Trevethan, A., Song, Y., Barber, J., Frew, J., Gale, J., Faust, G., Brock, S., McGovern, U., Parikh, O., Enting, D., Sundar, S., Ratnayake, G., Lees, K., Birtle, A. J., Powles, T., Jones, R. J. (2023) A randomized, double-blind, biomarker-selected, phase ii clinical trial of maintenance poly adp-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41, pp. 54-64. (doi: 10.1200/JCO.22.00405)

Kotzur, M., Amiri, R., Gatting, L., Robb, K. A., Ling, J., Mooney, J. D., Christie-de Jong, F. (2023) Adapting participatory workshops to a virtual setting: co-design with Muslim women of a faith-based intervention to encourage cancer screening uptake. International Journal of Qualitative Methods, 22, pp. 16094069231205194. (doi: 10.1177/16094069231205194)

McGovern, J., Delaney, J., Forshaw, M. J., McCabe, G., Crumley, A. B., McIntosh, D., Laird, B. J., Horgan, P. G., McMillan, D. C., McSorley, S. T., Dolan, R. D. (2023) The relationship between computed tomography-derived sarcopenia, cardiopulmonary exercise testing performance, systemic inflammation, and survival in good performance status patients with oesophago-gastric cancer undergoing neoadjuvant treatment. JCSM Clinical Reports, 8, pp. 3-11. (doi: 10.1002/crt2.57)

Kirkøen, B., Berstad, P., Hoff, G., Bernklev, T., Randel, K. R., Holme, Ø., de Lange, T., Robb, K. A., Botteri, E. (2023) Type and severity of mental illness and participation in colorectal cancer screening. American Journal of Preventive Medicine, 64, pp. 76-85. (doi: 10.1016/j.amepre.2022.08.011)

O'Connor, D. B., Wilding, S., Ferguson, E., Cleare, S., Wetherall, K., McClelland, H., Melson, A. J., Niedzwiedz, C., O'Carroll, R. E., Platt, S., Scowcroft, E., Watson, B., Zortea, T., Robb, K. A., O'Connor, R. C. (2023) Effects of COVID-19-related worry and rumination on mental health and loneliness during the pandemic: longitudinal analyses of adults in the UK COVID-19 mental health & wellbeing study. Journal of Mental Health, 32, pp. 1122-1133. (doi: 10.1080/09638237.2022.2069716)

Gatting, L., Hanna, C., Robb, K. (2023) Prevalence and characteristics of pictures in cancer screening information: Content analysis of UK print decision support materials. Health Communication, 38, pp. 1601-1611. (doi: 10.1080/10410236.2021.2022869)

Cavers, D., Nelson, M., Rostron, J., Robb, K. A., Brown, L. R., Campbell, C., Akram, A. R., Dickie, G., Mackean, M., van Beek, E. J. R., Sullivan, F., Steele, R. J., Neilson, A. R., Weller, D. (2022) Understanding patient barriers and facilitators to uptake of lung screening using low dose computed tomography: a mixed methods scoping review of the current literature. Respiratory Research, 23, (doi: 10.1186/s12931-022-02255-8)

Román-Fernández, A. et al. (2022) Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Science Advances, 9, (doi: 10.1126/sciadv.abq1858)

Flanagan, D. J. et al. (2022) Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nature Communications, 13, (doi: 10.1038/s41467-022-35134-3)

Wilding, S., O'Connor, D. B., Ferguson, E., Cleare, S., Wetherall, K., O'Carroll, R. E., Robb, K. A., O'Connor, R. C. (2022) Probable COVID-19 infection is associated with subsequent poorer mental health and greater loneliness in the UK COVID-19 Mental Health and Wellbeing study. Scientific Reports, 12, (doi: 10.1038/s41598-022-24240-3)

Cousins, A., Olivares, O., Markert, E., Manoharan, A., Bubnova, X., Bresolin, S., Degn, M., Li, Z., Silvestri, D., McGregor, G., Tumanov, S., Sumpton, D., Kamphorst, J. J., Michie, A. M., Herzyk, P., Valsecchi, M. G., Yeoh, A. E., Schmiegelow, K., te Kronnie, G., Gottlieb, E., Halsey, C. (2022) Central nervous system involvement in childhood acute lymphoblastic leukemia is linked to upregulation of cholesterol biosynthetic pathways. Leukemia, 36, pp. 2903-2907. (doi: 10.1038/s41375-022-01722-x)

Cavers, D., Nelson, M., Rostron, J., Robb, K. A., Brown, L. R., Campbell, C., Akram, A. R., Dickie, G., Mackean, M., van Beek, E. J. R., Sullivan, F., Steele, R. J., Neilson, A. R., Weller, D. (2022) Optimizing the implementation of lung cancer screening in Scotland: focus group participant perspectives in the LUNGSCOT study. Health Expectations, 25, pp. 3246-3258. (doi: 10.1111/hex.13632)

Hay, J., Tarafdar, A., Holroyd, A. K., Moka, H. A., Dunn, K. M., Alshayeb, A., Lloyd, B. H., Cassels, J., Malik, N., Khan, A. F., Sou, I., Lees, J., Almuhanna, H. N.B., Kalakonda, N., Slupsky, J. R., Michie, A. M. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14, (doi: 10.3390/cancers14236006)

Johnstone, M. S., MacLeod, C., Digby, J., Al-Azzawi, Y., Pang, G., Watson, A. J.M., Strachan, J., Mowat, C., McSorley, S. T. (2022) Prevalence of repeat faecal immunochemical testing in symptomatic patients attending primary care. Colorectal Disease, 24, pp. 1498-1504. (doi: 10.1111/codi.16240)

Ali, A., Jamieson, N. B., Khan, I. Q., Chang, D., Giovannetti, E., Funel, N., Frampton, A.E., Morton, J., Sansom, O., Evans, T.R.J., Duthie, F., McKay, C. J., Samra, J.S., Gill, A. J., Biankin, A., Oien, K. A. (2022) Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. American Journal of Cancer Research, 12, pp. 5668-5683.

Smith, C., McMahon, A. D., Ross, A., Inman, G. J., Conway, D. I. (2022) Risk prediction models for head and neck cancer: a rapid review. Laryngoscope Investigative Otolaryngology, 7, pp. 1893-1908. (doi: 10.1002/lio2.982)

Keith, N., Welisch, G., Ross, K., Smykowski, A. (2022) The Curious Researchers.

Evans, J., Keith, N., Paul, J. (2022) An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma. (doi: 10.17504/protocols.io.ca5csg2w)

Parry, N., Busch, C., Aßmann, V., Cassels, J., Hair, A., Helgason, G. V., Wheadon, H., Copland, M. (2022) BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discovery, 8, (doi: 10.1038/s41420-022-01211-1)

Pennel, K. A. F., Quinn, J. A., Nixon, C., Inthagard, J., van Wyk, H. C., Chang, D., Rebus, S., GPOL Group, , Hay, J., Maka, N. N., Roxburgh, C. S.D., Horgan, P. G., McMillan, D. C., Park, J. H., Roseweir, A. K., Steele, C. W., Edwards, J. (2022) CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer. Journal of Pathology: Clinical Research, 8, pp. 509-520. (doi: 10.1002/cjp2.290)

Olajide, N., Robb, K., Niedzwiedz, C., Jani, B. (2022) Cervical Cancer Risk Factors in Eight West African Countries: Cross-sectional Analysis of the Demographic and Health Survey 2017–20. (doi: 10.1016/S0140-6736(22)02278-4)

Bryce, A. S., Dreyer, S. B., Froeling, F. E.M., Chang, D. K. (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14, (doi: 10.3390/cancers14215302)

Crabb, S. J., Griffiths, G., Dunkley, D., Downs, N., Ellis, M., Radford, M., Light, M., Northey, J., Whitehead, A., Wilding, S., Birtle, A. J., Khoo, V., Jones, R. J. (2022) Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. European Urology, 82, pp. 512-515. (doi: 10.1016/j.eururo.2022.05.019)

Edwards, S. C., Hedley, A., Hoevenaar, W. H.M., Wiesheu, R., Glauner, T., Kilbey, A., Shaw, R., Boufea, K., Batada, N., Hatano, S., Yoshikai, Y., Blyth, K., Miller, C., Kirschner, K., Coffelt, S. B. (2022) PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells. Journal of Experimental Medicine, 220, (doi: 10.1084/jem.20211431)

Yanchus, C. et al. (2022) A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science, 378, pp. 68-78. (doi: 10.1126/science.abj2890)

Stewart, G. D. et al. (2022) A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA) British Journal of Cancer, 127, pp. 1051-1060. (doi: 10.1038/s41416-022-01883-7)

Annese, V. F., Hu, C., Barrett, M. P., Jones, R., Cumming, D. R. S. (2022) A CMOS-based multi-omics detection platform for simultaneous quantification of proteolytically active prostate specific antigen and glutamate in urine. IEEE Sensors Journal, 22, pp. 18870-18877. (doi: 10.1109/JSEN.2022.3198282)

Freckmann, E. C., Sandilands, E., Cumming, E., Neilson, M., Roman-Fernandez, A., Nikolatou, K., Nacke, M., Lannagan, T. R.M., Hedley, A., Strachan, D., Salji, M., Morton, J. P., McGarry, L., Leung, H. Y., Sansom, O. J., Miller, C. J., Bryant, D. M. (2022) Traject3d allows label-free identification of distinct co-occurring phenotypes within 3D culture by live imaging. Nature Communications, 13, (doi: 10.1038/s41467-022-32958-x)

Hanna, C.R., Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P., Boyd, K.A., Jones, R.J. (2022) Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level. Clinical Oncology, 34, pp. 554-560. (doi: 10.1016/j.clon.2022.03.012)

van der Wiel, A. M. A., Schuitmaker, L., Cong, Y., Theys, J., Van Hoeck, A., Vens, C., Lambin, P., Yaromina, A., Dubois, L. J. (2022) Homologous recombination deficiency scar: mutations and beyond—implications for precision oncology. Cancers, 14, (doi: 10.3390/cancers14174157)

Kotzur, M., MacDonald, S., O'Carroll, R. E., O'Connor, R. C., Irvine, A., Steele, R. J. C., Robb, K. A. (2022) What are common barriers and helpful solutions to colorectal cancer screening? A cross-sectional survey to develop intervention content for a planning support tool. BMJ Open, 12, (doi: 10.1136/bmjopen-2022-062738)

Zeng, S., Lan, B., Ren, X., Zhang, S., Schreyer, D., Eckstein, M., Yang, H., Britzen-Laurent, N., Dahl, A., Mukhopadhyay, D., Chang, D., Kutschick, I., Pfeffer, S., Bailey, P., Biankin, A., Grützmann, R., Pilarsky, C. (2022) CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 41, (doi: 10.1186/s13046-022-02443-w)

James, N. D. et al. (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476) International Journal of Cancer, 151, pp. 422-434. (doi: 10.1002/ijc.34018)

Winter, M., Coleman, R., Kendall, J., Palmieri, C., Twelves, C., Howell, S., MacPherson, I., Wilson, C., Purohit, K., Gath, J., Taylor, C., Eastell, R., Murden, G., Brown, S. R., Rathbone, E., Brown, J. (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, (doi: 10.1016/j.jbo.2022.100442)

Jallow, M., Black, G., van Os, S., Baldwin, D. R., Brain, K. E., Donnelly, M., Janes, S. M., Kurtidu, C., McCutchan, G., Robb, K. A., Ruparel, M., Quaife, S. L. (2022) Acceptability of a standalone written leaflet for the National Health Service for England (NHSE) Targeted Lung Health Check Programme: a concurrent, think-aloud study. Health Expectations, 25, pp. 1776-1788. (doi: 10.1111/hex.13520)

James, N. D. et al. (2022) Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectrum, 6, (doi: 10.1093/jncics/pkac043)

Khan, K. S., Gall, L. S., Dreyer, S., McCollum, C., Chuntamongkol, R., Craig, C., MacKay, C., Macdonald, A., Forshaw, M. (2022) Stage migration in newly diagnosed oesophagogastric cancer during the first wave of the COVID-19 pandemic. British Journal of Surgery, 109, pp. 773-774. (doi: 10.1093/bjs/znac112)

Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D., MacPherson, I. (2022) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a quantitative systematic review. Breast, 64, pp. 63-84. (doi: 10.1016/j.breast.2022.04.010)

Patel, R., Ford, C. A., Rodgers, L., Rushworth, L. K., Fleming, J., Mui, E., Zhang, T., Watson, D., Lynch, V., Mackay, G., Sumpton, D., Sansom, O. J., Vande Voorde, J., Leung, H. Y. (2022) Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Research, 82, pp. 2565-2575. (doi: 10.1158/0008-5472.CAN-21-1301)

Morrison, A., Marshall-Mckenna, R., McFadyen, A. K., Hutchison, C., Rice, A.-M., Stirling, L., McIlroy, P., MacPherson, I. R. (2022) A randomised controlled trial of interventions for taxane-induced nail toxicity in women with early breast cancer. Scientific Reports, 12, (doi: 10.1038/s41598-022-13327-6)

El Helali, A., Plummer, R., Jayson, G. C., Coyle, V. M., Drew, Y., Mescallado, N., Harris, N., Clamp, A. R., McCann, J., Swaisland, H., Kennedy, R. D., Cranston, A. N., Wilson, R. H. (2022) A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. British Journal of Cancer, 127, pp. 92-101. (doi: 10.1038/s41416-022-01780-z)

Wilson, B. E., Armstrong, A. J., de Bono, J., Sternberg, C. N., Ryan, C. J., Scher, H. I., Smith, M. R., Rathkopf, D., Logothetis, C. J., Chi, K. N., Jones, R. J., Saad, F., De Porre, P., Tran, N., Hu, P., Gillessen, S., Carles, J., Fizazi, K., Joshua, A. M. (2022) Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 170, pp. 296-304. (doi: 10.1016/j.ejca.2022.03.042)

Johnstone, M. S., Miller, G., Pang, G., Burton, P., Kouronis, G., Winter, J., Crighton, E., Mansouri, D., Witherspoon, P., Smith, K., McSorley, S. T. (2022) Alternative diagnoses and demographics associated with a raised quantitative faecal immunochemical test in symptomatic patients. Annals of Clinical Biochemistry, 59, pp. 277-287. (doi: 10.1177/00045632221076771)

Sooriakumaran, P., Wilson, C., Rombach, I., Hassanali, N., Aning, J., D. Lamb, A., Cathcart, P., Eden, C., Ahmad, I., Rajan, P., Sridhar, A., Bryant, R. J., Elhage, O., Cook, J., Leung, H., Soomro, N., Kelly, J., Nathan, S., Donovan, J. L., Hamdy, F. C. (2022) Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo‐Metastases to the bone (TRoMbone) trial. BJU International, 130, pp. 43-53. (doi: 10.1111/bju.15669)

Sala, A., Cameron, J. M., Jenkins, C. A., Barr, H., Christie, L., Conn, J. J.A., Evans, T. R. J., Harris, D. A., Palmer, D. S., Rinaldi, C., Theakstone, A. G., Baker, M. J. (2022) Liquid biopsy for pancreatic cancer detection using infrared spectroscopy. Cancers, 14, (doi: 10.3390/cancers14133048)

Gillessen, S. et al. (2022) Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. European Urology, 82, pp. 115-141. (doi: 10.1016/j.eururo.2022.04.002)

Wetherall, K., Cleare, S., Mcclelland, H., Melson, A. J., Niedzwiedz, C. L., O’Carroll, R. E., O’Connor, D. B., Platt, S., Scowcroft, E., Watson, B., Zortea, T., Ferguson, E., Robb, K. A., O'Connor, R. C. (2022) Mental health and well-being during the second wave of COVID-19: longitudinal analyses of the UK COVID-19 Mental Health and Wellbeing study (UK COVID-MH) BJPsych Open, 8, (doi: 10.1192/bjo.2022.58)

Marlow, L. A.V., Schmeising-Barnes, N., Brain, K., Duncombe, S., Robb, K. A., Round, T., Sanderson, S. C., Waller, J. (2022) Multi-cancer early detection tests for cancer screening: a behavioural science perspective. Lancet Oncology, 23, pp. 837-839. (doi: 10.1016/S1470-2045(22)00161-9)

Henriksen, P. A., Hall, P., Oikonomidou, O., MacPherson, I. R., Maclean, M., Lewis, S., McVicars, H., Broom, A., Scott, F., McKay, P., Borley, A., Rowntree, C., Lord, S., Collins, G., Radford, J., Guppy, A., Payne, J. R., Newby, D. E., Mills, N. L., Lang, N. N. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15, (doi: 10.1161/CIRCHEARTFAILURE.121.009445)

Ianniciello, A., Helgason, G. V. (2022) Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia. Autophagy, 18, pp. 1734-1736. (doi: 10.1080/15548627.2022.2041152)

Turco, F. et al. (2022) What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82, pp. 6-11. (doi: 10.1016/j.eururo.2022.02.010)

Ahmed, A., Giampazolias, E., Patel, R., Leung, H., Tait, S. W.G. (2022) Caspase-independent cell death as a novel therapy for advanced prostate cancer.

Evans, J., Keith, N., Paul, J. (2022) An analysis of Relative Telomere Length (RTL) during chemotherapy in patients with advanced gastro-oesophageal adenocarcinoma. (doi: 10.17504/protocols.io.n92ldznenv5b/v1)

Coombes, R.C., Badman, P.D., Lozano-Kuehne, J.P., Liu, X., MacPherson, I. R., Zubairi, I., Baird, R.D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O.E., Seckl, M.J. (2022) Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature Communications, 13, (doi: 10.1038/s41467-022-30666-0)

Parker, C. C. et al. (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Medicine, 19, (doi: 10.1371/journal.pmed.1003998)

Clarke, C. S., Hunter, R. M., Gabrio, A., Brawley, C. D., Ingleby, F. C., Dearnaley, D. P., Matheson, D., Attard, G., Rush, H. L., Jones, R. J., Cross, W., Parker, C., Russell, J. M., Millman, R., Gillessen, S., Malik, Z., Lester, J. F., Wylie, J., Clarke, N. W., Parmar, M. K. B., Sydes, M. R., James, N. D. (2022) Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE, 17, (doi: 10.1371/journal.pone.0269192)

Patel, M., Pennel, K. A.F., Quinn, J. A., Hood, H., Chang, D. K., Biankin, A. V., Rebus, S., Roseweir, A. K., Park, J. H., Horgan, P. G., McMillan, D. C., Edwards, J. (2022) Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 126, pp. 1704-1714. (doi: 10.1038/s41416-022-01729-2)

Razis, E. et al. (2022) Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO Open, 7, (doi: 10.1016/j.esmoop.2022.100483)

Kay, E. J. et al. (2022) Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nature Metabolism, 4, pp. 693-710. (doi: 10.1038/s42255-022-00582-0)

Müller, M. et al. (2022) Human-correlated genetic HCC models identify combination therapy for precision medicine [Pre-print] Research Square, (doi: 10.21203/rs.3.rs-1638504/v1)

Hussain, S. A., Lester, J. F., Jackson, R., Gornall, M., Qureshi, M., Elliott, A., Crabb, S. J., Huddart, R. A., Vasudev, N., Birtle, A. J., Worlding, J., James, N. D., Parikh, O., Vilarino-Varela, M., Alonz, R., Linch, M. D., Riaz, I. B., Catto, J. W. F., Powles, T., Jones, R. J. (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncology, 23, pp. 650-658. (doi: 10.1016/S1470-2045(22)00158-9)

Kotzur, M., O'Connor, R. C., Robb, K. A. (2022) How has physical distancing impacted on health and well-being during the COVID-19 pandemic? A Scottish longitudinal qualitative study. BMJ Open, 12, (doi: 10.1136/bmjopen-2021-054506)

Christie-de Jong, F., Kotzur, M., Amiri, R., Ling, J., Mooney, J. D., Robb, K. A. (2022) Qualitative evaluation of a codesigned faith-based intervention for Muslim women in Scotland to encourage uptake of breast, colorectal and cervical cancer screening. BMJ Open, 12, (doi: 10.1136/bmjopen-2021-058739)

Salji, M. J., Blomme, A., Däbritz, J. H. M., Repiscak, P., Lilla, S., Patel, R., Sumpton, D., Van Den Broek, N. J. F., Daly, R., Zanivan, S., Leung, H. Y. (2022) Multi-omics and pathway analysis identify potential roles for tumour n-acetyl aspartate accumulation in murine models of castration resistant prostate cancer. iScience, 25, (doi: 10.1016/j.isci.2022.104056)

Brown, L. C., Graham, J., Fisher, D., Adams, R., Seligmann, J., Seymour, M., Kaplan, R., Yates, E., Parmar, M., Richman, S. D., Quirke, P., Butler, R., Shiu, K., Middleton, G., Samuel, L., Wilson, R. H., Maughan, T. S. (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19, pp. 146-157. (doi: 10.1177/17407745211069879)

Gómez, V., Galazi, M., Weitsman, G., Monypenny, J., Al-Salemee, F., Barber, P. R., Ng, K., Beatson, R., Szokol, B., Orfi, L., Mullen, G., Vanhaesebroeck, B., Chowdhury, S., Leung, H. Y., Ng, T. (2022) HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models. Molecular Cancer Therapeutics, 21, pp. 667-676. (doi: 10.1158/1535-7163.mct-21-0320)

Dunlop, E., Ferguson, A., Mueller, T., Baillie, K., Clarke, J., Laskey, J., Kurdi, A., Wu, O., Jones, R., Glen, H., Bennie, M. (2022) What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer. Supportive Care in Cancer, 30, pp. 3141-3150. (doi: 10.1007/s00520-021-06724-6)

Gaba, F., Tipping, W. J., Salji, M., Faulds, K., Graham, D., Leung, H. Y. (2022) Raman spectroscopy in prostate cancer: techniques, applications and advancements. Cancers, 14, (doi: 10.3390/cancers14061535)

Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14, (doi: 10.15252/emmm.202114764)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J., Jones, R. J., Petrie, M. C., Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4, pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096)

Malorni, L. et al. (2022) Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. European Journal of Cancer, 164, pp. 39-51. (doi: 10.1016/j.ejca.2021.12.030)

Johnstone, M. S., Burton, P., Kourounis, G., Winter, J., Crighton, E., Mansouri, D., Witherspoon, P., Smith, K., McSorley, S. T. (2022) Combining the quantitative faecal immunochemical test and full blood count reliably rules out colorectal cancer in a symptomatic patient referral pathway. International Journal of Colorectal Disease, 37, pp. 457-466. (doi: 10.1007/s00384-021-04079-2)

Copland, M., Slade, D., McIlroy, G., Horne, G., Byrne, J. L., Rothwell, K., Brock, K., De Lavallade, H., Craddock, C., Clark, R. E., Smith, M. L., Fletcher, R., Bishop, R., Milojkovic, D., Yap, C. (2022) Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematology, 9, pp. e121-e132. (doi: 10.1016/S2352-3026(21)00370-7)

Attard, G. et al. (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399, pp. 447-460. (doi: 10.1016/S0140-6736(21)02437-5)

Adam, C., Bray, T. L., Pérez-López, A. M., Tan, E. H., Rubio-Ruiz, B., Baillache, D. J., Houston, D. R., Salji, M. J., Leung, H. Y., Unciti-Broceta, A. (2022) A 5-FU precursor designed to evade anabolic and catabolic drug pathways and activated by Pd chemistry in vitro and in vivo. Journal of Medicinal Chemistry, 65, pp. 552-561. (doi: 10.1021/acs.jmedchem.1c01733)

Mueller, T., Laskey, J., Baillie, K., Clarke, J., Crearie, C., Kavanagh, K., Graham, J., Graham, K., Waterson, A., Jones, R., Kurdi, A., Morrison, D., Bennie, M. (2022) Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice. Health Informatics Journal, 28, pp. 14604582221077055. (doi: 10.1177/14604582221077055)

Dreyer, S. B., Upstill-Goddard, R., Legrini, A., Biankin, A. V., Jamieson, N. B., Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162, pp. 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022)

de Beauchamp, L., Himonas, E., Helgason, G. V. (2022) Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia, 36, pp. 1-12. (doi: 10.1038/s41375-021-01416-w)

Dreyer, S., Upstill-Goddard, R., Legrini, A., Biankin, A., Jamieson, N., Chang, D. (2022) Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. (doi: 10.1016/j.hpb.2022.05.086)

Love, S. B. et al. (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23, (doi: 10.1186/s13063-022-06680-4)

Rabas, N., Palmer, S., Mitchell, L., Ismail, S., Gohlke, A., Riley, J. S., Tait, S. W.G., Gammage, P., Lemgruber Soares, L., MacPherson, I. R., Norman, J. C. (2021) PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. Journal of Cell Biology, 220, (doi: 10.1083/jcb.202006049)

van Winsen, M., McSorley, S. T., McLeod, R., MacDonald, A., Forshaw, M. J., Shaw, M., Puxty, K. (2021) Postoperative C-reactive protein concentrations to predict infective complications following gastrectomy for cancer. Journal of Surgical Oncology, 124, pp. 1060-1069. (doi: 10.1002/jso.26613)

Gray, E., Figueroa, J.D., Oikonomidou, O., MacPherson, I., Urquhart, G., Cameron, D.A., Hall, P.S. (2021) Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open, 6, (doi: 10.1016/j.esmoop.2021.100331)

Darici, S., Zavatti, M., Braglia, L., Accordi, B., Serafin, V., Horne, G. A., Manzoli, L., Palumbo, C., Huang, X., Jørgensen, H. G., Marmiroli, S. (2021) Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. Advances in Biological Regulation, 82, (doi: 10.1016/j.jbior.2021.100830)

Hollis, R. L., Stillie, L. J., Hopkins, S., Bartos, C., Churchman, M., Rye, T., Nussey, F., Fegan, S., Nirsimloo, R., Inman, G. J., Herrington, C. S., Gourley, C. (2021) Clinicopathological determinants of recurrence risk and survival in mucinous ovarian carcinoma. Cancers, 13, (doi: 10.3390/cancers13225839)

Adams, R. A., Fisher, D. J., Graham, J., Seligmann, J. F., Seymour, M., Kaplan, R., Yates, E., Parmar, M., Richman, S. D., Quirke, P., Butler, R., Brown, E., Collinson, F., Falk, S., Wasan, H., Shiu, K.-K., Middleton, G., Samuel, L., Wilson, R. H., Brown, L. C., Maughan, T. S. (2021) Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology, 39, pp. 3693-3704. (doi: 10.1200/JCO.21.01436)

Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, (doi: 10.1038/s41467-021-27099-6)

Birch, J., Strathdee, K., Stevenson, K., Derby, S., Dutton, L., Clough, E., Koessinger, A., Gilmour, L., McGhee, E., McGarrity-Cottrell, C., Dibekeme, A. a., Collis, S., Rominiyi, O., Lembruber Soares, L., Solecki, G., Winkler, F., Carlin, L., Inman, G., Chalmers, A., Norman, J., Carruthers, R. (2021) Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM. Research Square, (doi: 10.21203/rs.3.rs-967109/v1)

Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A., Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S., Mulheran, P. A. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12, pp. 705-722. (doi: 10.4155/tde-2021-0041)

Turner, N. C. et al. (2021) Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study. Clinical Cancer Research, 27, pp. 5482-5491. (doi: 10.1158/1078-0432.CCR-21-0310)

Tsim, S. et al. (2021) Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. Journal of Thoracic Oncology, 16, pp. 1705-1717. (doi: 10.1016/j.jtho.2021.05.018)

Halabi, S., Yang, Q., Carmack, A., Zhang, S., Foo, W.-C., Eisen, T., Stadler, W., Jones, R. J., Garcia, J., Picus, J., Hawkins, R., Hainsworth, J., Kollmannsberger, C., Logan, T., Puzanov, I., Pickering, L., Ryan, C., Protheroe, A., George, D., Armstrong, A. (2021) Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. Kidney Cancer Journal, 19, pp. 64-72. (doi: 10.52733/kcj19n3-a1)

Young, B., Robb, K. A. (2021) Understanding patient factors to increase uptake of cancer screening: a review. Future Oncology, 17, pp. 3757-3775. (doi: 10.2217/fon-2020-1078)

Ianniciello, A., Zarou, M. M., Rattigan, K. M., Scott, M., Dawson, A., Dunn, K., Brabcova, Z., Kalkman, E. R., Nixon, C., Michie, A. M., Copland, M., Vetrie, D., Ambler, M., Saxty, B., Helgason, G. V. (2021) ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy. Science Translational Medicine, 13, (doi: 10.1126/scitranslmed.abd5016)

Ianniciello, A., Helgason, G. V. (2021) Autophagy in hematopoiesis and leukemogenesis. Academic Press

Chan, B. Y.L., McKinlay, S., Forshaw, M., Macdonald, A., Maitra, R., Orizu, M., McSorley, S. T. (2021) Impact of anaemia in oesophago-gastric cancer patients undergoing curative treatment by means of neoadjuvant chemotherapy and surgery. Surgical Oncology, 38, (doi: 10.1016/j.suronc.2021.101585)

Finn, R. S., Kudo, M., Cheng, A.-L., Wyrwicz, L., Ngan, R. K.C., Blanc, J.-F., Baron, A. D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K.-H., Qin, S., Minoshima, Y., Kanekiyo, M., Ren, M., Dairiki, R., Tamai, T., Dutcus, C. E., Ikezawa, H., Funahashi, Y., Evans, T. R. J. (2021) Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study. Clinical Cancer Research, 27, pp. 4848-4858. (doi: 10.1158/1078-0432.CCR-20-4219)

Bao, J., Närhi, K., Teodòsio, A., Hemmes, A., Linnavirta, N. M., Mäyränpää, M. I., Salmenkivi, K., Le Quesne, J., Verschuren, E. W. (2021) SOX9 has distinct roles in the formation and progression of different non‐small cell lung cancer histotypes. Journal of Pathology, 255, pp. 16-29. (doi: 10.1002/path.5733)

Stonier, T. et al. (2021) The "Is mpMRI Enough" or IMRIE Study: a multicentre evaluation of prebiopsy multiparametric magnetic resonance imaging compared with biopsy. European Urology Focus, 7, pp. 1027-1034. (doi: 10.1016/j.euf.2020.09.012)

Robb, K. A. (2021) The Integrated Screening Action Model (I-SAM): a theory-based approach to inform intervention development. Preventive Medicine Reports, 23, (doi: 10.1016/j.pmedr.2021.101427)

Hanna, C. R., Robles-Zurita, J. A., Briggs, A., Harkin, A., Kelly, C., McQueen, J., Allan, K., Pearson, S., Hollander, N. H., Glimelius, B., Salazar, R., Segelov, E., Saunders, M., Iveson, T., Jones, R. J., Boyd, K. A. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20, pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001)

Patterson, S. D., Huang, X., Jørgensen, H. G., Michie, A. M. (2021) Transcriptional regulation by the NFAT family in acute myeloid leukaemia. Hemato, 2, pp. 556-571. (doi: 10.3390/hemato2030035)

Marmiroli, S., Huang, X., Serafin, V., Michie, A. M. (2021) Editorial: Special issue on innovative multi-disciplinary approaches for precision studies in leukemia. Frontiers in Oncology, 11, (doi: 10.3389/fonc.2021.744009)

Middleton, M. R., Dean, E., Evans, T. R.J., Shapiro, G. I., Pollard, J., Hendriks, B. S., Falk, M., Diaz-Padilla, I., Plummer, R. (2021) Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. British Journal of Cancer, 125, pp. 510-519. (doi: 10.1038/s41416-021-01405-x)

Marini, A. et al. (2021) The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nature Communications, 12, (doi: 10.1038/s41467-021-25173-7)

Casolino, R., Paiella, S., Azzolina, D., Beer, P. A., Corbo, V., Lorenzoni, G., Gregori, D., GOlan, T., Braconi, C., Froeling, F. E.M., Milella, M., Scarpa, A., Pea, A., Malleo, G., Salvia, R., Bassi, C., Chang, D. K., Biankin, A. V. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39, pp. 2617-2631. (doi: 10.1200/JCO.20.03238)

Nelson, M., Patton, A., Robb, K., Weller, D., Sheikh, A., Ragupathy, K., Morrison, D., Campbell, C. (2021) Experiences of cervical screening participation and non‐participation in women from minority ethnic populations in Scotland. Health Expectations, 24, pp. 1459-1472. (doi: 10.1111/hex.13287)

Schwappacher, R., Dieterich, W., Reljic, D., Pilarsky, C., Mukhopadhyay, D., Chang, D. K., Biankin, A. V., Siebler, J., Herrmann, H. J., Neurath, M. F., Zopf, Y. (2021) Muscle-derived cytokines reduce growth, viability and migratory activity of pancreatic cancer cells. Cancers, 13, (doi: 10.3390/cancers13153820)

Johnstone, M. S., Lynch, G., Park, J., McSorley, S., Edwards, J. (2021) Novel methods of risk stratifying patients for metachronous, pre-malignant colorectal polyps: a systematic review. Critical Reviews in Oncology/Haematology, 164, (doi: 10.1016/j.critrevonc.2021.103421)

Vivekanandhan, S., Madamsetty, V. S., Angom, R. S., Dutta, S. K., Wang, E., Caulfield, T., Pletnev, A. A., Upstill-Goddard, R., Asmann, Y. W., Chang, D., Spaller, M. R., Mukhopadhyay, D. (2021) Role of PLEXIND1/TGFβ signaling axis in pancreatic ductal adenocarcinoma progression correlates with the mutational status of KRAS. Cancers, 13, (doi: 10.3390/cancers13164048)

Peddie, N., Agnew, S., Crawford, M., Dixon, D., MacPherson, I., Fleming, L. (2021) The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: a qualitative systematic review and thematic synthesis. Breast, 58, pp. 147-159. (doi: 10.1016/j.breast.2021.05.005)

Ghaddar, N., Wang, S., Woodvine, B., Krishnamoorthy, J., van Hoef, V., Darini, C., Kazimierczak, U., Ah-son, N., Popper, H., Johnson, M., Officer, L., Teodósio, A., Broggini, M., Mann, K. K., Hatzoglou, M., Topisirovic, I., Larsson, O., Le Quesne, J., Koromilas, A. E. (2021) The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer. Nature Communications, 12, (doi: 10.1038/s41467-021-24661-0)

Lei, M., Siemers, N. O., Pandya, D., Chang, H., Sanchez, T., Harbison, C., Szabo, P. M., Janjigian, Y., Ott, P. A., Sharma, P., Bendell, J., Evans, T. R. J., de Braud, F., Chau, I., Boyd1, Z. (2021) Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab±Ipilimumab in gastric cancer/gastroesophageal junction cancer. Clinical Cancer Research, 27, pp. 3926-3935. (doi: 10.1158/1078-0432.CCR-20-2790)

Ntala, C., Salji, M., Salmond, J., Officer, L., Teodosio, A. V., Blomme, A., McGhee, E. J., Powley, I., Ahmad, I., Kruithof-de Julio, M., Thalmann, G., Roberts, E., Goodyear, C. S., Jamaspishvili, T., Berman, D. M., Carlin, L. M., Le Quesne, J., Leung, H. Y. (2021) Analysis of prostate cancer tumor microenvironment identifies reduced stromal CD4 effector T-cell infiltration in tumors with pelvic nodal metastasis. European Urology Open Science, 29, pp. 19-29. (doi: 10.1016/j.euros.2021.05.001)

Haq, M. I., Drake, T. M., Goh, T. L., Ahmed, A., Forrest, E., Barclay, S., Gillespie, R., Priest, M., Evans, J., Graham, J., Ballantyne, S., McMillan, D. C., Hayes, P. C., Bird, T. G., Stanley, A. J. (2021) Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study. Journal of Clinical Medicine, 10, (doi: 10.3390/jcm10132770)

Welisch, G., Twelves, C., Plummer, R., Evans, J., Danson, S., Symeonides, S., Halsey, C., Jones, R., Hanna, C., Gallagher, P., Walls, G., Taylor, K., Barnett, S., Forde, C., White, M., Williams, C., El Badri, S., Chipole, B.'e. D., Keith, N. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? (doi: 10.17605/OSF.IO/KWHQF)

Martinez, R. S., Salji, M. J., Rushworth, L., Ntala, C., Rodriguez Blanco, G., Hedley, A., Clark, W., Peixoto, P., Hervouet, E., Renaude, E., Kung, S. H. Y., Galbraith, L. C.A., Nixon, C., Lilla, S., Mackay, G. M., Fazli, L., Gaughan, L., Sumpton, D., Gleave, M. E., Zanivan, S., Blomme, A., Leung, H. Y. (2021) SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer. Cancer Research, 81, pp. 3664-3678. (doi: 10.1158/0008-5472.CAN-20-3694)

Mansouri, D., McSorley, S. T., Park, J. H., Orange, C., Horgan, P. G., McMillan, D. C., Edwards, J. (2021) The inflammatory microenvironment in screen-detected premaligant adenomatous polyps: early results from the integrated technologies for improved polyp surveillance (INCISE) project. European Journal of Gastroenterology and Hepatology, 33, pp. 983-989. (doi: 10.1097/MEG.0000000000002202)

McSorley, S. T., Digby, J., Clyde, D., Cruickshank, N., Burton, P., Barker, L., Strachan, J. A., Fraser, C. G., Smith, K., Mowat, C., Winter, J., Steele, R. J.C. (2021) Yield of colorectal cancer at colonoscopy according to faecal haemoglobin concentration in symptomatic patients referred from primary care. Colorectal Disease, 23, pp. 1615-1621. (doi: 10.1111/codi.15405)

Leach, J. D.G. et al. (2021) Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis. Nature Communications, 12, (doi: 10.1038/s41467-021-23717-5)

Massett, M. E., Monaghan, L., Patterson, S., Mannion, N., Bunschoten, R. P., Hoose, A., Marmiroli, S., Liskamp, R. M.J., Jørgensen, H. G., Vetrie, D., Michie, A. M., Huang, X. (2021) A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival. Cell Death and Disease, 12, (doi: 10.1038/s41419-021-03738-0)

Palmieri, C., MacPherson, I. R. (2021) A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment. ESMO Open, 6, (doi: 10.1016/j.esmoop.2021.100162)

Armstrong, A. J., Nixon, A. B., Carmack, A., Eisen, T., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., Hainsworth, J. D., Kollmannsberger, C. K., Logan, T. F., Puzanov, I., Pickering, L. M., Ryan, C. W., Protheroe, A., George, D. J., Halabi, S. (2021) Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma. Clinical Cancer Research, 27, pp. 3317-3328. (doi: 10.1158/1078-0432.CCR-20-4504)

Zarou, M.-M., Vazquez, A., Helgason, G. V. (2021) Folate metabolism: a re-emerging therapeutic target in haematological cancers. Leukemia, 35, pp. 1539-1551. (doi: 10.1038/s41375-021-01189-2)

O'Connor, R. C., Wetherall, K., Cleare, S., Mcclelland, H., Melson, A. J., Niedzwiedz, C. L., O'Carroll, R. E., O'Connor, D. B., Platt, S., Scowcroft, E., Watson, B., Zortea, T., Ferguson, E., Robb, K. A. (2021) Mental health and wellbeing during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. British Journal of Psychiatry, 218, pp. 326-333. (doi: 10.1192/bjp.2020.212)

Horne, G. A., Laird, J., Latif, A.-L., Irvine, D., Wilson, M., Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36, pp. 513-515. (doi: 10.1002/jca.21871)

Richardson, C., Robb, K. A., O'Connor, R. C. (2021) A systematic review of suicidal behaviour in men: a narrative synthesis of risk factors. Social Science and Medicine, 276, (doi: 10.1016/j.socscimed.2021.113831)

Powles, T., Carroll, D., Chowdhury, S., Gravis, G., Joly, F., Carles, J., Fléchon, A., Maroto, P., Petrylak, D., Rolland, F., Cook, N., Balar, A. V., Sridhar, S. S., Galsky, M. D., Grivas, P., Ravaud, A., Jones, R., Cosaert, J., Hodgson, D., Kozarewa, I., Mather, R., McEwen, R., Mercier, F., Landers, D. (2021) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nature Medicine, 27, pp. 793-801. (doi: 10.1038/s41591-021-01317-6)

Cangiano, M., Grudniewska, M., Salji, M. J., Nykter, M., Jenster, G., Urbanucci, A., Grabcgu, Z., Janssen, B., Hamilton, G., Leung, H. Y., Beumer, I. J. (2021) Gene regulation network analysis on human prostate orthografts highlights a potential role for the JMJD6 regulon in clinical prostate cancer. Cancers, 13, (doi: 10.3390/cancers13092094)

Sereno, M., He, Z., Smith, C. R., Baena, J., Das, M., Hastings, R. K., Rake, G., Fennell, D. A., Nakas, A., Moore, D. A., Le Quesne, J. (2021) Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology, 78, pp. 838-848. (doi: 10.1111/his.14301)

Knight, J. R.P. et al. (2021) MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discovery, 11, pp. 1228-1247. (doi: 10.1158/2159-8290.CD-20-0652)

Richardson, C., Dickson, A., Robb, K. A., O'Connor, R. (2021) The male experience of suicide attempts and recovery: an interpretative phenomenological analysis. International Journal of Environmental Research and Public Health, 18, (doi: 10.3390/ijerph18105209)

Young, B., Kotzur, M., Gatting, L., Bonner, C., Ayre, J., McConnachie, A., Batcup, C., McCaffery, K., O'Carroll, R., Robb, K. A. (2021) The impact of theory-based messages on COVID-19 vaccination intentions: a structured summary of a study protocol for a randomised controlled trial. Trials, 22, (doi: 10.1186/s13063-021-05277-7)

Kingston, B., Cutts, R. J., Bye, H., Beaney, M., Walsh-Crestani, G., Hrebien, S., Swift, C., Kilburn, L. S., Kernaghan, S., Moretti, L., Wilkinson, K., Wardley, A. M., Macpherson, I. R., Baird, R. D., Roylance, R., Reis-Filho, J. S., Hubank, M., Faull, I., Banks, K. C., Lanman, R. B., Garcia-Murillas, I., Bliss, J. M., Ring, A., Turner, N. C. (2021) Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 12, (doi: 10.1038/s41467-021-22605-2)

Galbraith, L. C.A., Mui, E., Nixon, C., Hedley, A., Strachan, D., MacKay, G., Sumpton, D., Sansom, O. J., Leung, H. Y., Ahmad, I. (2021) PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer. Oncogene, 40, pp. 2355-2366. (doi: 10.1038/s41388-021-01707-7)

Busacca, S., Zhang, Q., Sharkey, A., Dawson, A. G., Moore, D. A., Waller, D. A., Nakas, A., Jones, C., Cain, K., Luo, J.-l., Salcedo, A., Salaroglio, I. C., Riganti, C., Le Quesne, J., John, T., Boutros, P. C., Zhang, S.-D., Fennell, D. A. (2021) Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. Scientific Reports, 11, (doi: 10.1038/s41598-021-86834-7)

McNamara, M. G., Bridgewater, J., Palmer, D.H., Faluyi, O., Wasan, H., Patel, A., Ryder, W.D., Barber, S., Gnanaranjan, C., Ghazaly, E., Evans, T.R.J., Valle, J.W. (2021) A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08) Oncologist, 26, pp. e669-e678. (doi: 10.1002/onco.13598)

Hanna, C., Lemmon, E., Ennis, H., Jones, R., Hay, J., Halliday, R., Clark, S., Morris, E., Hall, P. (2021) Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science, 6, (doi: 10.23889/ijpds.v6i1.1654)

Zhang, M. et al. (2021) Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nature Communications, 12, (doi: 10.1038/s41467-021-21798-w)

Macpherson, I. R., He, Y., Palmieri, C. (2021) Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. Breast Cancer Research, 23, (doi: 10.1186/s13058-021-01407-w)

Hanna, C. R., Robb, K. A., Blyth, K. G., Jones, R. J., Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109, pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003)

Nacke, M., Sandilands, E., Nikolatou, K., Román-Fernández, Á., Mason, S., Patel, R., Lilla, S., Yelland, T., Galbraith, L. C.A., Freckmann, E. C., McGarry, L., Morton, J. P., Shanks, E., Leung, H. Y., Markert, E., Ismail, S., Zanivan, S., Blyth, K., Bryant, D. M. (2021) An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nature Communications, 12, (doi: 10.1038/s41467-021-21847-4)

Hanna, C. R., Boyd, K. A., Jones, R. J. (2021) Evaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment. Health Research Policy and Systems, 19, (doi: 10.1186/s12961-020-00658-x)

Annese, V. F., Patil, S. B., Hu, C., Giagkoulovits, C., Al-Rawhani, M. A., Grant, J., Macleod, M., Clayton, D.J., Heaney, L.M., Daly, R., Accarino, C., Shah, Y. D., Cheah, B. C., Beeley, J., Evans, T.R.J., Jones, R., Barrett, M. P., Cumming, D. R.S. (2021) A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 7, (doi: 10.1038/s41378-021-00243-4)

Yun, S., Vincelette, N. D., Yu, X., Watson, G. W., Fernandez, M. R., Yang, C., Hitosugi, T., Cheng, C.-H., Freischel, A. R., Zhang, L., Li, W., Hou, H., Schaub, F. X., Vedder, A. R., Cen, L., McGraw, K. L., Moon, J., Murphy, D. J., Ballabio, A., Kaufmann, S. H., Berglund, A. E., Cleveland, J. L. (2021) TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discovery, 2, pp. 162-185. (doi: 10.1158/2643-3230.bcd-20-0029)

Phatak, V., von Grabowiecki, Y., Janus, J., Officer, L., Behan, C., Aschauer, L., Pinon, L., Mackay, H., Zanivan, S., Norman, J. C., Kelly, M., Le Quesne, J., Muller, P. A. J. (2021) Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane. Cell Death and Disease, 12, (doi: 10.1038/s41419-021-03497-y)

Laskar, P., Somani, S., Mullin, M., Tate, R. J., Warzecha, M., Bowering, D., Keating, P., Irving, C., Leung, H. Y., Dufès, C. (2021) Octadecyl chain-bearing PEGylated poly(propyleneimine)-based dendrimersomes: physicochemical studies, redox-responsiveness, DNA condensation, cytotoxicity and gene delivery to cancer cells. Biomaterials Science, 9, pp. 1431-1448. (doi: 10.1039/D0BM01441A)

Keith, N., Plummer, R., Coyle, V., Cameron, D., Evans, J., Twelves, C., Palmer, D., Danson, S., Graham, D., Welisch, G. (2021) Early Phase Cancer Research in the COVID-19 Pandemic: an ECMC North Initiative. (doi: 10.17605/OSF.IO/6WTN2)

Lakis, V. et al. (2021) DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4, (doi: 10.1038/s42003-020-01469-0)

Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S.B., Froeling, F.E.M., Chang, D.K., Biankin, A.V., Golan, T. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32, pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013)

Hartley, A., Leung, H. Y., Ahmad, I. (2021) Targeting the BAF complex in advanced prostate cancer. Expert Opinion on Drug Discovery, 16, pp. 173-181. (doi: 10.1080/17460441.2020.1821644)

McSorley, S. T., Steele, C. W., Anderson, J. H., McKinlay, S. (2021) Comment on 'Preoperative intravenous iron therapy and survival after colorectal cancer surgery: long term results from the IVICA randomised controlled trial' Colorectal Disease, 23, pp. 555-556. (doi: 10.1111/codi.15428)

Jensen, M. P., Le Quesne, J., Officer‐Jones, L., Teodòsio, A., Thaventhiran, J., Ficken, C., Goddard, M., Smith, C., Menon, D., Allinson, K. S. J. (2021) Neuropathological findings in two patients with fatal COVID‐19. Neuropathology and Applied Neurobiology, 47, pp. 17-25. (doi: 10.1111/nan.12662)

McSorley, S. T., Lau, H. Y.N., McIntosh, D., Forshaw, M. J., McMillan, D. C., Crumley, A. B. (2021) Staging the tumour and staging the host: Pre-treatment combined Neutrophil Lymphocyte Ratio and modified Glasgow Prognostic Score is associated with overall survival in patients with oesophagogastric cancers undergoing treatment with curative intent. Annals of Surgical Oncology, 28, pp. 722-731. (doi: 10.1245/s10434-020-09074-5)

Crabb, S. J., Griffiths, G., Marwood, E., Dunkley, D., Downs, N., Martin, K., Light, M., Northey, J., Wilding, S., Whitehead, A., Shaw, E., Birtle, A. J., Bahl, A., Elliott, T., Westbury, C., Sundar, S., Robinson, A., Jagdev, S., Kumar, S., Rooney, C., Salinas-Souza, C., Stephens, C., Khoo, V., Jones, R. J. (2021) Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID) Journal of Clinical Oncology, 39, pp. 190-201. (doi: 10.1200/JCO.20.01576)

Alhayyan, A. M., McSorley, S. T., Kearns, R. J., Horgan, P. G., Roxburgh, C. S.D., McMillan, D. C. (2021) The effect of anesthesia on the magnitude of the postoperative systemic inflammatory response in patients undergoing elective surgery for colorectal cancer in the context of an enhanced recovery pathway: A prospective cohort study. Medicine, 100, (doi: 10.1097/MD.0000000000023997)

Kotzur, M., O'Connor, R., Robb, K. (2021) Health and Wellbeing Implications of Physical Distancing Restrictions in Scotland: a Qualitative Study.

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160, pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043)

Froeling, F. E.M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K. (2021) Molecular subtyping and precision medicine for pancreatic cancer. Journal of Clinical Medicine, 10, (doi: 10.3390/jcm10010149)

Earl, H.M., Hiller, L., Dunn, J., Macpherson, I., Rea, D., Hughes-Davies, L., McAdam, K., Hall, P., Mansi, J., Wheatley, D., Abraham, J.E., Caldas, C., Gasson, S., O'Riordan, E., Wilcox, M., Miles, D., Cameron, D.A., Wardley, A. (2021) Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33, pp. 15-19. (doi: 10.1016/j.clon.2020.07.006)

Pascual, J. et al. (2021) Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. Cancer Discovery, 11, pp. 92-107. (doi: 10.1158/2159-8290.CD-20-0553)

Hanna, C. R., Boyd, K. A., Wincenciak, J., Graham, J., Iveson, T., Jones, R. J., Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, (doi: 10.1016/j.ctarc.2021.100445)

Klionsky, D. J. et al. (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) Autophagy, 17, pp. 1-382. (doi: 10.1080/15548627.2020.1797280)

Valtonen, S., Vuorinen, E., Kariniemi, T., Eskonen, V., Le Quesne, J., Bushell, M., Härmä, H., Kopra, K. (2020) Nanomolar Protein-Protein Interaction monitoring with a label-free protein-probe technique. Analytical chemistry, 92, pp. 15781-15788. (doi: 10.1021/acs.analchem.0c02823)

McAllister, M. J., McCall, P., Dickson, A., Underwood, M. A., Andersen, D., Holmes, E., Market, E., Leung, H. Y., Edwards, J. (2020) Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 23, pp. 596-606. (doi: 10.1038/s41391-020-0235-1)

Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., Chang, D.K., Garsed, D.W., Jonkers, J., Ledermann, J.A., Nik-Zainal, S., Ray-Coquard, I., Shah, S.P., Matias-Guiu, X., Swisher, E.M., Yates, L.R. (2020) ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 31, pp. 1606-1622. (doi: 10.1016/j.annonc.2020.08.2102)

Moekotte, A. L., Lof, S., Van Roessel, S., Fontana, M., Dreyer, S., Shablak, A., Casciani, F., Mavroeidis, V. K., Robinson, S., Khalil, K., Gradinariu, G., Mowbray, N., Al-Sarireh, B., Fusai, G. K., Roberts, K., White, S., Soonawalla, Z., Jamieson, N. B., Salvia, R., Besselink, M. G., Abu Hilal, M. (2020) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma. Annals of Surgery, 272, pp. 1086-1093. (doi: 10.1097/SLA.0000000000003177)

Dolan, R. D., Maclay, J. D., Abbass, T., Colville, D., Buali, F., MacLeod, N., McSorley, S. T., Horgan, P. G., McMillan, D. C. (2020) The relationship between 18F-FDG-PETCT-derived tumour metabolic activity, nutritional risk, body composition, systemic inflammation and survival in patients with lung cancer. Scientific Reports, 10, (doi: 10.1038/s41598-020-77269-7)

Malviya, G., Patel, R., Salji, M., Martinez, R. S., Repiscak, P., Mui, E., Champion, S., Mrowinska, A., Johnson, E., AlRasheedi, M., Pimlott, S., Lewis, D., Leung, H. Y. (2020) 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Research, 10, (doi: 10.1186/s13550-020-00728-9)

Young, B., Robb, K. (2020) How to get people to comply with COVID-19 public health measures – lessons from cancer screening. Conversation, pp. 24 Nov.

Hanna, C. R., Blyth, K. G., Burley, G., Carmichael, S., Evans, C., Hinsley, S., Khadra, I., Khoo, S., Lewsley, L.-A., Jones, R. R., Sharma, R., Taladriz-Sender, A., Thomson, E. C., Scott, J. T. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21, (doi: 10.1186/s13063-020-04891-1)

Fercoq, F., Remion, E., Vallarino-Lhermitte, N., Alonso, J., Raveendran, L., Nixon, C., Le Quesne, J., Carlin, L. M., Martin, C. (2020) Microfilaria-dependent thoracic pathology associated with eosinophilic and fibrotic polyps in filaria-infected rodents. Parasites and Vectors, 13, (doi: 10.1186/s13071-020-04428-0)

McAllister, M., Constancio, V., Patek, S., Gan, H., Bailey, P., Wheadon, H., Underwood, M., Leung, H., Edwards, J. (2020) Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancer. Prostate, 80, pp. 1353-1364. (doi: 10.1002/pros.24064)

Beer, P. A., Cooke, S. L., Chang, D. K., Biankin, A. V. (2020) Defining the clinical genomic landscape for real-world precision oncology. Genomics, 112, pp. 5324-5330. (doi: 10.1016/j.ygeno.2020.10.032)

Middleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., Gupta, A., Vardeu, A., Leach, E., Naidoo, R., Stanhope, S., Lewis, S., Hurstb, J., O’Kelly, I., Sznol, M. (2020) Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clinical Cancer Research, 26, pp. 5869-5878. (doi: 10.1158/1078-0432.CCR-20-1247)

Kemp, O., Horne, G. A., Soutar, R. (2020) The psychological impact of COVID19 on a shielding high-risk cohort. Scottish Medical Journal, 65, pp. 120-122. (doi: 10.1177/0036933020951900)

Kristeleit, R. et al. (2020) Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 123, pp. 1360-1369. (doi: 10.1038/s41416-020-1010-8)

Dolan, R. D., Alwahid, M., McSorley, S. T., Park, J. H., Stevenson, R. P., Roxburgh, C. S., Horgan, P. G., McMillan, D. C. (2020) A comparison of the prognostic value of composite ratios and cumulative scores in patients with operable rectal cancer. Scientific Reports, 10, (doi: 10.1038/s41598-020-73909-0)

Mevel, R., Steiner, I., Mason, S., Galbraith, L. C.A., Patel, R., Fadlullah, M. Z.H., Ahmad, I., Leung, H. Y., Oliveira, P., Blyth, K., Baena, E., Lacaud, G. (2020) RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development. eLife, 9, (doi: 10.7554/elife.60225)

Campbell, C., Douglas, A., Williams, L., Cezard, G., Brewster, D. H., Buchanan, D., Robb, K., Stanners, G., Weller, D., Steele, R. J.C., Steiner, M., Bhopal, R. (2020) Are there ethnic and religious variations in uptake of bowel cancer screening? A retrospective cohort study among 1.7 million people in Scotland. BMJ Open, 10, (doi: 10.1136/bmjopen-2020-037011)

Turner, N. C. et al. (2020) Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncology, 21, pp. 1296-1308. (doi: 10.1016/S1470-2045(20)30444-7)

Kocher, H. M., Basu, B., Froeling, F. E.M., Sarker, D., Slater, S., Carlin, D., deSouza, N. M., De Paepe, K. N., Goulart, M. R., Hughes, C., Imrali, A., Roberts, R., Pawula, M., Houghton, R., Lawrence, C., Yogeswaran, Y., Mousa, K., Coetzee, C., Sasieni, P., Prendergast, A., Propper, D. J. (2020) Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Communications, 11, (doi: 10.1038/s41467-020-18636-w)

Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, (doi: 10.1038/s41467-020-18151-y)

Ivanova, Y., Aitchison, I., Cannon, P., Butler, D., Gadegaard, N., Keith, N. (2020) Mapping of University Research Output and Impact to the United Nations Sustainable Development Goals. (doi: 10.17605/OSF.IO/UFYTA)

Hall, P. E., Shepherd, S. T.C., Brown, J., Larkin, J., Jones, R., Ralph, C., Hawkins, R., Chowdhury, S., Boleti, E., Bahl, A., Fife, K., Webb, A., Crabb, S. J., Geldart, T., Hill, R., Dunlop, J., McLaren, D., Ackerman, C., Wimalasingham, A., Beltran, L., Nathan, P., Powles, T. (2020) Radiological response heterogeneity is of prognostic significance in metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. European Urology Focus, 6, pp. 999-1005. (doi: 10.1016/j.euf.2019.01.010)

Moekotte, A. L. et al. (2020) Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. European Journal of Surgical Oncology, 46, pp. 1717-1726. (doi: 10.1016/j.ejso.2020.04.011)

Pritchard, J. J.G., Hamilton, G., Hurst, C. D., Fraser, S., Orange, C., Knowles, M. A., Jones, R. J., Leung, H. Y., Iwata, T. (2020) Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Urologic Oncology: Seminars and Original Investigations, 38, pp. 731.e1-737.e10. (doi: 10.1016/j.urolonc.2020.05.012)

Darici, S., Alkhaldi, H., Horne, G., Jørgensen, H. G., Marmiroli, S., Huang, X. (2020) Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence. Journal of Clinical Medicine, 9, (doi: 10.3390/jcm9092934)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, (doi: 10.1038/s41467-020-17359-2)

Wei, Q., Young, J., Holle, A., Li, J., Bieback, K., Inman, G., Spatz, J. P., Cavalcanti-Adam, E. A. (2020) Soft hydrogels for balancing cell proliferation and differentiation. ACS Biomaterials Science and Engineering, 6, pp. 4687-4701. (doi: 10.1021/acsbiomaterials.0c00854)

Wei, Q., Holle, A., Liu, J., Posa, F., Biagioni, F., Croci, O., Benk, A. S., Young, J., Noureddine, F., Deng, J., Zhang, M., Inman, G. J., Spatz, J. P., Campaner, S., Cavalcanti‐Adam, E. A. (2020) BMP‐2 signaling and mechanotransduction synergize to drive osteogenic differentiation via YAP/TAZ. Advanced Science, 7, (doi: 10.1002/advs.201902931)

Azar, A. A., Michie, A. M., Tarafdar, A., Malik, N., Menon, G. K., Till, K. J., Vlatković, N., Slipsky, J. R. (2020) A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populations. Scientific Reports, 10, (doi: 10.1038/s41598-020-70191-y)

Jones, R., Crabb, S., Chester, J., Elliott, T., Huddart, R., Birtle, A., Evans, L., Lester, J., Jagdev, S., Casbard, A., Huang, C., Madden, T.-A., Griffiths, G. (2020) A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International, 126, pp. 292-299. (doi: 10.1111/bju.15096)

Golder, A.M., Steele, C.W., Conn, D., Mackay, G.J., McMillan, D.C., Horgan, P.G., Roxburgh, C.S., McSorley, S.T. (2020) Authors' reply: Effect of preoperative oral antibiotics in combination with mechanical bowel preparation on inflammatory response and short-term outcomes following left-sided colonic and rectal resections. BJS Open, 4, pp. 730-731. (doi: 10.1002/bjs5.50286)

Moekotte, A.L. et al. (2020) Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. British Journal of Surgery, 107, pp. 1171-1182. (doi: 10.1002/bjs.11555)

Rodrigues, F. S., Miranda, V. S., Carneiro-Lobo, T. C., Scalabrini, L. C., Kruspig, B., Levantini, E., Murphy, D. J., Bassères, D. S. (2020) IKKβ kinase promotes stemness, migration, and invasion in KRAS-driven lung adenocarcinoma cells. International Journal of Molecular Sciences, 21, (doi: 10.3390/ijms21165806)

Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., , (2020) MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial. Clinical Cancer Research, 26, pp. 3936-3946. (doi: 10.1158/1078-0432.CCR-20-0414)

Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272, pp. 366-376. (doi: 10.1097/SLA.0000000000003143)

Curtin, N., Bányai, K., Thaventhiran, J., Le Quesne, J., Helyes, Z., Bai, P. (2020) Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome? British Journal of Pharmacology, 177, pp. 3635-3645. (doi: 10.1111/bph.15137)

Lewis, R., Todd, R., Newton, M., Jones, R. J., Wilson, C., Donovan, J. L., Bryan, R. T., Birtle, A., Hall, E. (2020) The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. Trials, 21, (doi: 10.1186/s13063-020-04559-w)

Horne, G., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A.-L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmeider, S., Brümmendorf, T.H., Schafhausen, P., Gallipoli, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., Foroni, L., Nicoloni, F. E., Holyoake, T. L., Copland, M. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34, pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9)

Dobbin, S. J.H., Mangion, K., Berry, C., Roditi, G., Basak, S., Sourbron, S., White, J., Venugopal, B., Touyz, R. M., Jones, R. J., Petrie, M. C., Lang, N. N. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22, pp. 1276-1277. (doi: 10.1002/ejhf.1847)

AbdulJabbar, K. et al. (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 26, pp. 1054-1062. (doi: 10.1038/s41591-020-0900-x)

Rana, D., Geue, C., Baillie, K., Pan, J., Mueller, T., Laskey, J., Bennie, M., Clarke, J., Jones, R. J., Brown, A., Wu, O. (2020) Healthcare Costs for Metastatic Castration Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide in the Pre and Post Chemotherapy Setting.

McSorley, S. T., Anderson, J. H., Whittle, T., Roxburgh, C. S., Horgan, P. G., McMillan, D. C., Steele, C. W. (2020) The impact of preoperative systemic inflammation on the efficacy of intravenous iron infusion to correct anaemia prior to surgery for colorectal cancer. Perioperative Medicine, 9, (doi: 10.1186/s13741-020-00146-4)

Briggs, A., Daniele, B., Dick, K., Evans, T. R. J., Galle, P. R., Hubner, R. A., Lopez, C., Siebert, U., Tremblay, G. (2020) Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. British Journal of Cancer, 122, pp. 1754-1759. (doi: 10.1038/s41416-020-0817-7)

Corrie, P.G. et al. (2020) Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122, pp. 1760-1768. (doi: 10.1038/s41416-020-0846-2)

Hanna, C. R., Gatting, L. P., Boyd, K. A., Robb, K. A., Jones, R. J. (2020) Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. Trials, 21, (doi: 10.1186/s13063-020-04425-9)

Kinstrie, R., Horne, G., Morrison, H., Irvine, D., Munje, C., Gómez Castañeda, E., Moka, H. A., Dunn, K., Cassels, J., Parry, N., Clarke, C., Scott, M., Clark, R. E., Holyoake, T. L., Wheadon, H., Copland, M. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34, pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5)

Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., Neidler, S., Rink, C., Karim, S. A., Gyuraszova, K., Nixon, C., Clark, W., Biankin, A. V., Carlin, L. M., Coffelt, S. B., Sansom, O. J., Morton, J. P., Murphy, D. J. (2020) Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in pancreatic ductal adenocarcinoma. Cancer Discovery, 10, pp. 872-887. (doi: 10.1158/2159-8290.CD-19-0620)

Conefrey, C., Donovan, J.L., Stein, R.C., Paramasivan, S., Marshall, A., Bartlett, J., Cameron, D., Campbell, A., Dunn, J., Earl, H., Hall, P., Harmer, V., Hughes-Davies, L., Macpherson, I., Makris, A., Morgan, A., Pinder, S., Poole, C., Rea, D., Rooshenas, L. (2020) Strategies to improve recruitment to a de-escalation trial: a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology, 32, pp. 382-389. (doi: 10.1016/j.clon.2020.01.029)

Baillie, K., Mueller, T., Pan, J., Laskey, J., Bennie, M., Crearie, C., Kavanagh, K., Alvarez‐Madrazo, S., Morrison, D., Clarke, J., Keel, A., Cameron, D., Wu, O., Kurdi, A., Jones, R. J. (2020) Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety, 29, pp. 653-663. (doi: 10.1002/pds.4998)

Kotzur, M., McCowan, C., Macdonald, S., Wyke, S., Gatting, L., Campbell, C., Weller, D., Crighton, E., Steele, R. J.C., Robb, K. A. (2020) Why colorectal screening fails to achieve the uptake rates of breast and cervical cancer screening: a comparative qualitative study. BMJ Quality and Safety, 29, pp. 482-490. (doi: 10.1136/bmjqs-2019-009998)

Blomme, A. et al. (2020) 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nature Communications, 11, (doi: 10.1038/s41467-020-16126-7)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31, (doi: 10.1016/j.celrep.2020.107625)

Kos, Z. et al. (2020) Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. npj Breast Cancer, 6, (doi: 10.1038/s41523-020-0156-0)

Scarsbrook, A. F., Bottomley, D., Teoh, E. J., Bradley, K. M., Payne, H., Afaq, A., Bomanji, J., van As, N., Chua, S., Hoskin, P., Chambers, A., Cook, G. J., Warbey, V. S., Han, S., Leung, H. Y., Chau, A., Miller, M. P., Gleeson, F. V., on behalf of the FALCON Study Group, . (2020) Effect of 18F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: Results from the FALCON Trial. International Journal of Radiation Oncology, Biology, Physics, 107, pp. 316-324. (doi: 10.1016/j.ijrobp.2020.01.050)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31, (doi: 10.1016/j.celrep.2020.107550)

Tzolos, E., Adamson, P.D., Hall, P.S., MacPherson, I.R., Oikonomidou, O., MacLean, M., Lewis, S.C., McVicars, H., Newby, D.E., Mills, N.L., Lang, N.N., Henriksen, P.A. (2020) Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. Clinical Oncology, 32, pp. 292-297. (doi: 10.1016/j.clon.2019.11.008)

ALHAYYAN, A., McSorley, S. T., Kearns, R. J., Horgan, P. G., Roxburgh, C. S.D., McMillan, D. C. (2020) The relationship between anaesthetic technique, clinicopathological characteristics and the magnitude of the postoperative systemic inflammatory response in patients undergoing elective surgery for colon cancer. PLoS ONE, 15, (doi: 10.1371/journal.pone.0228580)

Fulton, B., Jones, R., Powles, T., Crabb, S., Paul, J., Birtle, A., Chowdhury, S., Hussain, S., Morris, A., Soulis, E., Morrison, P. (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials, 21, (doi: 10.1186/s13063-020-04283-5)

Birtle, A., Johnson, M., Chester, J., Jones, R., Dolling, D., Bryan, R. T., Harris, C., Winterbottom, A., Blacker, A., Catto, J. W.F., Chakraborti, P., Donovan, J. L., Elliott, P. A., French, A., Jagdev, S., Jenkins, B., Keeley, F. X., Kockelbergh, R., Powles, T., Wagstaff, J., Wilson, C., Todd, R., Lewis, R., Hall, E. (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 395, pp. 1268-1277. (doi: 10.1016/S0140-6736(20)30415-3)

O'Connor, R. C., Robb, K. A. (2020) Identifying suicide risk factors in children is essential for developing effective prevention interventions. Lancet Psychiatry, 7, pp. 292-293. (doi: 10.1016/S2215-0366(20)30094-8)

Gonzalez‐Ericsson, P. I. et al. (2020) The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 250, pp. 667-684. (doi: 10.1002/path.5406)

Sepp, K., Lee, M., Bluntzer, M., Helgason, G. V., Hulme, A. N., Brunton, V. G. (2020) Utilizing stimulated Raman scattering microscopy to study intracellular distribution of label-free ponatinib in live cells. Journal of Medicinal Chemistry, 63, pp. 2028-2034. (doi: 10.1021/acs.jmedchem.9b01546)

Robb, K. A., Gatting, L. P., von Wagner, C., McGregor, L. M. (2020) Preference for deliberation and perceived usefulness of standard- and narrative-style leaflet designs: implications for equitable cancer-screening communication. Annals of Behavioral Medicine, 54, pp. 193-201. (doi: 10.1093/abm/kaz039)

Neal, D. E. et al. (2020) Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT Randomised Controlled Trial according to treatment received. European Urology, 77, pp. 320-330. (doi: 10.1016/j.eururo.2019.10.030)

Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R., Leung, H. Y. (2020) Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 122, pp. 517-527. (doi: 10.1038/s41416-019-0681-5)

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, , Bailey, P. J., Chang, D. K., Cooke, S. L., Biankin, A. V., Duthie, F. R., Graham, J. S., Jamieson, N. B., Musgrove, E. A., Martin, S., Yuan, K., Wright, D. W., Oien, K. A. (2020) Pan-cancer analysis of whole genomes. Nature, 578, pp. 82-93. (doi: 10.1038/s41586-020-1969-6)

Jiao, W., Atwal, G., Polak, P., Karlic, R., Cuppen, E., PCAWG Tumor Subtypes and Clinical Translation Working Group, , Danyi, A., de Ridder, J., van Herpen, C., Lolkema, M. P., Steeghs, N., Getz, G., Morris, Q., Stein, L. D., PCAWG Consortium, , Bailey, P. J., Biankin, A. V., Chang, D. K., Cooke, S. L., Martin, S., Wright, D. W. (2020) A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature Communications, 11, (doi: 10.1038/s41467-019-13825-8)

Patel, R., Brzezinska, E. A., Repiscak, P., Ahmad, I., Mui, E., Gao, M., Blomme, A., Harle, V., Tan, E. H., Malviya, G., Mrowinska, A., Loveridge, C. J., Rushworth, L. K., Edwards, J., Ntala, C., Nixon, C., Hedley, A., Mackay, G., Tardito, S., Sansom, O. J., Leung, H. Y. (2020) Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer. Cancer Research, 80, pp. 576-590. (doi: 10.1158/0008-5472.CAN-19-1684)

Niedzwiedz, C. L., Robb, K. A., Katikireddi, S. V., Pell, J. P., Smith, D. J. (2020) Depressive symptoms, neuroticism and participation in breast and cervical cancer screening: cross-sectional and prospective evidence from UK Biobank. Psycho-Oncology, 29, pp. 381-388. (doi: 10.1002/pon.5272)

Witjes, J. A. et al. (2020) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort† EU*ACME: under the auspices of the EAU-ESMO guidelines committees. European Urology, 77, pp. 223-250. (doi: 10.1016/j.eururo.2019.09.035)

Alsina, A., Kudo, M., Vogel, A., Cheng, A.-L., Tak, W. Y., Ryoo, B.-Y., Evans, T. R. J., López López, C., Daniele, B., Misir, S., Ren, M., Izumi, N., Qin, S., Finn, R. S. (2020) Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. Liver Cancer, 9, pp. 93-104. (doi: 10.1159/000504624)

Mohan, S., Foy, V., Ayub, M., Leong, H. S., Schofield, P., Sahoo, S., Descamps, T., Kilerci, B., Smith, N. K., Carter, M., Priest, L., Zhou, C., Carr, T. H., Miller, C., Faivre-Finn, C., Blackhall, F., Rothwell, D. G., Dive, C., Brady, G. (2020) Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC. Journal of Thoracic Oncology, 15, pp. 216-230. (doi: 10.1016/j.jtho.2019.10.007)

Kotzur, M., Macdonald, S., O'Connor, R., O'Carroll, R., Irvine, A., Steele, R., Robb, K. (2020) Barriers to Self-completed FIT Bowel Cancer Screening and How to Overcome Them: a Qualitative Study.

Coleman, R., Brown, J., Rathbone, E., Flanagan, L., Reid, A., Kendall, J., Howell, S., Twelves, C., Palmieri, C., Anand, A., MacPherson, I., Brown, S. (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 21, (doi: 10.1186/s13063-019-3643-6)

Mateo, J. et al. (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, 21, pp. 162-174. (doi: 10.1016/S1470-2045(19)30684-9)

Dreyer, S.B., Jamieson, N.B., Cooke, S.L., Valle, J.W., McKay, C.J., Biankin, A.V., Chang, D.K. (2020) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, 32, pp. 1-4. (doi: 10.1016/j.clon.2019.07.011)

Dreyer, S.B., Jamieson, N.B., Morton, J.P., Sansom, O.J., Biankin, A.V., Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32, pp. 5-8. (doi: 10.1016/j.clon.2019.08.007)

Cebon, J. S. et al. (2020) Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. Journal for ImmunoTherapy of Cancer, 8, (doi: 10.1136/jitc-2019-000410)

Alhayyan, A., McSorley, S., Roxburgh, C., Kearns, R., Horgan, P., McMillan, D. (2020) The effect of anesthesia on the postoperative systemic inflammatory response in patients undergoing surgery: a systematic review and meta-analysis. Surgery Open Science, 2, pp. 1-21. (doi: 10.1016/j.sopen.2019.06.001)

Officer, L. K., Andreou, K. E., Teodósio, A. V., He, Z., Le Quesne, J. P. (2020) Automated co-in situ hybridization and immunofluorescence using archival tumor tissue. Springer

Loveridge, C. J., Slater, S., Campbell, K. J., Nam, N. A., Knight, J., Ahmad, I., Hedley, A., Lilla, S., Repiscak, P., Patel, R., Salji, M., Fleming, J., Mitchell, L., Nixon, C., Strathdee, D., Neilson, M., Ntala, C., Bryson, S., Zanivan, S. R., Edwards, J., Robson, C. N., Goodyear, C. S., Blyth, K., Leung, H. Y. (2020) BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 39, pp. 1797-1806. (doi: 10.1038/s41388-019-1106-x)

McSorley, S. T., Tham, A., Dolan, R. D., Steele, C. W., Ramsingh, J., Roxburgh, C., Horgan, P. G., McMillan, D. C. (2020) Perioperative blood transfusion is associated with the postoperative systemic inflammatory response and poorer outcomes following surgery for colorectal cancer. Annals of Surgical Oncology, 27, pp. 833-843. (doi: 10.1245/s10434-019-07984-7)

Ghaddar, N., Wang, S., Woodvine, B., Krishnamoorthy, J., Darini, C., Van Hoef, V., Popper, H., Topisirovic, I., Larsson, O., Le Quesne, J., Koromilas, A. (2020) The integrated stress response exposes a therapeutic vulnerability in KRAS driven lung cancer. European Journal of Cancer, 138, pp. S23. (doi: 10.1016/S0959-8049(20)31126-6)

Vetrie, D., Helgason, V., Copland, M. (2020) The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer, 20, pp. 158-173. (doi: 10.1038/s41568-019-0230-9)

MacPherson, I. R., Spiliopoulou, P., Rafii, S., Saggese, M., Baird, R. D., Garcia-Corbacho, J., Italiano, A., Bonneterre, J., Campone, M., Cresti, N., Posner, J., Takeda, Y., Arimura, A., Spicer, J. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, (doi: 10.1186/s13058-019-1178-0)

Waldron, J. A., Tack, D. C., Ritchey, L. E., Gillen, S. L., Wilczynska, A., Turro, E., Bevilacqua, P. C., Assmann, S. M., Bushell, M., Le Quesne, J. (2019) mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity. Genome Biology, 20, (doi: 10.1186/s13059-019-1901-2)

Clark, E., Morton, M., Sharma, S., Fisher, H., Howel, D., Walker, J., Wood, R., Hancock, H., Maier, R., Marshall, J., Bahl, A., Crabb, S., Jain, S., Pedley, I., Jones, R., Staffurth, J., Heer, R. (2019) Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 9, (doi: 10.1136/bmjopen-2019-034708)

Le Quesne, J., Pritchard, C., Officer, L., Kamata, T., Smith, C., Sereno, M., Das, M., Baena, J., Al Dujaily, E. (2019) Reduced protumorigenic tumor-associated macrophages with statin use in premalignant human lung adenocarcinoma. JNCI Cancer Spectrum, 4, (doi: 10.1093/jncics/pkz101)

Wilczynska, A., Gillen, S. L., Schmidt, T., Meijer, H. A., Jukes-Jones, R., Langlais, C., Kopra, K., Lu, W.-T., Godfrey, J. D., Hawley, B. R., Hodge, K., Zanivan, S., Cain, K., Le Quesne, J., Bushell, M. (2019) eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5’UTR. Genome Biology, 20, (doi: 10.1186/s13059-019-1857-2)

Paterson, C., Thomson, M., Caldwell, B., Young, R., McLean, A., Porteous, S., Clark, S., Messow, C. M., Kean, S., Grose, D., Lamb, C., Rizwannullah, M., James, A., Schipani, S., Wilson, C., Rulach, R., Jones, R. (2019) Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck. British Journal of Oral and Maxillofacial Surgery, 57, pp. 1119-1125. (doi: 10.1016/j.bjoms.2019.10.300)

Hoyle, A. P. et al. (2019) Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology, 76, pp. 719-728. (doi: 10.1016/j.eururo.2019.08.006)

Clarke, N. W. et al. (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30, pp. 1992-2003. (doi: 10.1093/annonc/mdz396)

Golder, A. M., McSorley, S. T., Kearns, R. J., McMillan, D. C., Horgan, P. G., Roxburgh, C. S. (2019) Attitudes towards the use of perioperative steroids in resectional colorectal cancer surgery in the UK: a qualitative study. Annals of Medicine and Surgery, 48, pp. 23-28. (doi: 10.1016/j.amsu.2019.10.007)

Golder, A.M., Steele, C.W., Conn, D., Mackay, G.J., McMillan, D.C., Horgan, P.G., Roxburgh, C.S., McSorley, S.T. (2019) Effect of preoperative oral antibiotics in combination with mechanical bowel preparation on inflammatory response and short‐term outcomes following left‐sided colonic and rectal resections. BJS Open, 3, pp. 830-839. (doi: 10.1002/bjs5.50224)

Almasaudi, A. S., McSorley, S. T., Dolan, R. D., Edwards, C. A., McMillan, D. C. (2019) The relation between Malnutrition Universal Screening Tool (MUST), computed tomography-derived body composition, systemic inflammation, and clinical outcomes in patients undergoing surgery for colorectal cancer. American Journal of Clinical Nutrition, 110, pp. 1327-1334. (doi: 10.1093/ajcn/nqz230)

Horwich, A. et al. (2019) EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 30, pp. 1697-1727. (doi: 10.1093/annonc/mdz296)

Malik, N., Dunn, K. M., Cassels, J., Hay, J., Estell, C., Sansom, O. J., Michie, A. M. (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, (doi: 10.1038/s41598-019-53141-1)

Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M.-J., Oaknin, A., Kerger, J., López-Picazo, J. M., Machiels, J.-P., Delord, J.-P., Evans, T. R.J., Boni, V., Calvo, E., Topalian, S. L., Chen, T., Soumaoro, I., Li, B., Gu, J., Zwirtes, R., Moore, K. N. (2019) Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology, 37, pp. 2825-2834. (doi: 10.1200/JCO.19.00739)

Joharatnam-Hogan, N. et al. (2019) Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology, 4, pp. 854-862. (doi: 10.1016/S2468-1253(19)30289-4)

Hasan, M. N., Rouprêt, M., Keeley, F., Cracco, C., Jones, R., Straub, M., Traxer, O., Osther, P. J. S., Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World Journal of Urology, 37, pp. 2289-2296. (doi: 10.1007/s00345-019-02739-1)

Jung, H., Giusti, G., Fajkovic, H., Herrmann, T., Jones, R., Straub, M., Baard, J., Osther, P. J. S., Brehmer, M. (2019) Consultation on UTUC, Stockholm 2018: aspects of treatment. World Journal of Urology, 37, pp. 2279-2287. (doi: 10.1007/s00345-019-02811-w)

Beer, P. A., Cooke, S. L., Chang, D. K., Biankin, A. V. (2019) Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. Annals of Oncology, 30, pp. 1691-1694. (doi: 10.1093/annonc/mdz392)

Almasaudi, A. S., Dolan, R. D., McSorley, S. T., Horgan, P. G., Edwards, C., McMillan, D. C. (2019) Relationship between computed tomography-derived body composition, sex, and post-operative complications in patients with colorectal cancer. European Journal of Clinical Nutrition, 73, pp. 1450-1457. (doi: 10.1038/s41430-019-0414-0)

Bott, A. J. et al. (2019) Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism. Cell Reports, 29, pp. 1287-1298.e6. (doi: 10.1016/j.celrep.2019.09.056)

Hay, J., Moles, M. W., Cassels, J., Michie, A. M. (2019) Subcellular fractionation of primary chronic lymphocytic leukemia cells to monitor nuclear/ cytoplasmic protein trafficking. Journal of Visualized Experiments, (doi: 10.3791/60426)

McCowan, C., McSkimming, P., Papworth, R., Kotzur, M., McConnachie, A., Macdonald, S., Wyke, S., Crighton, E., Campbell, C., Weller, D., Steele, R. J.C., Robb, K. A. (2019) Comparing uptake across breast, cervical and bowel screening at an individual level: a retrospective cohort study. British Journal of Cancer, 121, pp. 710-714. (doi: 10.1038/s41416-019-0564-9)

Niedzwiedz, C. L., Knifton, L., Robb, K. A., Katikireddi, S. V., Smith, D. J. (2019) Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. BMC Cancer, 19, (doi: 10.1186/s12885-019-6181-4)

Robb, K., O'Carroll, R. (2019) Simpler is better—the case of colorectal cancer screening. BMJ Opinion,

Birrell, F., Leung, H. Y. (2019) The Scottish prostate cryotherapy service-the role of the clinical nurse specialist. British Journal of Nursing, 28, pp. S12-S16. (doi: 10.12968/bjon.2019.28.18.S12)

Jones, R. L. et al. (2019) Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, pp. 132-139. (doi: 10.1016/j.ejca.2019.07.024)

Chemi, F. et al. (2019) Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine, 25, pp. 1534-1539. (doi: 10.1038/s41591-019-0593-1)

Kotzur, M., Macdonald, S., O'Connor, R., O'Carroll, R., Irvine, A., Steele, R., Robb, K. (2019) Identifying Barriers and Solutions to Self-completed FIT Bowel Screening to Develop a Volitional Help-sheet.

McSorley, S. T., Dolan, R. D., Roxburgh, C. S.D., Horgan, P. G., MacKay, G. J., McMillan, D. C. (2019) Possible dose dependent effect of perioperative dexamethasone and laparoscopic surgery on the postoperative systemic inflammatory response and complications following surgery for colon cancer. European Journal of Surgical Oncology, 45, pp. 1613-1618. (doi: 10.1016/j.ejso.2019.05.020)

Bilsland, A. E., Liu, Y., Turnbull, A., Sumpton, D., Stevenson, K., Cairney, C. J., Boyd, S. M., Roffey, J., Jenkinson, D., Keith, W. N. (2019) A novel pyrazolopyrimidine ligand of human PGK1 and stress sensor DJ1 modulates the shelterin complex and telomere length regulation. Neoplasia, 21, pp. 893-907. (doi: 10.1016/j.neo.2019.07.008)

Fercoq, F., Remion, E., Frohberger, S. J., Vallarino-Lhermitte, N., Hoerauf, A., Le Quesne, J., Landmann, F., Hübner, M. P., Carlin, L. M., Martin, C. (2019) IL-4 receptor dependent expansion of lung CD169+ macrophages in microfilaria-driven inflammation. PLoS Neglected Tropical Diseases, 13, (doi: 10.1371/journal.pntd.0007691)

Fox, T. A., Horne, G. A., Craddock, C., Cook, G., O'Brien, S., Fox, S., Hockaday, A., Silk, G., Hillmen, P. (2019) Trial re-investment to build better research for better impact. Lancet, 394, pp. 635-636. (doi: 10.1016/S0140-6736(19)31363-7)

Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, (doi: 10.1038/s41467-019-10968-6)

Brunton, H. et al. (2019) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Press Sneak Peek, (doi: 10.2139/ssrn.3430714)

Attard, G., Merseburger, A. S., Arlt, W., Sternberg, C. N., Feyerabend, S., Berruti, A., Joniau, S., Géczi, L., Lefresne, F., Lahaye, M., Shelby, F. N., Pissart, G., Chua, S., Jones, R. J., Tombal, B. (2019) Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate formetastatic castration-resistant prostate Cancer: a randomized, open-label phase 2 study. JAMA Oncology, 5, pp. 1159-1167. (doi: 10.1001/jamaoncol.2019.1011)

Banerji, U., van Herpen, C. M.L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G.E., Rottey, S., Greenen, J., Eskens, F., Gil-Martin, M., Mommers, E. C., Koper, N. P., Aftimos, P. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, 20, pp. 1124-1135. (doi: 10.1016/S1470-2045(19)30328-6)

Evans, T. R. J., Kudo, M., Finn, R. S., Han, K.-H., Cheng, A.-L., Ikeda, M., Kraljevic, S., Ren, M., Ductus, C. E., Piscaglia, F., Sung, M. W. (2019) Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 121, pp. 218-221. (doi: 10.1038/s41416-019-0506-6)

Reader, C. S., Vallath, S., Steele, C. W., Haider, S., Brentnall, A., Desai, A., Moore, K. M., Jamieson, N. B., Chang, D., Bailey, P., Scarpa, A., Lawlor, R., Chelala, C., Keyse, S. M., Biankin, A., Morton, J. P., Evans, T.R. J., Barry, S. T., Sansom, O. J., Kocher, H. M., Marshall, J. F. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 249, pp. 332-342. (doi: 10.1002/path.5320)

McSorley, S. T., Tham, A., Steele, C. W., Dolan, R. D., Roxburgh, C. S.D., Horgan, P. G., McMillan, D. C. (2019) Quantitative data on red cell measures of iron status and their relation to the magnitude of the systemic inflammatory response and survival in patients with colorectal cancer. European Journal of Surgical Oncology, 45, pp. 1205-1211. (doi: 10.1016/j.ejso.2019.02.027)

Halbrook, C. J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., Hong, H. S., Kremer, D. M., Nelson, B. S., Kemp, S., Zhang, L., Chang, D., Biankin, A., Shi, J., Frankel, T. L., Crawford, H. C., Morton, J. P., Pasca di Magliano, M., Lyssiotis, C. A. (2019) Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabolism, 29, pp. 1390-1399.e6. (doi: 10.1016/j.cmet.2019.02.001)

Palmieri, C., Macpherson, I. (2019) Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. Lancet Oncology, 20, pp. e289. (doi: 10.1016/S1470-2045(19)30296-7)

Memon, D., Bi, J., Miller, C. J. (2019) In silico prediction of housekeeping long intergenic non-coding RNAs reveals HKlincR1 as an essential player in lung cancer cell survival. Scientific Reports, 9, (doi: 10.1038/s41598-019-43758-7)

Roseweir, A. K., Clark, J., McSorley, S. T., vanWyk, H. C., Quinn, J. A., Horgan, P. G., McMillan, D. C., Park, J. H., Edwards, J. (2019) The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. International Journal of Cancer, 144, pp. 2320-2329. (doi: 10.1002/ijc.32045)

Kotzur, M., Robb, K. (2019) Cancer: Breast. Cambridge University Press

Badshah, I.I., Brown, S., Weibel, L., Rose, A., Way, B., Sebire, N., Inman, G., Harper, J., O'Shaughnessy, R.F.L. (2019) Differential expression of secreted factors SOSTDC1 and ADAMTS8 cause profibrotic changes in linear morphoea fibroblasts. British Journal of Dermatology, 180, pp. 1135-1149. (doi: 10.1111/bjd.17352)

McSorley, S. T., Tham, A., Jones, I., Talwar, D., McMillan, D. C. (2019) Regression correction equation to adjust serum iron and ferritin concentrations based on C-reactive protein and albumin in patients receiving primary and secondary care. Journal of Nutrition, 149, pp. 877-883. (doi: 10.1093/jn/nxz008)

Rothwell, D. G. et al. (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nature Medicine, 25, pp. 738-743. (doi: 10.1038/s41591-019-0380-z)

Neidler, S., Kruspig, B., Hewit, K., Monteverde, T., Gyuraszova, K., Braun, A., Clark, W., James, D., Hedley, B., Nieswandt, B., Shanks, E., Dick, C., Murphy, D. J. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11, (doi: 10.3390/cancers11050600)

Salvucci, M., Rahman, A., Resler, A. J., Udupi, G. M., McNamara, D. A., Kay, E. W., Laurent-Puig, P., Longley, D. B., Johnston, P. G., Lawler, M., Wilson, R., Salto-Tellez, M., Van Schaeybroeck, S., Rafferty, M., Gallagher, W. M., Rehm, M., Prehn, J. H.M. (2019) A machine learning platform to optimize the translation of personalized network models to the clinic. JCO Clinical Cancer Informatics, pp. 1-17. (doi: 10.1200/CCI.18.00056)

Neves, K. B., Rios, F. J., Jones, R., Evans, T. R. J., Montezano, A. C., Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115, pp. 978-988. (doi: 10.1093/cvr/cvz021)

Moore, D. A., Sereno, M., Das, M., Baena Acevedo, J. D., Sinnadurai, S., Smith, C., McSweeney, A., Su, X., Officer, L., Jones, C., Dudek, K., Guttery, D., Taniere, P., Spriggs, R. V., Le Quesne, J. (2019) In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth—a clinically relevant distinction. Modern Pathology, 32, pp. 1095-1105. (doi: 10.1038/s41379-019-0257-1)

Dolan, R. D., McLees, N. G., Irfan, A., McSorley, S. T., Horgan, P. G., Colville, D., McMillan, D. C. (2019) The relationship between tumour glucose metabolism and host systemic inflammatory responses in patients with cancer: a systematic review. Journal of Nuclear Medicine, 60, pp. 467-471. (doi: 10.2967/jnumed.118.216697)

McAllister, M. J., Underwood, M. A., Leung, H. Y., Edwards, J. (2019) A review on the interactions between the tumour microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 206, pp. 91-106. (doi: 10.1016/j.trsl.2018.11.004)

Baquero, P., Dawson, A., Helgason, G. V. (2019) Autophagy and mitochondrial metabolism: insights into the role and therapeutic potential in chronic myeloid leukaemia. FEBS Journal, 286, pp. 1271-1283. (doi: 10.1111/febs.14659)

Conway, J. R.W., Herrmann, D., Evans, T.R. J., Morton, J. P., Timpson, P. (2019) Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 68, pp. 742-758. (doi: 10.1136/gutjnl-2018-316822)

Dreyer, S. B., Jamieson, N. B., Evers, L., Duthie, F., Cooke, S., Marshall, J., Beraldi, D., Knight, S., Upstill-Goddard, R., Dickson, E. J., Carter, C. R., McKay, C. J., Biankin, A. V., Chang, D. K. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8, (doi: 10.21037/cco.2019.04.06)

Cunningham, Y., Wyke, S., Blyth, K. G., Rigg, D., Macdonald, S., Macleod, U., Harrow, S., Robb, K. A., Whitaker, K. L. (2019) Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: a qualitative interview study. Psycho-Oncology, 28, pp. 718-725. (doi: 10.1002/pon.5005)

Collisson, E. A., Bailey, P., Chang, D. K., Biankin, A. V. (2019) Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 16, pp. 207-220. (doi: 10.1038/s41575-019-0109-y)

Baquero, P., Dawson, A., Mukhopadhyay, A., Kuntz, E. M., Mitchell, R., Olivares, O., Ianniciello, A., Scott, M. T., Dunn, K., Nicastri, M. C., Winkler, J. D., Michie, A. M., Ryan, K. M., Halsey, C., Gottlieb, E., Keaney, E. P., Murphy, L. O., Amaravadi, R. K., Holyoake, T. L., Helgason, G. V. (2019) Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 33, pp. 981-994. (doi: 10.1038/s41375-018-0252-4)

Almasaudi, A. S., McSorley, S. T., Horgan, P. G., McMillan, D. C., Edwards, C. A. (2019) The relationship between body mass index, sex, and postoperative outcomes in patients undergoing potentially curative surgery for colorectal cancer. Clinical Nutrition ESPEN, 30, pp. 185-189. (doi: 10.1016/j.clnesp.2018.12.084)

Rosenthal, R. et al. (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature, 567, pp. 479-485. (doi: 10.1038/s41586-019-1032-7)

Twelves, C., Anthoney, A., Savulsky, C. I., Guo, M., Reyderman, L., Cresti, N., Semiglazov, V., Timcheva, C., Zubairi, I., Morrison, R., Plummer, R., Evans, T.R. J. (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120, pp. 579-586. (doi: 10.1038/s41416-018-0366-5)

Wetherall, K., Robb, K. A., O'Connor, R. C. (2019) Social rank theory of depression: A systematic review of self-perceptions of social rank and their relationship with depressive symptoms and suicide risk. Journal of Affective Disorders, 246, pp. 300-319. (doi: 10.1016/j.jad.2018.12.045)

Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., Marshall, J. F., Panico, M. B., Shaw, J. A., Steeg, P. S., Sullivan, M., Tong, W., Westwell, A. D., Ritchie, J. W.A. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16, pp. 185-204. (doi: 10.1038/s41571-018-0134-8)

Cosimo, E., Tarafdar, A., Moles, M. W., Holroyd, A. K., Malik, N., Catherwood, M. A., Hay, J., Dunn, K. M., Macdonald, A. M., Guichard, S. M., O'Rourke, D. M., Leach, M. T., Sansom, O. J., Cosulich, S. C., McCaig, A. M., Michie, A. M. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25, pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036)

McSorley, S., Johnstone, M., Steele, C. W., Roxburgh, C. S.D., Horgan, P. G., McMillan, D. C., Mansouri, D. (2019) Normocytic anaemia is associated with systemic inflammation and poorer survival in patients with colorectal cancer treated with curative intent. International Journal of Colorectal Disease, 34, pp. 401-408. (doi: 10.1007/s00384-018-3211-7)

Kdadra, M., Höckner, S., Leung, H., Kremer, W., Schiffer, E. (2019) Metabolomics biomarkers of prostate cancer: A systematic review. Diagnostics, 9, (doi: 10.3390/diagnostics9010021)

Scopelliti, A., Bauer, C., Yu, Y., Zhang, T., Kruspig, B., Murphy, D. J., Vidal, M., Maddocks, O. D.K., Cordero, J. B. (2019) A neuronal relay mediates a nutrient responsive gut/fat body axis regulating energy homeostasis in adult Drosophila. Cell Metabolism, 29, pp. 269-284.e10. (doi: 10.1016/j.cmet.2018.09.021)

Wetherall, K., Robb, K. A., O'Connor, R. C. (2019) An examination of social comparison and suicide ideation through the lens of the integrated motivational–volitional model of suicidal behavior. Suicide and Life-Threatening Behavior, 49, pp. 167-182. (doi: 10.1111/sltb.12434)

Parry, M. A., Srivastava, S., Ali, A., Cannistraci, A., Antonello, J., Barros-Silva, J. D., Ubertini, V., Ramani, V., Lau, M., Shanks, J., Nonaka, D., Oliveira, P., Hambrock, T., Leong, H. S., Dhomen, N., Miller, C., Brady, G., Dive, C., Clarke, N. W., Marais, R., Baena, E. (2019) Genomic evaluation of multiparametric magnetic resonance imaging-visible and -nonvisible lesions in clinically localised prostate cancer. European Urology Oncology, 2, pp. 1-11. (doi: 10.1016/j.euo.2018.08.005)

Macdonald, S., Conway, E., Bikker, A., Browne, S., Robb, K., Campbell, C., Steele, R. J.C., Weller, D., MacLeod, U. (2019) Making sense of bodily sensations: do shared cancer narratives influence symptom appraisal? Social Science and Medicine, 223, pp. 31-39. (doi: 10.1016/j.socscimed.2018.12.034)

Spender, L. C., Ferguson, G. J., Hughes, G. D., Davies, B. R., Goldberg, F. W., Herrera, B., Taylor, R. G., Strathearn, L. S., Sansom, O. J., Barry, S. T., Inman, G. I. (2019) Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor β superfamily type 1 receptors. Molecular Pharmacology, 95, pp. 222-234. (doi: 10.1124/mol.118.112946)

Dolan, R., Almasaudi, A. S., Dieu, L. B., Horgan, P. G., McSorley, S. T., McMillan, D. C. (2019) The relationship between computed tomography‐derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer. Journal of Cachexia, Sarcopenia and Muscle, 10, pp. 111-122. (doi: 10.1002/jcsm.12357)

Evans, T.R. J., Dean, E., Molife, L. R., Lopez, J., Ranson, M., El-Khouly, F., Zubairi, I., Savulsky, C., Reyderman, L., Jia, Y., Sweeting, L., Greystroke, A., Barriuso, J., Kristeleit, R. (2019) Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. British Journal of Cancer, (doi: 10.1038/s41416-019-0377-x)

Lallo, A., Gulati, S., Schenk, M. W., Khandelwal, G., Berglund, U. W., Pateras, I. S., Chester, C. P. E., Pham, T. M., Kalderen, C., Frese, K. K., Gorgoulis, V. G., Miller, C., Blackhall, F., Helleday, T., Dive, C. (2019) Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. British Journal of Pharmacology, 176, pp. 436-450. (doi: 10.1111/bph.14542)

Hassan, S., Purdie, K. J., Wang, J., Harwood, C. A., Proby, C. M., Pourreyron, C., Mladkova, N., Nagano, A., Dhayade, S., Athineos, D., Caley, M., Mannella, V., Blyth, K., Inman, G. J., Leigh, I. M. (2019) A unique panel of patient-derived cutaneous squamous cell carcinoma cell lines provides a preclinical pathway for therapeutic testing. International Journal of Molecular Sciences, 20, (doi: 10.3390/ijms20143428)

Smith, L. D., Minton, A. R., Blunt, M. D., Karydis, L. I., Dutton, D. A., Rogers-Broadway, K.-R., Dobson, R., Liu, R., Norster, F., Hogg, E., Ashton-Key, M., Strefford, J. C., Jia, L., Efremov, D. G., Helgason, G. V., Johnson, P. W.M., Stevenson, F. K., Forconi, F., Cragg, M. S., Tumbarello, D. A., Packham, G., Steele, A. J. (2019) BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia, 34, pp. 640-644. (doi: 10.1038/s41375-019-0557-y)

Rakhit, C. P., Trigg, R. M., Le Quesne, J., Kelly, M., Shaw, J. A., Pritchard, C., Martins, L. M. (2019) Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Disease Models and Mechanisms, 12, (doi: 10.1242/dmm.036863)

Bikker, A. P., Macdonald, S., Robb, K., Conway, E., Browne, S., Campbell, C., Weller, D., Steele, R., Macleod, U. (2019) Perceived colorectal cancer candidacy and the role of candidacy in colorectal cancer screening. Health, Risk and Society, 21, pp. 352-372. (doi: 10.1080/13698575.2019.1680816)

Laskar, P., Somani, S., Altwaijry, N., Mullin, M., Bowering, D., Warzecha, M., Keating, P., Tate, R. J., Leung, H. Y., Dufès, C. (2018) Redox-sensitive, cholesterol-bearing PEGylated poly(propylene imine)-based dendrimersomes for drug and gene delivery to cancer cells. Nanoscale, 2018, pp. 22830-22847. (doi: 10.1039/c8nr08141g)

Kotzur, M., Wyke, S., Steele, R., Weller, D., Campbell, C., Crighton, E., Mccowan, C., Robb, K. (2018) Which Behaviour Change Techniques Lead to Completion of Bowel Cancer Screening? Participants’ and Non-participants’ Descriptions of their Experience.

Kim, C. S., Mohan, S., Ayub, M., Rothwell, D. G., Dive, C., Brady, G., Miller, C. (2018) In silico error correction improves cfDNA mutation calling. Bioinformatics, 35, pp. 2380-2385. (doi: 10.1093/bioinformatics/bty1004)

Woods, B. S. et al. (2018) Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. European Urology Oncology, 1, pp. 449-458. (doi: 10.1016/j.euo.2018.06.004)

Hussain, S. A., Birtle, A., Crabb, S., Huddart, R., Small, D., Summerhayes, M., Jones, R., Protheroe, A. (2018) From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. European Urology Oncology, 1, pp. 486-500. (doi: 10.1016/j.euo.2018.05.011)

Knudsen, M. D., Hjartåker, A., Robb, K. A., de Lange, T., Hoff, G., Berstad, P. (2018) Improving cancer preventive behaviors: a randomized trial of tailored lifestyle feedback in colorectal cancer screening. Cancer Epidemiology, Biomarkers and Prevention, 27, pp. 1442-1449. (doi: 10.1158/1055-9965.EPI-18-0268)

Salji, M., Hendry, J., Patel, A., Ahmad, I., Nixon, C., Leung, H. Y. (2018) Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer. European Urology Focus, 4, pp. 858-866. (doi: 10.1016/j.euf.2017.01.019)

Parker, C. C. et al. (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392, pp. 2353-2366. (doi: 10.1016/S0140-6736(18)32486-3)

Chou, A. et al. (2018) Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 67, pp. 2142-2155. (doi: 10.1136/gutjnl-2017-315144)

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi: 10.1016/j.breast.2018.09.003)

Dobbin, S. J.H., Cameron, A. C., Petrie, M. C., Jones, R. J., Touyz, R. M., Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104, pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, (doi: 10.1038/s41467-018-07339-y)

Veenstra, V.L., Damhofer, H., Waasdorp, C., van Rijssen, L.B., van de Vijver, M.J., Dijk, F., Wilmink, H.W., Besselink, M.G., Busch, O.R., Chang, D.K., Bailey, P.J., Biankin, A.V., Kocher, H.M., Medema, J.P., Li, J.S., Jiang, R., Pierce, D.W., van Laarhoven, H.W.M., Bijlsma, M.F. (2018) ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis, 7, (doi: 10.1038/s41389-018-0096-9)

Amelio, I., Mancini, M., Petrova, V., Cairns, R. A., Vikhreva, P., Nicolai, S., Marini, A., Antonov, A. A., Le Quesne, J., Baena Acevedo, J. D., Dudek, K., Sozzi, G., Pastorino, U., Knight, R. A., Mak, T. W., Melino, G. (2018) p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 115, pp. E10869-E10878. (doi: 10.1073/pnas.1808314115)

Arkenau, H.-T., Italiano, A., Mak, G., Toulmonde, M., Baird, R.D., Garcia-Corbacho, J., Plummer, R., Flynn, M., Forster, M., Wilson, R.H., Tosi, D., Adenis, A., Donaldson, K., Posner, J., Kawabata, I., Arimura, A., Deva, S., Spicer, J. (2018) An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer, 103, pp. 17-23. (doi: 10.1016/j.ejca.2018.07.134)

Hewit, K., Sandilands, E., Sanchez Martinez, R., James, D., Leung, H. Y., Bryant, D. M., Shanks, E., Markert, E. K. (2018) A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor. Cell Death and Disease, 9, (doi: 10.1038/s41419-018-1115-7)

Malik, N., Sansom, O. J., Michie, A. M. (2018) The role of mTOR-mediated signals during haemopoiesis and lineage commitment. Biochemical Society Transactions, 46, pp. 1313-1324. (doi: 10.1042/BST20180141)

Bray, T. L., Salji, M., Brombin, A., Pérez-López, A. M., Rubio-Ruiz, B., Galbraith, L. C.A., Patton, E. E., Leung, H. Y., Unciti-Broceta, A. (2018) Bright insights into palladium-triggered local chemotherapy. Chemical Science, 9, pp. 7354-7361. (doi: 10.1039/c8sc02291g)

Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., de Braud, F., Chau, I., Harbison, C. T., Dorange, C., Tschaika, M., Le, D. T. (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. Journal of Clinical Oncology, 36, pp. 2836-2844. (doi: 10.1200/JCO.2017.76.6212)

Smit, S., Kwakkel, J., Keith, N. (2018) Accomplissh: creating societal impact from social sciences and humanities research. European Commission

Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3, (doi: 10.1136/esmoopen-2018-000408)

Lallo, A., Frese, K. K., Morrow, C. J., Sloane, R., Gulati, S., Schenk, M. W., Trapani, F., Simms, N., Galvin, M., Brown, S., Hodgkinson, C. L., Priest, L., Hughes, A., Lai, Z., Cadogan, E., Khandelwal, G., Simpson, K. L., Miller, C., Blackhall, F., O'Connor, M. J., Dive, C. (2018) The combination of the PARP inhibitor Olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clinical Cancer Research, 24, pp. 5153-5164. (doi: 10.1158/1078-0432.CCR-17-2805)

Inman, G. J., Wang, J., Nagano, A., Alexandrov, L. B., Purdie, K. J., Taylor, R. G., Sherwood, V., Thomson, J., Hogan, S., Spender, L. C., South, A. P., Stratton, M., Chelala, C., Harwood, C. A., Proby, C. M., Leigh, I. M. (2018) The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nature Communications, 9, (doi: 10.1038/s41467-018-06027-1)

Park, J. H., Ishizuka, M., McSorley, S. T., Kubota, K., Roxburgh, C. S.D., Nagata, H., Takagi, K., Iwasaki, Y., Aoki, T., Horgan, P. G., McMillan, D. C. (2018) Staging the tumor and staging the host: A two centre, two country comparison of systemic inflammatory responses of patients undergoing resection of primary operable colorectal cancer. American Journal of Surgery, 216, pp. 458-464. (doi: 10.1016/j.amjsurg.2017.08.044)

Ianniciello, A., Rattigan, K. M., Helgason, G. V. (2018) The ins and outs of autophagy and metabolism in hematopoietic and leukemic stem cells: food for thought. Frontiers in Cell and Developmental Biology, 6, (doi: 10.3389/fcell.2018.00120)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29, pp. 1918-1925. (doi: 10.1093/annonc/mdy245)

Cross, W. et al. (2018) The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2, pp. 1661-1672. (doi: 10.1038/s41559-018-0642-z)

Kotzur, M., Wyke, S., Macdonald, S., Steele, R., Weller, D., Campbell, C., Crighton, E., Mccowan, C., Robb, K. (2018) Identifying Micro Actions in Colorectal Cancer Screening: a Secondary Analysis of Qualitative Data.

Lazarus, K. A., Hadi, F., Zambon, E., Bach, K., Santolla, M.-F., Watson, J. K., Correia, L. L., Das, M., Ugur, R., Pensa, S., Becker, L., Campos, L. S., Ladds, G., Liu, P., Evan, G. I., McCaughan, F. M., Le Quesne, J., Lee, J.-H., Calado, D., Khaled, W. T. (2018) BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma. Nature Communications, 9, (doi: 10.1038/s41467-018-05790-5)

Purdie, K. J., Proby, C. M., Rizvi, H., Griffin, H., Doorbar, J., Sommerlad, M., Feltkamp, M. C., Meijden, E. V. d., Inman, G. J., South, A. P., Leigh, I. M., Harwood, C. A. (2018) The role of human papillomaviruses and polyomaviruses in BRAF-inhibitor induced cutaneous squamous cell carcinoma and benign squamoproliferative lesions. Frontiers in Microbiology, 9, (doi: 10.3389/fmicb.2018.01806)

Mackay, H. L., Moore, D., Hall, C., Birkbak, N. J., Jamal-Hanjani, M., Karim, S. A., Phatak, V. M., Piñon, L., Morton, J. P., Swanton, C., Le Quesne, J., Muller, P. A.J. (2018) Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nature Communications, 9, (doi: 10.1038/s41467-018-05368-1)

Krol, I., Castro-Giner, F., Maurer, M., Gkountela, S., Szczerba, B., Scherrer, R., Coleman, N., Carreira, S., Bachmann, F., Anderson, S., Engelhardt, M., Lane, H., Evans, T. R. J., Plummer, R., Kristeleit, R., Lopez, J., Aceto, N. (2018) Detection of circulating tumor cell clusters in human glioblastoma. British Journal of Cancer, 119, pp. 487-491. (doi: 10.1038/s41416-018-0186-7)

Baxter, M.A., Glen, H., Evans, T.R.J. (2018) Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Future Oncology, 14, pp. 2021-2029. (doi: 10.2217/fon-2017-0689)

McSorley, S.T., Steele, C.W., McMahon, A.J. (2018) Meta‐analysis of oral antibiotics, in combination with preoperative intravenous antibiotics and mechanical bowel preparation the day before surgery, compared with intravenous antibiotics and mechanical bowel preparation alone to reduce surgical‐site infections in elective colorectal surgery. BJS Open, 2, pp. 185-194. (doi: 10.1002/bjs5.68)

McSorley, S. T., Black, D. H., Horgan, P. G., McMillan, D. C. (2018) The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer. Clinical Nutrition, 37, pp. 1279-1285. (doi: 10.1016/j.clnu.2017.05.017)

Dolan, R. D., McSorley, S. T., Park, J. H., Watt, D. G., Roxburgh, C. S., Horgan, P. G., McMillan, D. C. (2018) The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. British Journal of Cancer, 119, pp. 40-51. (doi: 10.1038/s41416-018-0095-9)

McSorley, S. T., Talwar, D., McMillan, D. C. (2018) Comment on the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. American Journal of Clinical Nutrition, 108, pp. 204-205. (doi: 10.1093/ajcn/nqx071)

Muthalagu, N., Murphy, D. J. (2018) Is oxidative stress MYC’s Achilles heel? Cell Death and Differentiation, 25, pp. 1189-1190. (doi: 10.1038/s41418-018-0117-4)

Torres-Ayuso, P., Sahoo, S., Ashton, G., An, E., Simms, N., Galvin, M., Leong, H. S., Frese, K. K., Simpson, K., Cook, N., Hughes, A., Miller, C. J., Marais, R., Dive, C., Krebs, M. G., Brognard, J. (2018) Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. npj Genomic Medicine, 3, (doi: 10.1038/s41525-018-0055-6)

Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., Le Quesne, J., Dick, C., Vousden, K., Martins, C. P., Murphy, D. J. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10, (doi: 10.1126/scitranslmed.aao2565)

McSorley, S. T., Roxburgh, C. S.D., Horgan, P. G., McMillan, D. C. (2018) The relationship between cardiopulmonary exercise test variables, the systemic inflammatory response, and complications following surgery for colorectal cancer. Perioperative Medicine, 7, (doi: 10.1186/s13741-018-0093-8)

Allen, W. L. et al. (2018) Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy. JCO Precision Oncology, pp. 1-15. (doi: 10.1200/PO.17.00241)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29, pp. 1235-1248. (doi: 10.1093/annonc/mdy072)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23, pp. 1448-1460. (doi: 10.1016/j.celrep.2018.03.131)

Port, J. et al. (2018) Colorectal tumors require NUAK1 for protection from oxidative stress. Cancer Discovery, 8, pp. 632-647. (doi: 10.1158/2159-8290.CD-17-0533)

Galbraith, L., Leung, H. Y., Ahmad, I. (2018) Lipid pathway deregulation in advanced prostate cancer. Pharmacological Research, 131, pp. 177-184. (doi: 10.1016/j.phrs.2018.02.022)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R., Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA) Toxicological Sciences, 163, pp. 293-306. (doi: 10.1093/toxsci/kfy035)

Mitchell, R., Hopcroft, L. E.M., Baquero, P., Allan, E. K., Hewit, K., James, D., Hamilton, G., Mukhopadhyay, A., O'Prey, J., Hair, A., Melo, J. V., Chan, E., Ryan, K. M., Maguer-Satta, V., Druker, B. J., Clark, R. E., Mitra, S., Herzyk, P., Nicolini, F. E., Salomoni, P., Helgason, G. V. (2018) Targeting BCR-ABL independent TKI resistance in chronic myeloid leukaemia by mTOR and autophagy inhibition. Journal of the National Cancer Institute, 110, pp. 467-478. (doi: 10.1093/jnci/djx236)

McSorley, S. T., Khor, B. Y., Tsang, K., Colville, D., Han, S., Horgan, P. G., McMillan, D. C. (2018) The relationship between 18F FDG-PETCT derived markers of tumour metabolism and systemic inflammation in patients with recurrent disease following surgery for colorectal cancer. Colorectal Disease, 20, pp. 407-415. (doi: 10.1111/codi.13973)

Macdonald, S., Cunningham, Y., Patterson, C., Robb, K., Macleod, U., Anker, T., Hilton, S. (2018) Mass media and risk factors for cancer: the under-representation of age. BMC Public Health, 18, (doi: 10.1186/s12889-018-5341-9)

Carvajal, R. D. et al. (2018) Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT) Journal of Clinical Oncology, 36, pp. 1232-1239. (doi: 10.1200/JCO.2017.74.1090)

Hudson, A. M., Stephenson, N. L., Li, C., Trotter, E., Fletcher, A. J., Katona, G., Bieniasz-Krzywiec, P., Howell, M., Wirth, C., Furney, S., Miller, C. J., Brognard, J. (2018) Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases. Science Signaling, 11, (doi: 10.1126/scisignal.aan6776)

Arce Vargas, F. et al. (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell, 33, pp. 649-663.e4. (doi: 10.1016/j.ccell.2018.02.010)

Waldron, J. A., Raza, F., Le Quesne, J. (2018) eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes. Nucleic Acids Research, 46, pp. 3075-3087. (doi: 10.1093/nar/gky108)

Pellicano, F., Park, L., Hopcroft, L. E.M., Shah, M. M., Jackson, L., Scott, M. T., Clarke, C. J., Sinclair, A., Abraham, S. A., Hair, A., Helgason, G. V., Aspinall-O'Dea, M., Bhatia, R., Leone, G., Kranc, K. R., Whetton, A. D., Holyoake, T. L. (2018) Hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood, 131, pp. 1532-1544. (doi: 10.1182/blood-2017-05-783845)

Patel, R., Fleming, J., Mui, E., Loveridge, C., Repiscak, P., Blomme, A., Harle, V., Salji, M., Ahmad, I., Teo, K., Hamdy, F. C., Hedley, A., van den Broek, N., Mackay, G., Edwards, J., Sansom, O. J., Leung, H. Y. (2018) Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 10, (doi: 10.15252/emmm.201708347)

Schmidinger, M., Danesi, R., Jones, R., McDermott, R., Pyle, L., Rini, B., Négrier, S. (2018) Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 14, pp. 861-875. (doi: 10.2217/fon-2017-0455)

Holroyd, A. K., Michie, A. M. (2018) The role of mTOR-mediated signaling in the regulation of cellular migration. Immunology Letters, 196, pp. 74-79. (doi: 10.1016/j.imlet.2018.01.015)

Kudo, M., Finn, R., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M., Cheng, A.-L. (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391, pp. 1163-1173. (doi: 10.1016/S0140-6736(18)30207-1)

Marchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M., Haider, S. M., Morton, J. P., Marsico, G., Vo, T., Laughlin-Toth, S., Ahmed, A. A., Di Vita, G., Pazitna, I., Gunaratnam, M., Besser, R. J., Andrade, A. C.G., Diocou, S., Pike, J. A., Tannahill, D., Pedley, R. B., Evans, T.R. J., Wilson, W. D., Balasubramanian, S., Neidle, S. (2018) Targeting multiple effector pathways in pancreatic ductal adenocarcinoma with a G-quadruplex-binding small molecule. Journal of Medicinal Chemistry, 61, pp. 2500-2517. (doi: 10.1021/acs.jmedchem.7b01781)

Woodcock, V. K., Clive, S., Wilson, R. H., Coyle, V. M., Stratford, M. R. L., Folkes, L. K., Eastell, R., Barton, C., Jones, P., Kazmi-Stokes, S., Turner, H., Halford, S., Harris, A. L., Middleton, M. R. (2018) A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 118, pp. 770-776. (doi: 10.1038/bjc.2017.484)

Cook, N., Basu, B., Smith, D.-M., Gopinathan, A., Evans, T.R. J., Steward, W. P., Palmer, D., Propper, D., Venugopal, B., Hategan, M., Anthoney, D. A., Hampson, L. V., Nebozhyn, M., Tuveson, D., Farmer-Hall, H., Turner, H., McLeod, R., Halford, S., Jodrell, D. (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118, pp. 793-801. (doi: 10.1038/bjc.2017.495)

Rose, A. M., Spender, L. C., Stephen, C., Mitchell, A., Rickaby, W., Bray, S., Evans, A. T., Dayal, J., Purdie, K. J., Harwood, C. A., Proby, C. M., Leigh, I. M., Coates, P. J., Inman, G. j. (2018) Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma. Oncotarget, 9, pp. 14552-14566. (doi: 10.18632/oncotarget.24545)

McSorley, S. T., Mansouri, D., Horgan, P. G., McMillan, D. C. (2018) Comment on "the important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial" Annals of Surgery, 267, pp. e49. (doi: 10.1097/SLA.0000000000002053)

Dolan, R., McSorley, S. T., Horgan, P. G., McMillan, D. C. (2018) Determinants of lymph node count and positivity in patients undergoing surgery for colon cancer. Medicine, 97, (doi: 10.1097/MD.0000000000010185)

Adams, R., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., Kaplan, R., Quirke, P., Richman, S., Samuel, L., Seligmann, J., Seymour, M., Shiu, K. K., Wasan, H., Wilson, R., Maughan, T. (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3, pp. 162-171. (doi: 10.1016/S2468-1253(17)30394-1)

Patel, M., McSorley, S. T., Park, J. H., Roxburgh, C. S.D., Edwards, J., Horgan, P. G., McMillan, D. C. (2018) The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. British Journal of Cancer, 118, pp. 705-712. (doi: 10.1038/bjc.2017.441)

Monteverde, T., Tait-Mulder, J., Hedley, A.,, Knight, J.R., Sansom, O.J., Murphy, D.J. (2018) Calcium signalling links MYC to NUAK1. Oncogene, 37, pp. 982-992. (doi: 10.1038/onc.2017.394)

Michie, A.M., Paunovic, V., Harnett, M.M. (2018) Cellular homeostasis: Cell growth and cancer. Elsevier

Wilson, R. A.M., Evans, T.R. J., Fraser, A. R., Nibbs, R. J.B. (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 191, pp. 133-148. (doi: 10.1111/cei.13081)

Rulach, R. J., McKay, S., Neilson, S., White, L., Wallace, J., Carruthers, R., Lamb, C., Cascales, A., Marashi, H., Glen, H., Venugopal, B., Sadoyze, A., Sidek, N., Russell, J. M., Alhasso, A., Dodds, D., Laskey, J., Jones, R. J., MacLeod, N. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121, pp. 268-274. (doi: 10.1111/bju.14025)

Kolluri, K. K. et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife, 7, (doi: 10.7554/eLife.30224)

Morrison, A., Marshall-Mckenna, R., Hutchison, C., MacPherson, I., Rice, A.M., McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions.

Morrison, A., Marshall-Mckenna, R., Hutchison, C., MacPherson, I., Rice, A.M., McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens.

Hurst, L. A., Dunmore, B. J., Long, L., Crosby, A., Al-Lamki, R., Deighton, J., Southwood, M., Yang, X., Nikolic, M. Z., Herrera, B., Inman, G. J., Bradley, J. R., Rana, A. A., Upton, P. D., Morrell, N. W. (2018) TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nature Communications, 8, (doi: 10.1038/ncomms14079)

Dreyer, S.B., Jamieson, N.B., Upstill-Goddard, R., Bailey, P.J., McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V., Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105, pp. e183-e191. (doi: 10.1002/bjs.10772)

Blyth, K. G., Murphy, D. J. (2018) Progress and challenges in Mesothelioma: from bench to bedside. Respiratory Medicine, 134, pp. 31-41. (doi: 10.1016/j.rmed.2017.11.015)

Almasaudi, A. S., McSorley, S. T., Edwards, C. A., McMillan, D. C. (2018) The relationship between body mass index and short term postoperative outcomes in patients undergoing potentially curative surgery for colorectal cancer: a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 121, pp. 68-73. (doi: 10.1016/j.critrevonc.2017.12.004)

Bilsland, A., Kelly, C., Roccisana, J., Paul, J., Jones, R., Edwards, J., Roseweir, A., Stein, T., West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. (doi: 10.1038/s41416-018-0299-z)

de Beauchamp, L., Baquero, P., Kuntz, E. M., Gottlieb, E., Helgason, G. V. (2018) Auto-commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells” Molecular and Cellular Oncology, 5, (doi: 10.1080/23723556.2017.1403532)

Keith, W. N., Yu, X., Barbeau, R.-M. (2018) Diversity of institutional support for research impact implementation. Zeitschrift für Diversitätsforschung und –management, 3, pp. 199-207.

Dolan, R., Tilling, E., Kong, C. Y., MacLeod, N. J., McSorley, S. T., Park, J. H., Glen, P., Horgan, P. G., Laird, B., McMillan, D. C. (2018) Evaluation of Systemic Inflammation Based Prognostic Scores in Patients with Advanced Oesophageal Cancer Receiving Palliative Radiotherapy.

Bennett, L., Howell, M., Memon, D., Smowton, C., Zhou, C., Miller, C. J. (2018) Mutation pattern analysis reveals polygenic mini-drivers associated with relapse after surgery in lung adenocarcinoma. Scientific Reports, 8, (doi: 10.1038/s41598-018-33276-3)

Jones, R. J. (2018) Neoadjuvant vs. adjuvant chemotherapy: which is right? Springer

Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha, M., Mackenzie, G. R., Leung, H. Y., Dufès, C. (2018) Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12. Drug Delivery, 25, pp. 679-689. (doi: 10.1080/10717544.2018.1440666)

Dolan, R., McSorley, S. T., Park, J. H., Roxburgh, C. S.D., Horgan, P. G., McMillan, D. C. (2018) The Prognostic Value of Systemic Inflammation in Patients Undergoing Surgery for Rectal Cancer: Comparison of Composite Ratios and Cumulative Scores. (doi: 10.1200/JCO.2018.36.4_suppl.579)

Jones, R. J. (2018) The role of medical oncologist. Springer

Kotzur, M., Wyke, S., Macdonald, S., Steele, R., Weller, D., Campbell, C., Crighton, E., Mccowan, C., Robb, K. (2017) Involving Future Users in Developing Cancer Screening Interventions: a Case Study.

Dornier, E., Rabas, N., Mitchell, L., Novo, D., Dhayade, S., Marco, S., Mackay, G., Sumpton, D., Pallares, M., Nixon, C., Blyth, K., MacPherson, I. R., Rainero, E., Norman, J. C. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8, (doi: 10.1038/s41467-017-02101-2)

Kotzur, M., Wyke, S., Macdonald, S., Steele, R., Weller, D., Campbell, C., Crighton, E., Mccowan, C., Robb, K. (2017) Strategies to Increase Bowel Screening Uptake: a Focus Group Study of Non-participants.

Lawler, M., Alsina, D., Adams, R. A., Anderson, A. S., Brown, G., Fearnhead, N. S., Fenwick, S. W., Halloran, S. P., Hochhauser, D., Hull, M. A., Koelzer, V. H., McNair, A. G.K., Monahan, K. J., Näthke, I., Norton, C., Novelli, M. R., Steele, R. J.C., Thomas, A. L., Wilde, L. M., Wilson, R. H., Tomlinson, I. (2017) Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 67, pp. 179-193. (doi: 10.1136/gutjnl-2017-315333)

Walton, J. B., Farquharson, M., Mason, S., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D., Matzuk, M., Kim, J., Coffelt, S., Blyth, K., Mcneish, I. A. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, (doi: 10.1038/s41598-017-17119-1)

Dolan, R. D., Lim, J., Mcsorley, S. T., Horgan, P. G., McMillan, D. C. (2017) The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. Scientific Reports, 7, (doi: 10.1038/s41598-017-16955-5)

Lindner, A. U., Salvucci, M., Morgan, C., Monsefi, N., Resler, A. J., Cremona, M., Curry, S., Toomey, S., O'Byrne, R., Bacon, O., Stühler, M., Flanagan, L., Wilson, R., Johnston, P. G., Salto-Tellez, M., Camilleri-Broët, S., McNamara, D. A., Kay, E. W., Hennessy, B. T., Laurent-Puig, P., Van Schaeybroeck, S., Prehn, J. H.M. (2017) BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 66, pp. 2141-2148. (doi: 10.1136/gutjnl-2016-312287)

Cousins, A., Markert, E., Degn, M., Olivares, O., Yousafzai, Y. M., Bhatti, S., Herzyk, P., Michie, A., Schmiegelow, K., Gottlieb, E., Halsey, C. (2017) Upregulated cholesterol biosynthesis is a biomarker for isolated central nervous system relapse in acute lymphoblastic leukaemia. Blood, 130,

Hall, P. S., Smith, A., Hulme, C., Vargas-Palacios, A., Makris, A., Hughes-Davies, L., Dunn, J. A., Bartlett, J. M.S., Cameron, D. A., Marshall, A., Campbell, A., Macpherson, I. R., Rea, D., Francis, A., Earl, H., Morgan, A., Stein, R. C., McCabe, C. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20, pp. 1311-1318. (doi: 10.1016/j.jval.2017.04.021)

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi: 10.1038/nature24462)

Farrell, A. S. et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications, 8, (doi: 10.1038/s41467-017-01967-6)

Chernova, T., Murphy, F. A., Galavotti, S., Sun, X.-M., Powley, I. R., Grosso, S., Schinwald, A., Zacarias-Cabeza, J., Dudek, K. M., Dinsdale, D., Le Quesne, J., Bennett, J., Nakas, A., Greaves, P., Poland, C. A., Donaldson, K., Bushell, M., Willis, A. E., MacFarlane, M. (2017) Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a ( Ink4a/Arf ) Current Biology, 27, pp. 3302-3314.e6. (doi: 10.1016/j.cub.2017.09.007)

Port, J., Murphy, D. J. (2017) Mesothelioma: identical routes to malignancy from asbestos and carbon nanotubes. Current Biology, 27, pp. R1173-R1176. (doi: 10.1016/j.cub.2017.07.026)

Ross, K., Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131, pp. 2627-2642. (doi: 10.1042/CS20160894)

MacLennan, S. et al. (2017) A core outcome set for localised prostate cancer effectiveness trials. BJU International, 120, pp. E64-E79. (doi: 10.1111/bju.13854)

Schrock, A. B., Devoe, C. E., McWilliams, R., Sun, J., Aparicio, T., Stephens, P. J., Ross, J. S., Wilson, R., Miller, V. A., Ali, S. M., Overman, M. J. (2017) Genomic profiling of small-bowel adenocarcinoma. JAMA Oncology, 3, pp. 1546. (doi: 10.1001/jamaoncol.2017.1051)

Robb, K. A., Gatting, L., Wardle, J. (2017) What impact do questionnaire length and monetary incentives have on mailed health psychology survey response? British Journal of Health Psychology, 22, pp. 671-685. (doi: 10.1111/bjhp.12239)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550, pp. 548. (doi: 10.1038/nature24026)

Alvi, M. A., Wilson, R. H., Salto-Tellez, M. (2017) Rare cancers: the greatest inequality in cancer research and oncology treatment. British Journal of Cancer, 117, pp. 1255-1257. (doi: 10.1038/bjc.2017.321)

Loveridge, C. J., van ’t Hof, R. J., Charlesworth, G., King, A., Tan, E. H., Rose, L., Daroszewska, A., Prior, A., Ahmad, I., Welsh, M., Mui, E. J., Ford, C., Salji, M., Sansom, O., Blyth, K., Leung, H. Y. (2017) Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity. Scientific Reports, 7, (doi: 10.1038/s41598-017-13346-8)

Munkley, J., Oltean, S., Vodák, D., Wilson, B. T., Livermore, K. E., Zhou, Y., Star, E., Floros, V. I., Johannessen, B., Knight, B., McCullagh, P., McGrath, J., Crundwell, M., Skotheim, R. I., Robson, C. N., Leung, H. Y., Harries, L. W., Rajan, P., Mills, I. G., Elliott, D. J. (2017) The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget, 6, pp. 34358-34374. (doi: 10.18632/oncotarget.6024)

Escudier, B., Faivre, S., Van Cutsem, E., Germann, N., Pouget, J.-C., Plummer, R., Vergote, I., Thistlethwaite, F., Bjarnason, G. A., Jones, R., Mackay, H., Edeline, J., Fartoux, L., Hirte, H., Oza, A. (2017) A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. Targeted Oncology, 12, pp. 655-661. (doi: 10.1007/s11523-017-0525-2)

Cain, H., MacPherson, I.R., Beresford, M., Pinder, S.E., Pong, J., Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29, pp. 642-652. (doi: 10.1016/j.clon.2017.06.003)

Crabb, S. J., Birtle, A. J., Martin, K., Downs, N., Ratcliffe, I., Maishman, T., Ellis, M., Griffiths, G., Thompson, S., Ksiazek, L., Khoo, V., Jones, R. J. (2017) ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Investigational New Drugs, 35, pp. 599-607. (doi: 10.1007/s10637-017-0433-4)

Cammareri, P., Vincent, D. F., Hodder, M. C., Ridgway, R. A., Murgia, C., Nobis, M., Campbell, A. D., Varga, J., Huels, D. J., Subramani, C., Prescott, K. L.H., Nixon, C., Hedley, A., Barry, S. T., Greten, F. R., Inman, G. J., Sansom, O. J. (2017) TGFβ pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis. Cell Death and Differentiation, 24, pp. 1681-1693. (doi: 10.1038/cdd.2017.92)

Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K., Tardito, S., Holyoake, T. L., Helgason, G. V., Gottlieb, E. (2017) Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, 23, pp. 1234-1240. (doi: 10.1038/nm.4399)

Chiu, A., Ayub, M., Dive, C., Brady, G., Miller, C. J., Hancock, J. (2017) twoddpcr: an R/Bioconductor package and Shiny app for Droplet Digital PCR analysis. Bioinformatics, 33, pp. 2743-2745. (doi: 10.1093/bioinformatics/btx308)

Dolan, R. D., McSorley, S. T., McMillan, D. C., Horgan, P. G. (2017) Attitudes of surgeons to the use of postoperative markers of the systemic inflammatory response following elective surgery. Annals of Medicine and Surgery, 21, pp. 14-19. (doi: 10.1016/j.amsu.2017.07.046)

Watt, D. G., Ramanathan, M. L., McSorley, S. T., Walley, K., Park, J. H., Horgan, P. G., McMillan, D. C. (2017) Clinicopathological determinants of an elevated systemic inflammatory response following elective potentially curative resection for colorectal cancer. Annals of Surgical Oncology, 24, pp. 2588-2594. (doi: 10.1245/s10434-017-5987-z)

Murphy, D. J., Blyth, K. G. (2017) Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution' Cell Death and Differentiation, 24, pp. 1473-1474. (doi: 10.1038/cdd.2017.97)

Phillips, T. J. et al. (2017) Treating the placenta to prevent adverse effects of gestational hypoxia on fetal brain development. Scientific Reports, 7, (doi: 10.1038/s41598-017-06300-1)

Cairney, C. J., Godwin, L. S., Bilsland, A. E., Burns, S., Stevenson, K. H., McGarry, L., Revie, J., Moore, J. D., Wiggins, C. M., Collinson, R. S., Mudd, C., Tsonou, E., Sadaie, M., Bennett, D. C., Narita, M., Torrance, C. J., Keith, W. N. (2017) A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genetics, 13, (doi: 10.1371/journal.pgen.1006942)

Raphael, B. J. et al. (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell, 32, pp. 185-203.e13. (doi: 10.1016/j.ccell.2017.07.007)

Khandelwal, G., Girotti, M. R., Smowton, C., Taylor, S., Wirth, C., Dynowski, M., Frese, K. K., Brady, G., Dive, C., Marais, R., Miller, C. (2017) Next-generation sequencing analysis and algorithms for PDX and CDX models. Molecular Cancer Research, 15, pp. 1012-1016. (doi: 10.1158/1541-7786.MCR-16-0431)

Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., Stubbs, C., Stocken, D. D., Wall, L., Watkinson, A., Hacking, N., Evans, T.R. J., Collins, P., Hubner, R. A., Cunningham, D., Primrose, J. N., Johnson, P. J., Palmer, D. H. (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterology and Hepatology, 2, pp. 565-575. (doi: 10.1016/S2468-1253(17)30156-5)

Mcsorley, S. T., Roxburgh, C. S.D., Horgan, P. G., McMillan, D. C. (2017) The impact of preoperative dexamethasone on the magnitude of the postoperative systemic inflammatory response and complications following surgery for colorectal cancer. Annals of Surgical Oncology, 24, pp. 2104-2112. (doi: 10.1245/s10434-017-5817-3)

Grose, D., McIntosh, D., Jamieson, N., Carter, R., Dickson, E., Chang, D., Marashi, H., Wilson, C., Alfayez, M., Kerr, A., O’Donoghue, R., Haskins, L., Duthie, F., McKay, C. J., Graham, J. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8, pp. 683-695. (doi: 10.21037/jgo.2017.04.01)

Dolan, R. D., McSorley, S. T., Horgan, P. G., Laird, B., McMillan, D. C. (2017) The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 116, pp. 134-146. (doi: 10.1016/j.critrevonc.2017.06.002)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377, pp. 338-351. (doi: 10.1056/NEJMoa1702900)

Munkley, J., McClurg, U. L., Livermore, K. E., Ehrmann, I., Knight, B., Mccullagh, P., Mcgrath, J., Crundwell, M., Harries, L. W., Leung, H. Y., Mills, I. G., Robson, C. N., Rajan, P., Elliott, D. J. (2017) The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports, 7, (doi: 10.1038/s41598-017-05489-5)

de la Cruz-Merino, L., Di Guardo, L., Grob, J.-J., Venosa, A., Larkin, J., McArthur, G. A., Ribas, A., Acierto, P. A., Evans, J. T.R., Gomez‑Escobar, A., Barteselli, G., Eng, S., Hsu, J. J., Uyei, A., Dréno, B. (2017) Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine, 15, (doi: 10.1186/s12967-017-1246-0)

Alderdice, M., Dunne, P. D., Cole, A. J., O’Reilly, P. G., McArt, D. G., Bingham, V., Fuchs, M.-A., McQuaid, S., Loughrey, M. B., Murray, G. I., Samuel, L. M., Lawler, M., Wilson, R. H., Salto-Tellez, M., Coyle, V. M. (2017) Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 30, pp. 1287-1298. (doi: 10.1038/modpathol.2017.47)

Kelly, A. U., McSorley, S. T., Patel, P., Talwar, D. (2017) Interpreting iron studies. British Medical Journal, 357, (doi: 10.1136/bmj.j2513)

Alvi, M. A., Loughrey, M. B., Dunne, P., McQuaid, S., Turkington, R., Fuchs, M.-A., McGready, C., Bingham, V., Pang, B., Moore, W., Maxwell, P., Lawler, M., James, J. A., Murray, G. I., Wilson, R. H., Salto-Tellez, M. (2017) Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 117, pp. 203-209. (doi: 10.1038/bjc.2017.168)

Jones, R. J., Hussain, S. A., Protheroe, A. S., Birtle, A., Chakraborti, P., Huddart, R. A., Jagdev, S., Bahl, A., Stockdale, A., Sundar, S., Crabb, S. J., Dixon-Hughes, J., Alexander, L., Morris, A., Kelly, C., Stobo, J., Paul, J., Powles, T. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35, pp. 1770-1777. (doi: 10.1200/JCO.2016.70.7828)

Jamal-Hanjani, M. et al. (2017) Tracking the evolution of non–small-cell lung cancer. New England Journal of Medicine, 376, pp. 2109-2121. (doi: 10.1056/NEJMoa1616288)

Loveridge, C. J., Mui, E. J., Patel, R., Tan, E. H., Ahmad, I., Welsh, M., Galbraith, J., Hedley, A., Nixon, C., Blyth, K., Sansom, O., Leung, H. Y. (2017) Increased T cell infiltration elicited by Erk5 deletion in a Pten-deficient mouse model of prostate carcinogenesis. Cancer Research, 77, pp. 3158-3168. (doi: 10.1158/0008-5472.CAN-16-2565)

Feigin, M. E., Garvin, T., Bailey, P., Waddell, N., Chang, D. K., Kelley, D. R., Shuai, S., Gallinger, S., McPherson, J. D., Grimmond, S. M., Khurana, E., Stein, L. D., Biankin, A. V., Schatz, M. C., Tuveson, D. A. (2017) Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 49, pp. 825-833. (doi: 10.1038/ng.3861)

Gore, M. E., Jones, R. J., Ravaud, A., Kuczyk, M., Demkow, T., Bearz, A., Shapiro, J., Strauss, U. P., Porta, C. (2017) Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. BJU International, 119, pp. 846-853. (doi: 10.1111/bju.13740)

Abbosh, C. et al. (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545, pp. 446-451. (doi: 10.1038/nature22364)

Hock, A. K., Cheung, E. C., Humpton, T. J., Monteverde, T., Paulus-Hock, V., Lee, P., McGhee, E., Scopelliti, A., Murphy, D. J., Strathdee, D., Blyth, K., Vousden, K. H. (2017) Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo. Scientific Reports, 7, (doi: 10.1038/s41598-017-01741-0)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35, pp. 1530-1541. (doi: 10.1200/JCO.2016.69.0677)

Rewhorn, M.J., Baxter, G., Leung, H.Y. (2017) Delayed fistula post-salvage prostate cryotherapy. Journal of Clinical Urology, 10, pp. 189-190. (doi: 10.1177/2051415814565201)

Kerr, L., Leung, H. Y., Melquiot, N., Arestis, N., Sidek, N. (2017) Lymphoma masquerading as advanced prostate cancer with lymphadenopathy. Journal of Clinical Urology, 10, pp. 174-176. (doi: 10.1177/2051415814560081)

Dreyer, S. B., Powell, A. G.M.T., McSorley, S. T., Waterston, A., Going, J. J., Edwards, J., McMillan, D. C., Horgan, P. G. (2017) The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Annals of Surgical Oncology, 24, pp. 1295-1303. (doi: 10.1245/s10434-016-5684-3)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, (doi: 10.1186/s13073-017-0430-4)

McSorley, S. T., Roxburgh, C. S., Horgan, P. G., McMillan, D. C. (2017) Re: Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial) British Medical Journal, 357,

Arce Vargas, F. et al. (2017) Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity, 46, pp. 577-586. (doi: 10.1016/j.immuni.2017.03.013)

Karekla, E., Liao, W.-J., Sharp, B., Pugh, J., Reid, H., Le Quesne, J., Moore, D., Pritchard, C., MacFarlane, M., Pringle, J. H. (2017) Ex vivo explant cultures of non–small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. Cancer Research, 77, pp. 2029-2039. (doi: 10.1158/0008-5472.CAN-16-1121)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9, (doi: 10.1126/scitranslmed.aai8504)

Watt, D., Mcsorley, S. T., Park, J. H., Horgan, P. G., McMillan, D. C. (2017) A postoperative systemic inflammation score predicts short- and long-term outcomes in patients undergoing surgery for colorectal cancer. Annals of Surgical Oncology, 24, pp. 1100-1109. (doi: 10.1245/s10434-016-5659-4)

Pishvaian, M. J., Biankin, A. V., Bailey, P., Chang, D. K., Laheru, D., Wolfgang, C. L., Brody, J. R. (2017) BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. British Journal of Cancer, 116, pp. 1021-1026. (doi: 10.1038/bjc.2017.40)

Jones, R. J., Brown, J. (2017) Circulating biomarkers in cancer care: what possible use? Practical Laboratory Medicine, 7, pp. 45-48. (doi: 10.1016/j.plabm.2016.04.004)

Dreyer, S. B., Chang, D. K., Bailey, P., Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23, pp. 1638-1646. (doi: 10.1158/1078-0432.CCR-16-2411)

Letsolo, B. T., Jones, R. E., Rowson, J., Grimstead, J. W., Keith, W. N., Jenkins, G. J.S., Baird, D. M. (2017) Extensive telomere erosion is consistent with localised clonal expansions in Barrett's metaplasia. PLoS ONE, 12, (doi: 10.1371/journal.pone.0174833)

Wilson, R. H., Evans, T.R. J., Middleton, M. R., Molife, L. R., Spicer, J., Dieras, V., Roxburgh, P., Giordano, H., Jaw-Tsai, S., Goble, S., Plummer, R. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116, (doi: 10.1038/bjc.2017.36)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543, pp. 65-71. (doi: 10.1038/nature21063)

Salvucci, M. et al. (2017) A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer. Clinical Cancer Research, 23, pp. 1200-1212. (doi: 10.1158/1078-0432.CCR-16-1084)

Cousins, A. F., Olivares, O., Michie, A. M., Gottlieb, E., Halsey, C. (2017) Association of CNS Involvement in Childhood Acute Lymphoblastic Leukaemia with Cholesterol Biosynthesis Upregulation. (doi: 10.1016/S0140-6736(17)30431-2)

Vallejo, A., Perurena, N., Guruceaga, E., Mazur, P. K., Martinez-Canarias, S., Zandueta, C., Valencia, K., Arricibita, A., Gwinn, D., Sayles, L. C., Chuang, C.-H., Guembe, L., Bailey, P., Chang, D. K., Biankin, A., Ponz-Sarvise, M., Andersen, J. B., Khatri, P., Bozec, A., Sweet-Cordero, E. A., Sage, J., Lecanda, F., Vicent, S. (2017) An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 8, (doi: 10.1038/ncomms14294)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, (doi: 10.1038/ncomms14206)

Dolan, R., McSorley, S. T., McMillan, D. C., Horgan, P. G. (2017) Association of Ongoing Systemic Inflammatory Response (SIR) at Diagnosis With Lymph Node Retrieval and Node Positivity in Patients Undergoing Surgery for Colonic Cancer. (doi: 10.1200/jco.2017.35.4_suppl.550)

Dolan, R., MacLeod, N. J., McSorley, S. T., Horgan, P. G., Laird, B., McMillan, D. C. (2017) Evaluation of Systemic Inflammation-based Prognostic Scores in Patients With Advanced Colorectal Cancer Receiving Palliative Pelvic Radiotherapy (RT) (doi: 10.1200/jco.2017.35.4_suppl.558)

Smowton, C., Balla, A., Antoniades, D., Miller, C., Pallis, G., Dikaiakos, M. D., Xing, W. (2017) A cost-effective approach to improving performance of big genomic data analyses in clouds. Future Generation Computer Systems, 67, pp. 368-381. (doi: 10.1016/j.future.2015.11.011)

Mcsorley, S. T., Khor, B. Y., MacKJay, G. J., Horgan, P. G., McMillan, D. C. (2017) Examination of a CRP first approach for the detection of postoperative complications in patients undergoing surgery for colorectal cancer: a pragmatic study. Medicine, 96, (doi: 10.1097/MD.0000000000006133)

Evans, T.R.J., Van Cutsem, E., Moore, M.J., Bazin, I.S., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., O'Dwyer, P.J. (2017) Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 28, pp. 354-361. (doi: 10.1093/annonc/mdw607)

Spender, L. C., Inman, G. J. (2017) Targeting BRAF-mutant tumours with TGFBR1 inhibitors. Aging, 9, pp. 5-6. (doi: 10.18632/aging.101169)

Byrne, A. T. et al. (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 17, pp. 254-268. (doi: 10.1038/nrc.2016.140)

Tarafdar, A., Hopcroft, L. E.M., Gallipolli, P., Pellicano, F., Cassels, J., Hair, A., Korfi, K., Jørgensen, H. G., Vetrie, D., Holyoake, T. L., Michie, A. M. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129, pp. 199-208. (doi: 10.1182/blood-2016-09-742049)

Sarosiek, K. A., Fraser, C., Muthalagu, N., Bhola, P. D., Chang, W., McBrayer, S. K., Cantlon, A., Fisch, S., Golomb-Mello, G., Ryan, J. A., Deng, J., Jian, B., Corbett, C., Goldenberg, M., Madsen, J. R., Liao, R., Walsh, D., Sedivy, J., Murphy, D. J., Carrasco, D. R., Robinson, S., Moslehi, J., Letai, A. (2017) Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell, 31, pp. 142-156. (doi: 10.1016/j.ccell.2016.11.011)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I., Edwards, J., Zanivan, S., Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130, pp. 697-711. (doi: 10.1242/jcs.190835)

Iltzsche, F., Simon, K., Stopp, S., Pattschull, G., Francke, S., Wolter, P., Hauser, S., Murphy, D.J., Garcia, P., Rosenwald, A., Gaubatz, S. (2017) An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma. Oncogene, 36, pp. 110-121. (doi: 10.1038/onc.2016.181)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152, pp. 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060)

Powles, T., Huddart, R. A., Elliott, T., Sarker, S.-J., Ackerman, C., Jones, R., Hussain, S., Crabb, S., Jagdev, S., Chester, J., Hilman, S., Beresford, M., Macdonald, G., Santhanam, S., Frew, J. A., Stockdale, A., Hughes, S., Berney, D., Chowdhury, S. (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. Journal of Clinical Oncology, 35, pp. 48-55. (doi: 10.1200/JCO.2015.66.3468)

Khor, B. Y., McSorley, S. T., Horgan, P. G., McMillan, D. C. (2017) The relationship between systemic inflammation and stoma formation following anterior resection for rectal cancer: a cross-sectional study. International Journal of Surgery, 37, pp. 79-84. (doi: 10.1016/j.ijsu.2016.12.010)

Horne, G. A., Copland, M. (2017) Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. Expert Opinion on Drug Discovery, 12, pp. 465-474. (doi: 10.1080/17460441.2017.1303477)

Dolan, R., McLeod, N., McSorley, S., McMillan, D., Horgan, P. (2017) Evaluation of Systemic Inflammation Based Prognostic Scoresin Patients with Advanced Rectal Cancer Receiving Palliative Pelvicradiotherapy.

McSorley, S. T., Dolan, R. D., Roxburgh, C. S.D., McMillan, D. C., Horgan, P. G. (2017) How and why systemic inflammation worsens quality of life in patients with advanced cancer. Expert Review of Quality of Life in Cancer Care, 2, pp. 167-175. (doi: 10.1080/23809000.2017.1331705)

Rose, A. M., Sansom, O. J., Inman, G. J. (2017) Loss of TGF-β signaling drives cSCC from skin stem cells – More evidence. Cell Cycle, 16, pp. 386-387. (doi: 10.1080/15384101.2016.1259892)

Carter, L., Rothwell, D. G., Mesquita, B., Smowton, C., Leong, H. S., Fernandez-Gutierrez, F., Li, Y., Burt, D. J., Antonello, J., Morrow, C. J., Hodgkinson, C. L., Morris, K., Priest, L., Carter, M., Miller, C., Hughes, A., Blackhall, F., Dive, C., Brady, G. (2017) Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nature Medicine, 23, pp. 114-119. (doi: 10.1038/nm.4239)

Draper, J. E., Sroczynska, P., Leong, H. S., Fadlullah, M. Z. H., Miller, C., Kouskoff, V., Lacaud, G. (2017) Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors. Blood, 130, pp. 271-284. (doi: 10.1182/blood-2016-06-723635)

Dolan, R., McSorley, S., McMillan, D., Horgan, P. (2017) Ongoing Systemic Inflammatory Response at Diagnosis is Notassociated with Lower Lymph Node Retrieval and Higher Node Positivityin Patients Undergoing Surgery for Colonic Cancer.

Horne, G., Jackson, L., Helgason, V., Holyoake, T. L. (2017) Stem cell guardians – old and new perspectives in LSC biology. Current Drug Targets, 18, pp. 405-413. (doi: 10.2174/1389450117666160712092944)